Sunday September 6 2015
WCLC2015-Scientific-Program
WCLC2015-Scientific-Program
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Sunday</strong>, <strong>September</strong> 6, <strong>2015</strong><br />
<strong>Sunday</strong>, <strong>September</strong> 6, <strong>2015</strong><br />
07:00 - 11:00 International Thoracic Oncology Nursing Forum (ITONF) Workshop (Ticketed<br />
Session)*<br />
Chair: Beth Ivimey, Australia<br />
Room: 201 + 203<br />
Meeting the Needs of Nurses…<br />
The ITONF are delighted to present this workshop. Officially launched at the<br />
WCLC 2011 Conference in Amsterdam, ITONF aims to be an internationally<br />
recognized body of expert knowledge in thoracic oncology nursing. It provides<br />
members with leadership, a united voice, support, education and a unique<br />
forum to network internationally. This interactive workshop will provide an<br />
excellent opportunity for learning, sharing of knowledge as well as networking,<br />
and renewal of friendships. Nurses at all levels involved in the delivery of care to<br />
patients with lung cancer will find this workshop stimulating and informative.<br />
Attendance will provide the opportunity to network with other nurses<br />
interested in lung cancer with outcomes from this workshop will provide<br />
direction for the future work of the ITONF Steering Committee.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Registration Opens (Breakfast provided)<br />
Welcome: ITONF Chair - Beth Ivimey, Australia<br />
Sympton Burden in Lung Cancer: Key note Speaker - Rebecca Lehto,<br />
USA<br />
Update on Positive Impact of Specialist Lung Cancer Nurses on Better<br />
Patient Outcomes - Angela Tod, United Kingdom<br />
Management of Toxicity of TKIs in a Nurse Practitioner Clinic - Michelle<br />
Turner ,USA<br />
Early Intervention - John McPhelim, United Kingdom<br />
Lung Cancer in Vulnerable Populations - Anne Fraser, New Zealand<br />
Radiation Induced Oesophagitis and Management - Mary Duffy,<br />
Australia<br />
*Registration fee: 25 USD<br />
07:30 - 11:00 Thoracic Alliance for Cancer Trials (TACT) Meetings<br />
Chair: Paul Mitchell, Australia<br />
Room: 205 + 207<br />
TACT is an emerging international non-profit umbrella organisation for<br />
academic research groups from around the world, dedicated to facilitating<br />
thoracic oncology research. Meetings will focus on discussion of progress<br />
updates as well as clinical research proposals.<br />
<br />
<br />
Steering Committee Meeting (Closed) - Paul Mitchell, Australia<br />
TACT Group Leaders' Meeting - Paul Mitchell, Australia<br />
3
<strong>Sunday</strong>, <strong>September</strong> 6, <strong>2015</strong><br />
07:30 - 11:00 Pancake Fun Walk<br />
<br />
Location: Sculpture Park, across the street from Colorado Convention<br />
Center, Champa and North Speer Blvd<br />
07:30 - 10:30 Joint IASLC – Chinese Society for Clinical Oncology – Chinese Alliance Against<br />
Lung Cancer Session*<br />
Supported by the China Health Promotion Foundation:<br />
Track: Joint Chinese/English Session<br />
Chairs: ChunXue Bai, China & Yi-Long Wu, China<br />
Room: Mile High Ballroom 1a - 1f<br />
Introduction - ChunXue Bai, China & Yi-Long Wu, China<br />
Molecular Epidemiology of Lung Cancer in China - Baohui Han, China<br />
Development of New Drugs by Chinese Pharmaceutical Companies -<br />
Qing Zhou, China<br />
Current Status of Molecular Testing in China: Application and<br />
Technology - Shun Lu, China<br />
Asian Contributions to Global Drug Development - Tony Mok, Hong<br />
Kong<br />
New Diagnostic Techniques for Lung Cancer - ChunXue Bai, China<br />
Oral Abstract Session (3 Abstracts and 1 Discussion) - Discussant: Yilong<br />
Wu, China<br />
Overview the Publishing of Cancer Special Issue - ChunXue Bai, China<br />
Challenges of Tobacco Related Lung Cancer in China - Suresh<br />
Ramalingam, USA<br />
Progress of Management for Lung Cancer: Focus on China - Jie Hu,<br />
China<br />
* Simultaneous translation English ↔ Mandarin provided<br />
07:30 - 11:00 YIS: Young Investigator Session: Q & A with Longstanding IASLC Members<br />
Track: YIS<br />
Chairs: Laurie Carr, USA & James Jett, USA<br />
Room: Mile High Ballroom 4a - 4f<br />
<br />
<br />
<br />
<br />
Introduction to IALSC: What It Can Do For You - David Carbone, USA<br />
Planning an Academic Career in Lung Cancer - Heather Wakelee, USA<br />
How to Write a Grant Application for Young Investigators - Steven<br />
Dubinett, USA<br />
How to Get Your Paper Published - Alex Adjei, USA<br />
4
<strong>Sunday</strong>, <strong>September</strong> 6, <strong>2015</strong><br />
<br />
<br />
<br />
How to Present Data at a Conference - Tony Mok, Hong Kong<br />
Making the Most of the WCLC: A Guide for First Time Attendees - Silvia<br />
Novello, Italy<br />
Q&A with Longstanding IASLC Members - Paul A. Bunn, Jr, USA &<br />
Desmond Carney, Ireland & Frances Shepherd, Canada & Masahiro<br />
Tsuboi, Japan<br />
08:00 - 11:00 Workshop: Fact and Myth of Pleural Effusion in Lung Cancer Patient (Ticketed<br />
Session)* - FULL<br />
Room: 102 + 104 + 106<br />
This workshop is now FULL<br />
3 hour workshop that includes didactic lectures on Pleuroscopy for the<br />
evaluation of cancer patients with pleural effusions; Pleurodesis and Indwelling<br />
Pleural Catheters as palliation measures; and surviving pleural effusion in lung<br />
cancer. Lectures are followed by hands on practice in pleuroscopy and<br />
indwelling pleural catheters.<br />
<br />
<br />
<br />
<br />
<br />
Fact and Myth of Pleuroscopy for Pleural Effusion in Lung Cancer - Pyng<br />
Lee, Singapore<br />
Fact and Myth of Pleurodesis and Indwelling Pleural Catheter for<br />
Malignant Pleural Effusion - Fabian Maldonado, USA<br />
HANDS ON: Assigned into Groups<br />
1 IPC Station: 2 Models and IPC Sets - TBA<br />
1 Olympus Flex-Rigid Pleuroscopy Stations and 2 Models - Pyng Lee,<br />
Singapore<br />
*Registration fee: 25 USD<br />
09:00 - 11:00 Workshop: Contouring for Radiation Treatment Planning of Lung Cancer<br />
(Ticketed Session)*<br />
Room: 601 + 603<br />
Important additional information: Early registration is encouraged. After<br />
registration, weekly emails with contouring homework exercises will be sent<br />
directly to the participant. To get the most from this workshop, the participant<br />
will complete and submit their contouring homework exercises as instructed,<br />
prior to the workshop, and are encouraged to bring their laptop to the<br />
workshop for post didactic contouring exercises.<br />
*Registration fee: 25 USD<br />
**Max. 100 attendees<br />
11:00 - 13:00 Navigation Bronchoscopy Workshop (Ticketed Session)*<br />
Chairs: Ali I. Musani, USA<br />
Faculty: Kendra Hammond, USA & Pyng Lee, Singapore<br />
5
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
07:00 - 08:00 Symposium supported by Helsinn Therapeutics, Inc.: Finding Solutions to<br />
Difficult Problems in Lung Cancer: Treatment of Cancer Cachexia<br />
Rooms: 601 + 603<br />
<br />
Webpage: www.prIMEoncology.org/nsclc_cachexia_denver<strong>2015</strong><br />
Target audience: This educational activity is specifically designed for medical,<br />
radiation, and surgical oncologists and other healthcare professionals interested<br />
and/or involved in the treatment of cancer cachexia in patients with non-small<br />
cell lung cancer (NSCLC).<br />
Symposium supported by AstraZeneca: Transforming Advanced Lung Cancer<br />
Into a Chronic Disease: Answering Key Questions<br />
Rooms: 205 + 207<br />
<br />
Webpage: www.prIMEoncology.org/<strong>2015</strong>nsclcdenver<br />
Target audience: This activity is designed to meet the needs of medical<br />
oncologists, surgical and radiation oncologists, pulmonologists, pathologists,<br />
and other healthcare professionals involved in the treatment of patients with<br />
NSCLC.<br />
Symposium supported by Biodesix: Blood-Based Biomarkers to Guide the<br />
Treatment of Advanced NSCLC<br />
Speaker: Leora Horn, USA<br />
Room: Mile High Ballroom 2a - 3b<br />
For some time now, the oncology community has been seeking easily accessible,<br />
non-invasive methods to identify molecular alterations and biomarkers that<br />
characterize advanced cancer. Following tissue diagnosis for advanced lung<br />
cancer, there may be insufficient tissue for further molecular testing and<br />
another biopsy is not always feasible. Blood-based testing is evolving as a useful<br />
prognostic and predictive tool and may have the potential to measure emerging<br />
resistance prior to detection of progression on conventional imaging. This<br />
educational program will:<br />
<br />
<br />
<br />
Review the unmet clinical needs across the continuum of care in nonsmall<br />
cell lung cancer (NSCLC)<br />
Assess genomic and proteomic technologies being utilized to measure<br />
blood-based biomarkers that are prognostic, predictive, and useful for<br />
detecting emerging resistance prior to conventional imaging<br />
Examine the analytic and clinical data associated with the current bloodbased<br />
tests that exist across the continuum care in NSCLC (both<br />
genomic and proteomic biomarkers)<br />
8
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
<br />
Introduce the challenges of tissue-based testing to predict response to<br />
immunotherapies<br />
Introduce early phase development of blood-based tests to predict<br />
response to immunotherapies<br />
© Biodesix, Inc. <strong>2015</strong>. ALL RIGHTS RESERVED.<br />
Symposium supported by Genentech: The PD-L1 Pathway in Cancer Immune<br />
Evasion<br />
Speakers: Daniel Morgensztern, USA<br />
Room: 401 - 404<br />
07:00 - 08:00 MTE 01: Meet the Expert: Endpoints in Clinical Trials in Advanced NSCLC<br />
(Ticketed Session)<br />
Track: Treatment of Advanced Disease - NSCLC<br />
Speakers: Tony Mok, Hong Kong & Gideon Blumenthal, USA<br />
Room: 103<br />
07:00 - 08:00 MTE 02: Meet the Expert: Patients, Investigators and Pharmaceuticals<br />
Working Together to Accelerate Research and Access: The Lung Cancer Master<br />
Protocol (Lung-MAP) Clinical Trial (Ticketed Session)<br />
Track: Advocacy<br />
Speakers: Vassiliki Papadimitrakopoulou, USA & Kim Norris, USA<br />
Room: 105<br />
07:00 - 08:00 MTE 03: Meet the Expert: Squamous Cell Lung Cancer (Ticketed Session)<br />
Track: Biology, Pathology & Molecular Testing<br />
Speaker: Howard West, USA<br />
Room: 107<br />
07:00 - 08:00 MTE 04: Meet the Expert: Molecular Testing in Community Settings (Ticketed<br />
Session)<br />
Track: Community Practice<br />
Speaker: John Longshore, USA<br />
Room: 109<br />
07:00 - 08:00 MTE 05: Meet the Expert: Role of the Interventional Pulmonologist and<br />
Medical Pleuroscopy (Ticketed Session)<br />
Track: Treatment of Localized Disease - NSCLC<br />
Speaker: Pyng Lee, Singapore<br />
9
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Room: 111<br />
07:00 - 08:00 MTE 06: Meet the Expert: Curative Radiotherapy for Local or Locoregional<br />
Disease (Ticketed Session)<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Speakers: Yasuhi Nagata, Japan & Joseph Salama, USA<br />
Room: 102 + 104 + 106<br />
07:00 - 08:00 MTE 07: Meet the Expert: Pharmacologic and Non-Pharmacologic<br />
Management of Dyspnea (Ticketed Session)<br />
Track: Palliative and Supportive Care<br />
Speaker: Alex Molasiotis, Hong Kong<br />
Room: 108 + 110 + 112<br />
07:00 - 08:00 MTE 08: Meet the Expert: Tobacco Control: What Do the Experts Do? (Ticketed<br />
Session)<br />
Track: Prevention & Tobacco Control<br />
Speakers: Emily Stone, Australia & Ellen Gritz, USA<br />
Room: 702 + 704 + 706<br />
07:00 - 08:00 MTE 09: Meet the Expert: Treatment of Advanced SCLC Including Second Line<br />
(Ticketed Session)<br />
Track: Small Cell Lung Cancer<br />
Speakers: Taofeek Owonikoko, USA & Caicun Zhou, China<br />
Room: 708 + 710 + 712<br />
07:00 - 08:00 MTE 10: Meet the Expert: Subsolid Nodules: What the Clinicians Need to Know<br />
/ Clinical Workup of CT Detected Nodules (Ticketed Session)<br />
Track: Screening and Early Detection<br />
Room: 703<br />
<br />
<br />
Subsolid Nodules: What the Clinicians Need to Know – Kavita Garg, USA<br />
Clinical Workup of CT Detected Nodules – Reginald Munden, USA<br />
07:00 - 08:00 MTE 11: Meet the Expert: Mediastinal Tumors Including Thymic Tumors,<br />
Lymphoma, Germ-Cell Tumors: Biology, Diagnosis and Treatment (Ticketed<br />
Session)<br />
Track: Thymoma, Mesothelioma & other Thoracic Malignancies<br />
Speakers: Lawrence Einhorn, USA & Gregory Riely, USA & Enrico Ruffini, Italy<br />
Room: 201 + 203<br />
10
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
08:15 - 09:45 Plen 01: Plenary Session: Lung Cancer Prevention and Screening<br />
Track: Plenary<br />
Chairs: Harvey Pass, USA & Carolyn Dresler, USA<br />
Room: Plenary Hall (Bellco Theatre)<br />
<br />
<br />
<br />
Lung Cancer Screening - Christine Berg, USA<br />
Epidemiology of Lung Cancer/Smoking in the World - David Christiani,<br />
USA<br />
Smoking by Lung Cancer Patients: Clinical, Biologic and Behavioral<br />
Considerations - Graham Warren, USA<br />
09:45 - 10:45 Networking Break and Poster Session 1<br />
Room: Exhibit Hall (Hall B + C)<br />
Refreshments will be provided<br />
09:45 - 10:45 Press Conference 2<br />
Moderator: Dr. James Jett, Congress Co-Chair, Professor of Medicine at National<br />
Jewish Health in Denver, Colo.<br />
Room: 108 + 110 + 112<br />
<br />
<br />
<br />
<br />
<br />
<br />
Daily Theme: Lung Cancer Prevention & Screening - Dr. Claudia<br />
Henschke, Professor of Radiology and head of Lung and Cardiac<br />
Screening Program at Mount Sinai Medical Center, New York<br />
New Tobacco Declaration from IASLC - Dr. Kenneth Michael Cummings,<br />
Chair of Tobacco Control and Smoking Cessation Committee, IASLC<br />
Abstract – Impact of Time to Drug Approval on Potential Years of Life<br />
Lost: The Compelling Need for Improved Trial and Regulatory Efficiency -<br />
Dr. David Stewart, Head, Division of Medical Oncology, University of<br />
Ottawa/The Ottawa Hospital<br />
Abstract – Results From Phase III Trials of Anamorelin in Advanced Non-<br />
Small Cell Lung Cancer Patients with Cachexia: ROMANA 1 and 2 - Dr.<br />
Philip Bonomi, Professor, Rush University Medical Center – Medical<br />
Oncology, Chicago, Ill.<br />
Abstract – Bevacizumab 15mg/kg Plus Cisplatin-Pemetrexed (CP) vs CP<br />
in Malignant Pleural Mesothelioma (MPM): IFCT-GFPC-0701 MAPS<br />
Randomized Phase 3 Trial - Dr. Arnaud Scherpereel, Head of the<br />
Pulmonary and Thoracic Oncology Department and Professor at the<br />
University Hospital (CHU) of Lille, France<br />
Q & A<br />
10:00 - 10:30 Exhibit Showcase Session: Lilly Oncology Metastatic Non-Small Cell Lung<br />
Cancer (NSCLC) Promotional Presentation<br />
11
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Phase 3, Randomized Trial (CheckMate 017) of Nivolumab (NIVO) vs<br />
Docetaxel in Advanced Squamous (SQ) Cell Non-Small Cell Lung Cancer<br />
(NSCLC) - Karen Reckamp, USA<br />
Safety and Efficacy of Nivolumab in an Ongoing Trial of a PD-L1+/-<br />
Patient Population with Metastatic Non-Small Cell Lung Cancer - Maen<br />
Hussein, USA<br />
Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of<br />
Nivolumab in Patients with Advanced, Refractory Squamous Non-Small<br />
Cell Lung Cancer - Leora Horn, USA<br />
Discussant - Solange Peters, Switzerland<br />
Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed<br />
Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) -<br />
Naiyer Rizvi, USA<br />
Evaluation of PD-L1 Expression in Metachronous Tumor Samples and<br />
FDG-PET as a Predictive Biomarker in Ph2 Study (FIR) of Atezolizumab<br />
(MPDL3280A) - Jamie Chaft, USA<br />
Atezolizumab (MPDL3280A) Combined with Platinum-Based<br />
Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): A Phase Ib Safety<br />
and Efficacy Update - D. Ross Camidge, USA<br />
Discussant - Glenwood Goss, Canada<br />
10:45 - 12:15 Oral Session 03: New Kinase Targets<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Fiona Blackhall, United Kingdom & Rosalyn Juergens, Canada<br />
Room: Mile High Ballroom 4a - 4f<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Anlotinib as 3rd-Line Treatment for Refractory Advanced NSCLC: A<br />
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2<br />
Trial - Baohui Han, China<br />
Is EGFR Exon20 Mutation a Prognostic/Predictive Biomarker in Our Lung<br />
Cancer Patients? - Deepa Joy Philip, India<br />
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of<br />
Sensitivity to Afatinib or Neratinib but Not to Other EGFR-TKIs -<br />
Yoshihisa Kobayashi, Japan<br />
Discussant - Howard West, USA<br />
Clinical Outcomes with Pemetrexed-Based Systemic Therapy in RET-<br />
Rearranged Lung Cancers - Alexander Drilon, USA<br />
Activity of Crizotinib in MET Amplified NSCLC: Preliminary Results of the<br />
AcSé Trial - Denis Moro-Sibilot, France<br />
Response to MET Inhibitors in Stage IV Lung Adenocarcinoma Patients<br />
with Mutations That Cause MET Exon 14 Skipping - Paul Paik, USA<br />
Discussant - Ravi Salgia, USA<br />
10:45 - 12:15 Oral Session 04: Adjuvant Therapy for Early Stage Lung Cancer<br />
Track: Treatment of Localized Disease - NSCLC<br />
Moderators: Eric Vallieres, USA & Yuichiro Ohe, Japan<br />
13
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Rooms: 205 + 207<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Final Results of Phase III Trial of Adjuvant Chemo?Immunotherapy in<br />
Lung Cancer - Hideki Kimura, Japan<br />
Research of Vascular Targeted Therapy in the Postoperative Adjuvant<br />
Chemotherapy for Lung Cancer - Zhiwei Chen, China<br />
Preliminary Results of the International Tailored Chemotherapy<br />
Adjuvant Trial: The ITACA Trial - Silvia Novello, Italy<br />
Discussant - Hossein Borghaei, USA<br />
Results Ph III Trial Customized Adjuvant CT after Resection of NSCLC<br />
with Lymph Node Metastases SCAT: A Spanish Lung Cancer Group Trial -<br />
Bartomeu Massuti, Spain<br />
Impact of demographic and health system factors on adjuvant<br />
chemotherapy use in stage II Non-small Cell Lung Carcinoma: A National<br />
Cancer Database analysis from 2000 to 2012 - Gaurav Goyal, USA<br />
Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell-Lung<br />
Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study -<br />
Vitezslav Kolek, Czech Republic<br />
Discussant - Giorgio Scagliotti, Italy<br />
10:45 - 12:15 Oral Session 05: Surgery<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Moderators: Paul Van Schil, Belgium & Feng-Ming (Spring) Kong, USA<br />
Rooms: 201 + 203<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Prognostic Value of 18F-FDG PET/CT in Surgical NSCLC: A Meta-Analysis<br />
- Ligang Xing, China<br />
Quality of Resection in Pathological N2 NSCLC in the Phase 3 Lung<br />
Adjuvant Radiotherapy Trial (Lung ART): An Important Factor - John<br />
Edwards, United Kingdom<br />
Transcervical Mediastinal and Hilar Lymphadenectomy (TCML) Provides<br />
Accurate Pre-Treatment Cancer Staging and Facilitates Resection -<br />
Robert Cameron, USA<br />
Discussant - Isabelle Opitz, Switzerland<br />
Trimodality Therapy in the Treatment of Stage IIIA Non-Small Cell Lung<br />
Cancer (NSCLC): A National Cancer Database Analysis - Madhusmita<br />
Behera, USA<br />
Long-Term Survival after Lobectomy for Locally Advanced NSCLC<br />
between Improved Video-Assisted Thoracoscopic Lobectomy and<br />
Thoracotomy - Kezhong Chen, China<br />
Mediastinal Lymphadenectomy Fulfilling NCCN Criteria May Improve<br />
the Outcome of Clinical N0-1 and Pathological N2 Non-Small Cell Lung<br />
Cancer - Nan Wu, China<br />
Discussant - Enrico Ruffini, Italy<br />
10:45 - 12:15 Oral Session 06: Next Generation Sequencing and Testing Implications<br />
14
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Gilberto De Lima Lopes, Brasil & Vincent Miller, USA<br />
Room: Mile High Ballroom 1a - 1f<br />
Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors -<br />
Lynnette Fernandez-Cuesta, France<br />
Targeted Deep Sequencing of EGFR/KRAS/ALK-Negative Lung<br />
Adenocarcinoma Reveals Potential Therapeutic Targets - Hye Ryun Kim,<br />
South Korea<br />
Genome-Wide Gene Copy Number Analysis by OncoScanTM FFPE Assay<br />
in 976 Resected NSCLC From LACE-Bio2 - Ming Tsao, Canada<br />
Discussant - Ramaswamy Govindan, USA<br />
Molecular Tumor Board (MTB) in Non-Small Cell Lung Cancers (NSCLC)<br />
to Optimize Targeted Therapies: 4 Years' Experience at Gustave Roussy -<br />
David Planchard, France<br />
Impact of Reflex EGFR/ALK Testing on Time-To-Treatment and<br />
Integration of Personalized Medicine in Advanced Non-Small Cell Lung<br />
Cancer Patients - Parneet Cheema, Canada<br />
An Integrated Cost-Effectiveness and Outcome Analysis Based on<br />
Multiplex Lung Cancer Genotyping in the Network Genomic Medicine -<br />
Anna Kostenko, Germany<br />
Discussant - Pan-Chyr Yang, Taiwan<br />
10:45 - 12:15 Oral Session 07: Lung Cancer Pathogenesis<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Julien Sage, USA & Elisabeth Brambilla, France<br />
Rooms: 102 + 104 + 106<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Evaluation of Epigenetic Mechanisms of Pluripotency in Human<br />
Respiratory Epithelia - Vivek Shukla, USA<br />
Metabolic Reprogramming in the Airway Epithelium of Individuals at<br />
High Risk for Lung Cancer - S.M Jamshedur Rahman, USA<br />
MMP12 and LMO7 Are Key Genes Involved in the Early Pathogenesis of<br />
Squamous Cell Carcinoma of the Lung - Vitor Teixeira, United Kingdom<br />
Discussant - Mary Beth Beasley, USA<br />
Differential Tumorigenic Properties of Mesenchymal Cells From<br />
Neoplastic and Non-Neoplastic Human Lung in NSCLC - Federico Quaini,<br />
Italy<br />
Sox2 Cooperates with Lkb1 Loss to Promote Mouse Model of Squamous<br />
Cell Lung Cancer - Trudy Oliver, USA<br />
Evidence and Mechanism for the Transdifferentiation of Lung<br />
Adenocarcinoma to Squamous Cell Carcinoma - Xiangkun Han, China<br />
Discussant - Yasushi Yatabe, Japan<br />
10:45 - 12:15 Oral Session 08: Smoking Cessation, Tobacco Control and Lung Cancer<br />
Track: Prevention and Tobacco Control<br />
15
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Moderators: Graham Warren, USA & Jacek Jassem, Poland<br />
Rooms: 601 + 603<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
The History of Tobacco Litigation in the United States - Kenneth<br />
Cummings, USA<br />
Interest in Smoking Cessation Treatment among Patients in a<br />
Community-Based Multidisciplinary Thoracic Oncology Program -<br />
Kenneth Ward, USA<br />
Smoking Cessation Before the Initiation of Chemotherapy in Metastatic<br />
NSCLC: Impact on Overall Survival - Marie-Hélène Lelièvre, Canada<br />
Discussant - Jamie Ostroff, USA<br />
Impact of an Inpatient Tobacco Cessation Service - Kenneth Cummings,<br />
USA<br />
Introducing Smoking Cessation Across Ontario's Cancer Treatment<br />
System: Early Successes and Continuing Challenges - William K Evans,<br />
Canada<br />
Primary Prevention of Lung Cancer in Poland - Successes and Challenges<br />
- Jacek Jassem, Poland<br />
Discussant - Emily Stone, Australia<br />
10:45 - 12:15 Oral Session 09: CT Screening - New Data and Risk Assessment<br />
Track: Screening and Early Detection<br />
Moderators: James Mulshine, USA & John Field, United Kingdom<br />
Room: Mile High Ballroom 2a - 3b<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Discerning Malignant and Benign New Nodules at Incidence Rounds of<br />
CT Lung Cancer Screening: The Role of Volume and Predicted Volume<br />
Doubling Time - Rozemarijn Vliegenthart, Netherlands<br />
Results of the Fourth Screening Round of the NELSON Lung Cancer<br />
Screening Study - Uraujh Yousaf-Khan, Netherlands<br />
The Danish Lung Cancer Screening Trial: Results 5 Years after Last CT<br />
Screening - Jesper Pedersen, Denmark<br />
Discussant - Nir Peled, Israel<br />
Lung-RADS versus the McWilliams Nodule Malignancy Score for Risk<br />
Prediction: Evaluation on the Danish Lung Cancer Screening Trial - Sarah<br />
Van Riel, Netherlands<br />
The Cancer Risk Management Model: A Tool to Inform Canadian<br />
Policymakers Implementing Low-Dose CT Screening for Lung Cancer -<br />
William K Evans, Canada<br />
Economic Evidence for the Use of Risk-Selection and Risk-Stratification<br />
for Lung Cancer Screening Programs - Sonya Cressman*, Canada<br />
Discussant - Stephen Malkoski, USA<br />
10:45 - 12:15 Oral Session 10: SCLC<br />
Track: Small Cell Lung Cancer<br />
Moderators: Corinne Faivre-Finn, United Kingdom & Primo Lara, USA<br />
16
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Rooms: 605 + 607<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
A DLL3-Targeted ADC, Rovalpituzumab Tesirine, Demonstrates<br />
Substantial Activity in a Phase I Study in Relapsed and Refractory SCLC -<br />
Charles Rudin, USA<br />
A Prospective Randomized Phase III Study of Continuum Chemotherapy<br />
versus Chemo-Radiotherapy in ES-SCLC in Asian Indian - Satya Narayan,<br />
India<br />
Which Patients with ES-SCLC Should Receive Thoracic Radiotherapy<br />
(TRT) Routinely? - Berend Slotman, Netherlands<br />
Pembrolizumab for ED SCLC: Efficacy and Relationship with PD-L1<br />
Expression - Patrick Ott, USA<br />
Discussant – Primo Lara, USA<br />
Long-Term Survival after Surgery for Pathologic N1 and N2 Small Cell<br />
Lung Cancer: A Comparison with Nonoperative Management - Chi-Fu<br />
Yang, USA<br />
Clinical and Molecular Profiling of Surgically Resected Small Cell Lung<br />
Cancer - Kei Takamura, Japan<br />
Discussant - David Ball, Australia<br />
10:45 - 12:15 Oral Session 11: Clinical Trials 1<br />
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies<br />
Moderators: Anna Nowak, Australia & Frank Detterbeck, USA<br />
Rooms: 702 + 704 + 706<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Phase I Study of Anti-Mesothelin Antibody Drug Conjugate Anetumab<br />
Ravtansine - Raffit Hassan, USA<br />
Single-Agent Pembrolizumab for Patients with Malignant Pleural<br />
Mesothelioma (MPM) - Evan Alley, USA<br />
Bevacizumab 15mg/kg Plus Cisplatin-Pemetrexed (CP) vs CP in<br />
Malignant Pleural Mesothelioma (MPM): IFCT-GFPC-0701 MAPS<br />
Randomized Phase 3 Trial - Arnaud Scherpereel, France<br />
Discussant - Dean Fennell, United Kingdom<br />
Phase II Trial of Single Agent Amrubicin in Patients with Previously<br />
Treated Advanced Thymic Malignancies - Heather Wakelee, USA<br />
A Prospective Phase II Study of Cisplatin and Cremorphor EL-Free<br />
Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial<br />
Tumors:: Can 18F-FDG PET/CT play a role? - Hae Su Kim, South Korea<br />
Computed Tomography (CT) Characteristics Associated with the<br />
Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma -<br />
Sukhmani Padda, USA<br />
Discussant - Nicolas Girard, France<br />
10:45 - 12:15 Oral Session 12: Quality of Life and Trials<br />
Track: Advocacy<br />
Moderators: Evi Bachrach Makovsky, USA & Christie Malnati, USA<br />
17
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Rooms: 708 + 710 + 712<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Priority of Daily Life v's Medical Care Challenges for Lung Cancer<br />
Patients and Carers - Aoife McNamara, Ireland<br />
The PACE Continuous Innovation IndicatorsTM: A New Tool to<br />
Objectively Measure Progress and Identify Unmet Needs in Lung Cancer<br />
Treatments - Silvia Paddock, USA<br />
The Predictors and Effects of Explicit and Implicit Attitudes Against Lung<br />
Cancer (LC) - Tsung-wei Ma, USA<br />
Discussant - Michael Weitz, USA<br />
Impact of Time to Drug Approval on Potential Years of Life Lost: The<br />
Compelling Need for Improved Trial and Regulatory Efficiency - David<br />
Stewart, Canada<br />
Trial Eligibility of NSCLC Patients Receiving Proton Therapy: Are<br />
Cooperative Group Trials Being Designed for the Right Patients? -<br />
Megan Dunn, USA<br />
Twitter: Is There an Opportunity to Improve Participation in Lung Cancer<br />
Clinical Trials? - Mina Sedrak, USA<br />
Discussant - David Sturges, USA<br />
10:45 - 12:15 Mini Oral 01: Pathology<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Wilbur Franklin, USA & Andrew Nicholson, United Kingdom<br />
Room: Mile High Ballroom 2c - 3c<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Immunohistochemical Distinction between Primary Lung Squamous Cell<br />
Carcinoma and Pulmonary Metastasis of Head and Neck Squamous Cell<br />
Carcinoma - Junji Ichinose, Japan<br />
Is It Possible to Distinguish between Second Primary vs Metastasis in<br />
Resectable Synchronous Nodules with the Same Histotype of Lung<br />
Cancer? - Giulia Luciano, United Kingdom<br />
Pathology-Imaging Agreement in Distinguishing Separate Primary<br />
Tumours and Intrapulmonary Metastasis in Staging of Multiple Lung<br />
Cancers - Patrizia Viola, United Kingdom<br />
Discussant - Natasha Rekhtman, USA<br />
Local Diagnostic Practices for Advanced Non-Small-Cell Lung Cancer in<br />
Europe and Japan: ASSESS Study - Nicola Normanno, Italy<br />
Pathological Second-Predominant Component Predicts Recurrence in<br />
Lung Adenocarcinoma - Masaoki Ito, Japan<br />
Comparison of Grading Systems Based on Histologic Patterns and<br />
Mitotic Activity to Predict Recurrence in Stage I Lung Adenocarcinoma<br />
(ADC) - Kay See Tan, USA<br />
Survival Differences of Adenocarcinoma Lung Tumors with Squamous<br />
Cell Carcinoma or Neuroendocrine Profiles by Gene Expression<br />
Subtyping - Hawazin Faruki, USA<br />
Discussant - Erik Thunnissen, Netherlands<br />
18
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Analysis of the Status of Lymphocyte Infiltration in Patients with NSCLC -<br />
Martin Richardet, Argentina<br />
Transcriptome Sequencing of Tumor vs. Surrounding Non-Malignant<br />
Lung Tissue in Non-Small Cell Lung Cancer - Dirk De Ruysscher, Belgium<br />
Implementation of a Molecular Tumor Board: The Impact on Treatment<br />
Decisions for NSCLC Patients Evaluated at Dartmouth-Hitchcock in One<br />
Year - Laura Tafe, USA<br />
Biologically Driven Sub-Classification of Early Lung Adenocarcinomas -<br />
John Le Quesne, United Kingdom<br />
Discussant - Katerina Politi, USA<br />
10:45 - 12:15 Mini Oral 02: Immunotherapy<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Patrick Forde,USA & Scott Antonia, USA<br />
Room: Four Seasons Ballroom F3 + F4<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Pulmonary Large Cell Carcinoma and Solid Adenocarcinoma Are Highly<br />
Mutated with Frequent Expression of PDL1 - Lynette Sholl, USA<br />
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung<br />
Adenocarcinomas and Nodal Metastases - Hironori Uruga, USA<br />
Overexpression of CD47, Decrease of Apoptosis and Phagocytosis of<br />
Neutrophils in Advanced Non-Small Cell Lung Cancer Patients - Lourdes<br />
Barrera, Mexico<br />
Sequential Assessment of DNA Damage Response and PD-L1 Expression<br />
in Circulating Tumor Cells of Lung Cancer Patients during Radiotherapy -<br />
Steven Lin, USA<br />
Discussant - David Carbone, USA<br />
Humanized Immuno-Mouse for Study of Anti-PD-1 Therapy in KRAS-<br />
Mutated Lung Cancer Patient Derived Xenotransplant (PDX) - James<br />
Keck, USA<br />
Preclinical Rationale for a Phase I/II Study of Pembrolizumab (P) and<br />
Vorinostat (V) in Immune Therapy Naïve and Pretreated Stage IV NSCLC<br />
- Nishan Tchekmedyian, USA<br />
Bidirectional Cross-Talk between CD14+ Monocytes and Human Lung<br />
Cancer Cell Lines Results in Different Phenotypic and Functional<br />
Outcomes - Erin Schenk, USA<br />
ERK Activation Mediates Increased PD-L1 Expression in KRAS Mutated<br />
Premalignant Human Bronchial Epithelial Cells - Jay Lee, USA<br />
Discussant - Ignacio Wistuba, USA<br />
Immunological Markers Predict the Prognosis of Patients with<br />
Squamous Non-Small Cell Lung Cancer - Long Jiang, China<br />
Distribution of Immune Markers and Their Association with Overall<br />
Survival and Time to Progression in Non-Small-Cell Lung Cancer (NSCLC)<br />
- Andrew Kuykendall, USA<br />
Immune Related Gene Signature Reveal Potential Role for Leukocyte-<br />
Associated Immunoglobin-Like Receptor 2 (LAIR2) in Lung Cancer<br />
Regulation - Dalam Ly, Canada<br />
19
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
Discussant - Vassiliki Papadimitrakopoulou, USA<br />
12:30 - 14:00 Symposium supported by Lilly: Beyond The Guidelines - Management of<br />
Patients with Non-Small Cell Lung Cancer without Targetable Tumor<br />
Mutations<br />
Room: Plenary Hall (Bellco Theatre)<br />
<br />
Webpage: www.researchtopractice.com/Meetings/IASLC<strong>2015</strong>/NSCLC<br />
14:15 - 15:45 MS 01: Mini Symposium: How to Treat Multiple GGO’s<br />
Track: Treatment of Localized Disease - NSCLC<br />
Chairs: Jessica Donington, USA & Masahiro Tsuboi, Japan<br />
Rooms: 102 + 104 + 106<br />
What is the Appropriate Diagnostic Technique in the Setting of Multiple<br />
GGO’s? - Charles Powell, USA<br />
What is the Role of Surgical Resection in the Setting of Multiple GGO’s?<br />
- Raja Flores, USA<br />
Is There a Role for Targeted Therapy or Conventional Chemotherapy in<br />
Patients with Multiple GGO’s? - Benjamin Levy, USA<br />
The Pathologic Classification of GGO’s - Clinical Pathologic Correlation -<br />
Erik Thunnissen, Netherlands<br />
14:15 - 15:45 MS 02: Mini Symposium: Are Non-Tissue Biomarkers Ready for the Clinic?<br />
Track: Screening and Early Detection<br />
Chairs: Andreas-Claudius Hoffmann, Germany & Luis Montuenga, Spain<br />
Rooms: 401 - 404<br />
<br />
<br />
<br />
<br />
Free Circulating Tumor DNA - Philip Mack, USA<br />
Circulating Tumor Cells - Tilak Sundaresan, USA<br />
Blood-Based Proteomics Strategies for the Early Detection of Lung<br />
Cancer – Ruben Pío, Spain<br />
Exhaled Breath - Nir Peled, Israel<br />
14:15 - 15:45 MS 03: Mini Symposium: Is Tumor Angiogenesis Still a Viable Target in<br />
Advanced NSCLC?<br />
Track: Treatment of Advanced Disease - NSCLC<br />
Chairs: Sanjay Popat, United Kingdom & Qinghua Zhou, China<br />
Rooms: 605 + 607<br />
<br />
<br />
Current Understanding of the Biology - John Heymach, USA<br />
Anti-Angiogenic Therapy: Current and Future Agents - Suresh<br />
Ramalingam, USA<br />
20
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
<br />
Where are we with Defining Potential Biomarkers - Geoffrey Liu,<br />
Canada<br />
An Update on Clinical Trials: Is Tumor Angiogenesis Still a Viable Target<br />
in Advanced NSCLC? - Heather Wakelee, USA<br />
14:15 - 15:45 MS 04: Mini Symposium: Harnessing the Full Potential of the Immune System<br />
Track: Treatment of Advanced Disease - NSCLC<br />
Chairs: Charles Butts, Canada & Patrick Forde, USA<br />
Room: Four Seasons Ballroom F3 + F4<br />
<br />
<br />
<br />
<br />
PD1/PDL1 Studies - Roy Herbst, USA<br />
Other Immune Inhibitors - Naiyer Rizvi, USA<br />
Vaccines - Johan Vansteenkiste, Belgium<br />
Microenvironment as a Target - Steven Albelda, USA<br />
14:15 - 15:45 MS 05: Mini Symposium: Tumor Heterogeneity<br />
Track: Biology, Pathology & Molecular Testing<br />
Chairs: Sanja Dacic, USA & Andrew Nicholson, United Kingdom<br />
Room: Mile High Ballroom 1a – 1f<br />
<br />
<br />
<br />
<br />
Overview of Tumor Heterogeneity - Charles Swanton, United Kingdom<br />
How Does Tumor Heterogeneity Affect Molecular Testing on Biopsy<br />
Samples - Diagnostic vs. Rebiopsy (Resistance) - Keith Kerr, United<br />
Kingdom<br />
Genomic Evolution and Tumor Heterogeneity - David Sidransky, USA<br />
Heterogeneity and Drug Resistance - Solange Peters, Switzerland<br />
14:15 - 15:45 MS 06: Mini Symposium: Regulation of Tobacco Products<br />
Track: Prevention & Tobacco Control<br />
Chairs: Edgardo Santos, USA & Nise Yamaguchi, Brazil<br />
Rooms: 201 + 203<br />
<br />
<br />
<br />
<br />
Global Effects of Smoking, of Quitting, and of Taxing Tobacco - Luk<br />
Joossens, Belgium<br />
The Framework Convention on Tobacco Control - Geoffrey Fong,<br />
Canada<br />
FDA Regulation of Tobacco Products in the US - Mitch Zeller, USA<br />
The Role of Litigation in Controlling Tobacco Use - Richard Daynard,<br />
USA<br />
14:15 - 15:45 MS 07: Mini Symposium: SCLC Biology & Models<br />
Track: Small Cell Lung Cancer / Biology, Pathology & Molecular Testing<br />
Chairs: Desmond Carney, Ireland & Charles Rudin, USA<br />
21
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Room: Mile High Ballroom 4a – 4f<br />
PDX Models - Charles Rudin, USA<br />
GEM Models (p53/Rb) - Kate Sutherland, Australia<br />
Pre-Clinical Mouse Models of SCLC to Identify and Validate New<br />
Therapeutic Targets - Julien Sage, USA<br />
From GEMMs to ROCKs – An Assessment of In Vitro Models for the<br />
Study of SCLC - Adi Gazdar, USA<br />
Circulating Tumour Cells - Fiona Blackhall, United Kingdom<br />
14:15 - 15:45 MS 08: Mini Symposium: BAP1 Cancer Syndrome and Mesothelioma<br />
Track: Thymoma, Mesothelioma & other Thoracic Malignancies<br />
Chairs: Lee Krug, USA & Nico Van Zandwijk, Australia<br />
Rooms: 702 + 704 + 706<br />
<br />
<br />
<br />
<br />
Mesothelioma and BAP1 Germline Mutations - Michele Carbone, USA<br />
BAP1 and Ubiquitination - El Bachir Affar, Canada<br />
Screening for BAP1 in Danish Families - Karin Wadt, Denmark<br />
BAP1: Lessons from Renal Cell Carcinoma - James Brugarolas, USA<br />
14:15 - 15:45 MS 09: Mini Symposium: Worldwide Perspective/Review of Limitations,<br />
Resources, Programs and Accomplishments of Supportive Care and Palliative<br />
Care Multidisciplinary Teams, by Continent<br />
Track: Palliative and Supportive Care<br />
Chairs: Roberto Ivan Lopez, Panama & Ana Oton, USA<br />
Rooms: 108 + 110 + 112<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Part 1: The Palliative Care Multidisciplinary Team and Worldwide<br />
Perspective<br />
Nurse’s Perspective - Teresa Trabert, USA<br />
Doctor’s Perspective – Hitesh Bhanabhai, Canada<br />
Radiation Oncologist’s Perspective - Jeffrey Bradley, USA<br />
Patient and Caregiver’s Perspective - Regina Fink, USA<br />
Part 2: Review of Limitations, Resources, Programs and<br />
Accomplishments of Supportive Care and Palliative Care<br />
Multidisciplinary Teams, by Continent<br />
Latin America - Eduardo Arnoldo Richardet, Argentina<br />
Africa - Moawia Elhassan, Sudan<br />
Asia/Oceania - Craig Underhill, Australia<br />
Supportive Care and Palliative Care in Europe - Jorn Herrstedt, Denmark<br />
14:15 - 15:45 MS 10: Mini Symposium: Management of Screening Detected Lung Cancer<br />
Track: Treatment of Localized Disease - NSCLC / Screening and Early Detection<br />
Chairs: Peter Goldstraw, United Kingdom, Norihiko Ikeda, Japan, Bernard Park,<br />
USA & Luis Raez, USA<br />
22
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Room: Mile High Ballroom 2c - 3c<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Epidemiology of Lung Cancer and Smoking - Ping Yang, USA<br />
Positive Lung Cancer Screens - Which Ones are Lung Cancer? - Martin<br />
Tammemägi, Canada<br />
What is the Ideal Method of Diagnosis for Screening Detected Lung<br />
Nodules? - Doug Minnich, USA<br />
When to Intervene on Screening Detected Lung Nodules - Giulia<br />
Veronesi, Italy<br />
Rationale for Sublobar Resection for Early Cancer - Hisao Asamura,<br />
Japan<br />
Is There a Role for SBRT in Screening Detected Non-Diagnosed Lung<br />
Nodules? - David Palma, Canada<br />
Biomarkers: Current Status and Future Direction - Rob Young, New<br />
Zealand<br />
14:15 - 15:45 ED 01: Education Session: Update in Radiation Oncology<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Chairs: Walter Curran, USA & Paul van Houtte, Belgium<br />
Rooms: 205 + 207<br />
<br />
<br />
<br />
<br />
Current Status of Proton and Heavy Particle Therapy - Hak Choy, USA<br />
Optimal Dose and Fractionation - James Urbanic, USA<br />
Post-Operative Radiotherapy for Stage III Disease - Francoise Mornex,<br />
France<br />
Evolving Role of Radiation for Oligometastases - Benjamin Movsas, USA<br />
14:15 - 15:45 ED 02: Education Session: Molecular Testing Around the World (Genomics in<br />
Clinic (Timelines/Bioinformatics), Testing Platforms & Algorithms (NGS,<br />
Targeted Panels, FISH, IHC), Cost Considerations, Strategies for Identifying<br />
Rare Genomic Subsets in Clinical Trials)<br />
Track: Biology, Pathology & Molecular Testing<br />
Chairs: Marc Ladanyi, USA & Gilberto Lopes, Brazil<br />
Room: Four Seasons Ballroom F1 + F2<br />
<br />
<br />
<br />
<br />
North America - Vincent Miller, USA<br />
Asia - Jin-Haeng Chung, South Korea<br />
Europe – Céline Mascaux, Belgium<br />
Central/South America - Lilian (Mercedes) Dalurzo, Argentina<br />
14:15 - 15:45 ED 03: Education Session: Global Lung Cancer Coalition – Data-Driven Lung<br />
Cancer Advocacy<br />
Track: Advocacy<br />
Chairs: Maureen Rigney, USA & Joan Schiller, USA<br />
Room: 703<br />
23
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Global Lung Cancer E-Atlas - How Can This be Ssed as a Tool to Advocate<br />
for Change? - Sarah Winstone, United Kingdom<br />
Bibliometric Research on Published Lung Cancer Research - What are<br />
the Implications for Policy Work? - Richard Sullivan, United Kingdom<br />
The Value of National Lung Cancer Audit Data - The UK Experience -<br />
Jesme Fox, United Kingdom<br />
Advocating for Tobacco Control - The Australia Experience - Matthew<br />
Peters, Australia<br />
14:15 - 15:45 ED 04: Education Session: How to Set Up a Multidisciplinary Lung Cancer<br />
Program within a Community Care Environment and Provide Everyone with<br />
the Best Care for Lung Cancer<br />
Track: Community Practice<br />
Chairs: Juan Manuel Luna, Guatemala & Samir Witta, USA<br />
Room: Mile High Ballroom 2a - 3b<br />
<br />
<br />
<br />
<br />
<br />
<br />
How can Multi-Disciplinary Care be Executed at the Private Practice<br />
Level? - Eric Edell, USA<br />
How can we Strengthen MD Care in Large Hospital Systems? - Kathryn<br />
Mileham, USA<br />
Treating Diverse Communities - Laurie Carr, USA<br />
Differences in Rural/Urban Care - Craig Reynolds, USA<br />
The Use of Pathways to Guide Consistency - Edward Kim, USA<br />
Evaluating Quality of Care Outcomes from Screening to Treatment in<br />
Community Based Settings - Richard Booton, United Kingdom<br />
14:15 - 15:45 ED 05: Education Session: Case Presentations (3 lung cancer and 1<br />
mesothelioma) discussed in round table format<br />
Track: Nursing and Allied Professionals<br />
Chairs: Mary Duffy, Australia & Mary Hesdorffer, USA<br />
Rooms: 708 + 710 + 712<br />
<br />
<br />
<br />
<br />
<br />
<br />
Nursing - Patricia Palmer, USA<br />
Respiratory Therapy - Larry Di Fabrizio, USA<br />
Approach to Offering Remote Support to Mesothelioma Patients: The<br />
Mesothelioma Survivor Project – Gleneara Bates, USA<br />
Physician Assistant - Heather Grillo, USA<br />
PharmD - Ellen McGrath, USA<br />
Nurse Practitioner - Michelle Turner, USA<br />
14:15 - 15:45 Pro Con PC 01: Surgery vs. SBRT in Operable NSCLC<br />
Track: Treatment of Localized Disease - NSCLC / Treatment of Locoregional<br />
Disease - NSCLC<br />
Chairs: David Harpole, USA & Pan-Chyr Yang, Taiwan<br />
24
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Rooms: 601 + 603<br />
SBRT - Suresh Senan, Netherlands<br />
Surgery - Paul Van Schil, Belgium<br />
Pro Con PC 01: Pro vs Con: SBRT for Non-Biopsied Lung Nodules<br />
Track: Treatment of Localized Disease - NSCLC / Treatment of Locoregional<br />
Disease - NSCLC<br />
Chairs: Philip Bonomi, USA & Antoinette Wozniak, USA<br />
Rooms: 601 + 603<br />
<br />
<br />
Pro - Kenneth Rosenzweig, USA<br />
Con - Robert Timmerman, USA<br />
15:45 – 16:45 Networking Break and Poster Session 1<br />
Room: Exhibit Hall (Hall B + C)<br />
16:00 – 16:30 Exhibit Showcase Session: Lilly: Challenges with Squamous Non-Small Cell<br />
Lung Cancer<br />
Room: Exhibit Showcase Theater in the Exhibit Hall (Halls B + C)<br />
16:45 - 18:15 Advocacy in Action<br />
Room: 103<br />
Advocacy in Action (AIA) is Vital Options International’s signature platform for<br />
bringing together a cross-section of cancer advocates, patients, and healthcare<br />
professionals in settings across the globe to address key issues in cancer and the<br />
realities of those facing, fighting, and surviving cancer. At the <strong>2015</strong> World<br />
Conference on Lung Cancer AIA will be joining forces with IASLC and lung cancer<br />
advocates from around the globe to discuss:<br />
<br />
<br />
Lung Cancer Screening Worldwide<br />
Access to Care: What Are the Biggest Challenges for Lung Cancer<br />
Patients?<br />
16:45 - 18:15 Oral Session 13: Immunotherapy Biomarkers<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Dong-Wan Kim, South Korea & Dominique Grunenwald, France<br />
Room: Four Seasons Ballroom F3 + F4<br />
<br />
PD-L1 Expression in Lung Adenocarcinomas Correlates with KRAS<br />
Mutations and Th1/Cytotoxic T Lymphocyte Microenvironment - Mari<br />
Mino-Kenudson, USA<br />
25
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Characterization of PD-L1 Expression Related to Unique Genes in NSCLC<br />
Tissue Samples - Edward Garon, USA<br />
Spatiotemporal Effects on Programmed Death Ligand 1 (PD-L1)<br />
Expression and Immunophenotype of Non-Small Cell Lung Cancer<br />
(NSCLC) - Marcin Kowanetz, USA<br />
Discussant - Scott Gettinger, USA<br />
Predictive Biomarker Testing for Programmed Cell Death 1 Inhibition in<br />
Non-Small Cell Lung Cancer - Brandon Sheffield, Canada<br />
PDL-1 Expression in NSCLC: Analysis of a Large Early Stage Cohort; And<br />
Concordance of Expression in Primary, Nodes and Metastasis - Paul<br />
Mitchell, Australia<br />
EMT Is Associated with an Inflammatory Tumor Microenvironment with<br />
Elevation of Immune Checkpoints and Suppressive Cytokines in Lung<br />
Cancer - Yanyan Lou, USA<br />
Discussant - David Rimm, USA<br />
16:45 - 18:15 Oral Session 14: Biology 2<br />
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies<br />
Moderators: Takashi Nakano, Japan & Paul Baas, Netherlands<br />
Rooms: 702 + 704 + 706<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Early Contrast Enhancement as a Non-Invasive Objective Biomarker of<br />
Pleural Malignancy - Selina Tsim, United Kingdom<br />
Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma<br />
- Nobukazu Fujimoto, Japan<br />
Integrin Linked Kinase Pathway: A Potential Driver of Tumorigenesis of<br />
Malignant Pleural Mesothelioma - Assunta De Rienzo, USA<br />
Discussant - David Schrump, USA<br />
Intracavitary Cisplatin-Fibrin After Resection of Malignant Pleural<br />
Mesothelioma - Isabelle Opitz, Switzerland<br />
MesobanK - an International Mesothelioma Tissue Bioresource - Now<br />
Open for Tissue Requests - Robert Rintoul, United Kingdom<br />
Preclinical Investigation of the Therapeutic Potential of Nintedanib in<br />
Malignant Pleural Mesothelioma - Viktoria Laszlo, Austria<br />
Discussant - Hedy Lee Kindler, USA<br />
16:45 - 18:15 Oral Session 15: Outcome Management in Lung Cancer Patients<br />
Track: Nursing and Allied Professionals<br />
Moderators: Kahren White, USA & Molly Freeman, USA<br />
Rooms: 102 + 104 + 106<br />
Changes in Symptom Occurrence Rates from before through 12 Months<br />
following Lung Cancer Surgery - Trine Oksholm, Norway<br />
Identification and Management of Unique Immune Mediated Toxicities -<br />
Marianne Davies, USA<br />
26
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
Application of Ultrasound-Guided Femoral Venous Catheters Inserted at<br />
Various Sites in Patients with Superior Vena Cava Obstruction - Zhang<br />
Hui, China<br />
Discussant - Beth Sandy, USA<br />
Using Your Voice (UYV) - How to Use Your Nursing Voice at the Multi-<br />
Disciplinary Team (MDT) Meeting - Lavinia Magee, United Kingdom<br />
A Prospective Audit on Smoking Cessation and Lung Cancer Nurse<br />
Specialist Intervention within a Thoracic Oncology Service - Lavinia<br />
Magee, United Kingdom<br />
I Am Dying of Mesothelioma - Carol Davies, United Kingdom<br />
Discussant - Mary Duffy, Australia<br />
16:45 - 18:15 Mini Oral 03: PD1 Axis Inhibition and EGFR<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Leena Gandhi, USA & Yuichiro Ohe, Japan<br />
Room: Four Seasons Ballrom F1 + F2<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Prior TKI Therapy in NSCLC EGFR Mutant Patients Associates with Lack<br />
of Response to Anti-PD-1 Treatment - Jonathan W. Goldman, USA<br />
PD-L1 Displays a Funtional Effect in the Acquired Chemoresistance in<br />
Lung Cancer - Panpan Zhang, China<br />
Pembrolizumab 2 mg/kg Q3W for Previously Treated, PD-L1?Positive<br />
Advanced NSCLC - Øystein Fløtten, Norway<br />
Discussant - Julie Brahmer, USA<br />
Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced<br />
NSCLC - Matthew Hellmann, USA<br />
Phase II Studies of Nivolumab in Patients with Advanced Squamous (SQ)<br />
or Non-Squamous (NSQ) Non-Small-Cell Lung Cancer (NSCLC) - Kazuhiko<br />
Nakagawa, Japan<br />
Clinical Attributes of Lung Cancer in US Community Oncology Practice:<br />
Implications for Immunotherapy - Praveen Reddy, USA<br />
Discussant - Jhanelle Gray, USA<br />
Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with<br />
EGFR-Mutant Advanced Non-Small Cell Lung Cancer - Qiu -Yi Zhang,<br />
China<br />
Rociletinib in NSCLC Patients with Negative Central Testing for T790M in<br />
TIGER-X - Heather Wakelee, USA<br />
Discussant - Christian Rolfo, Belgium<br />
16:45 - 18:15 Mini Oral 04: Clinical Care of Lung Cancer<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Laurie Gaspar, USA & Virginie Westeel, France<br />
Room: Mile High Ballroom 2c - 3c<br />
<br />
Years of Life Lost and Lifetime Earnings Lost in Metastatic Lung Cancer:<br />
Potential Societal Benefits of Improved Survival by Age and Histology -<br />
Mark Danese, USA<br />
27
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Value of Innovation in Systemic Therapy for US Patients with<br />
Advanced/Metastatic NSCLC - Jonas Nilsson, Sweden<br />
Real-World Patterns of Access to Cancer Specialist Care Among Patients<br />
With Lung Cancer in the United States: A Claims Database Analysis -<br />
Hossein Borghaei, USA<br />
Economic Burden of Lung Cancer Patients Treated in Clinical Trials:<br />
Experience from a Comprehensive Cancer Center in Germany - Florian<br />
Kron, Germany<br />
Discussant - Natasha Leighl, Canada<br />
During-Treatment PET Metabolic Tumor Volume (MTV) Instead of FDG<br />
Activity Is Predictive of Survival in Patients with Non-Small Cell Lung<br />
Cancer - Feng-Ming (Spring) Kong, USA<br />
Changes in Skeletal Muscle Index and Body Mass Are Prognostic Factors<br />
in First Line Stage IV Non-Small Cell Lung Cancer (NCSCL) Patients - Mary<br />
Fidler, USA<br />
Malignant Pleural Effusions Are Predictive of Peritoneal Carcinomatosis<br />
in Patients with Advanced EGFR Positive Non-Small Cell Lung Cancer -<br />
Tejas Patil, USA<br />
The Impact of Next-Generation Sequencing on Clinical Decisions in Lung<br />
Cancer - Anna Belilovski Rozenblum, Israel<br />
Discussant - Karen Reckamp, USA<br />
Incidence of Brain Metastasis in Non-Small Cell Lung Cancer Over Eleven<br />
Years at a Single Canadian Institution - Adrijana D'Silva, Canada<br />
Systematic Review of Brain Metastases in Non-Small Cell Lung Cancer<br />
(NSCLC) in the United States, European Union, and Japan - D. Christian<br />
Fenske, USA<br />
Survival Analysis of 51 Leptomeningeal Metastatic Non Small Cell Lung<br />
Cancer Patients Treated with Whole Brain Radiotherapy - Erkan Topkan,<br />
Turkey<br />
Comparative Survival in Patients with Brain Metastases from Non-Small<br />
Cell Lung Cancer Treated before and after Implementation of<br />
Radiosurgery - Anand Swaminath, Canada<br />
Discussant - Sue Yom, USA<br />
16:45 - 18:15 Mini Oral 05: EGFR Mutant Lung Cancer 1<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderator: Yasushi Yatabe, Japan & Roman Perez-Soler, USA<br />
Room: Mile High Ballroom 2a - 3b<br />
A Progression Free Survival Score for EGFR Mutant Non-Small Cell Lung<br />
Cancer Patients Treat with First Line EGFR Tyrosine Kinase Inhibitors -<br />
Yu-Mu Chen, Taiwan<br />
Impact of ABCG2 Polymorphisms on the Clinical Outcome of TKIs<br />
Therapy in Chinese Advanced Non-Small-Cell Lung Cancer Patients -<br />
Xueqin Chen, China<br />
P53 Disruptive Mutation Is a Negative Predictive Factor in EGFR M+<br />
NSCLC Treated with TKI - Frank Griesinger, Germany<br />
28
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Survival Outcome Assessed According to Tumor Burden & Progression<br />
Patterns in Patients with EGFR Mutant NSCLC Undergoing EGFR-TKIs -<br />
Yoon Ki Cha, South Korea<br />
Discussant - Federico Cappuzzo, Italy<br />
Continuation of Epidermal Growth Factor Receptor Tyrosine Kinase<br />
Inhibitor Treatment Prolongs Disease Control in Non-Small-Cell Lung<br />
Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors - Qi<br />
Chen, China<br />
A Phase Ib/II Study of Afainib plus Nimotuzumab in Non-Small Cell Lung<br />
Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib - Ji<br />
Yun Lee, South Korea<br />
Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in<br />
EGFR Mutation/ALK Translocation Metastatic Non-Small Cell Lung<br />
Cancer - chunxia Su, China<br />
Comparison of the Efficacy of Dacomitinib v Erlotinib for NSCLC Pts with<br />
Del 19/L858R - Suresh Ramalingam, USA<br />
Discussant - Renato Martins, USA<br />
EGFR-TKI Alone or with Concomitant Radiotherapy for Brain Metastases<br />
in Lung Adenocarcinoma Patients with EGFR Gene Mutations -<br />
Yongshun Chen, China<br />
Exon 19 Deletion Prolongs Survival in Brain Metastases from Non-Small<br />
Cell Lung Cancer - Hongwei Li, China<br />
Erlotinib Combined with Chemotherapy versus Erlotinib Alone Treating<br />
Advanced Lung Adenocarcinoma with Brain Metastases (NCT01578668)<br />
- Haihong Yang, China<br />
Treatment of EGFR/ALK-Driven Non-Small Cell Lung Cancer (NSCLC)<br />
Brain Metastases: Impact of First-Line Whole Brain Radiotherapy on<br />
Outcome - Mark Doherty, Canada<br />
Discussant - Benjamin Solomon, Australia<br />
16:45 - 18:15 Mini Oral 06: Quality/Prognosis/Survival<br />
Track: Treatment of Localized Disease - NSCLC<br />
Moderators: Robert Meguid, USA & Junji Yoshida, Japan<br />
Rooms: 605 + 607<br />
<br />
<br />
<br />
<br />
<br />
Prognostic Impact of Visceral Pleural Invasion and Its Degrees in Non-<br />
Small Cell Lung Cancer: A SEER Database Analysis - Lilan Zhao, China<br />
T1a Lung Adenocarcinomas: Presence of Spread of Tumor through<br />
Alveolar Spaces (STAS), Micropapillary and Solid Patterns Determines<br />
Outcomes - Kyuichi Kadota, Japan<br />
Improved Survival in Patients with Stage I-II NSCLC Treated with Surgery<br />
or Radiotherapy in the Department of Veterans Affairs - Joseph Salama,<br />
USA<br />
Impact of Attainment of the American College of Surgeons Commission<br />
on Cancer Quality Measure on Patient Survival After Lung Cancer<br />
Resection - Xinhua Yu, USA<br />
Discussant - David Harpole, USA<br />
29
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Early-Stage Lung Cancer Treatment and Survival: Impact of Race -<br />
Michael Kelley, USA<br />
High Incidence of PD-L1 Expression in Surgically Resected Pulmonary<br />
Lymphoepithelioma-Like Carcinoma Is Linked to Prognosis - Yunpeng<br />
Yang, China<br />
Recognition Of "Aggressive" Nodal Metastatic Behavior In "Indolent"<br />
Ground Glass Opacity Lesions - Junyan Zha, China<br />
Aerogeneous Spread Is a Predictive Factor of Recurrence in Stage I Lung<br />
Adenocarcinoma - Satoshi Shiono, Japan<br />
Discussant - Odd Terje Brustugun, Norway<br />
The Influence of Body Mass Index on Overall Survival following Surgical<br />
Resection of Non-Small Cell Lung Cancer - Kathryn Gold, USA<br />
Prognostic Impact of Cancer-involved Lymph Node Ratio in Resected<br />
NSCLC Differ between 'N1' or 'N2' Disease - Wenhua Liang, China<br />
Multiple Lung Cancers: Is Their Survival Better or Worse Then Other<br />
Lung Cancers? - Jarushka Naidoo, USA<br />
The Impact of Serum EGFR Levels on Survival of Resected Patients with<br />
Non-Small Cell Lung Cancer - Elvin Hekimoglu, Turkey<br />
Discussant - Gavin Wright, Australia<br />
16:45 - 18:15 Mini Oral 07: ChemoRT and Translational Science<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Moderators: David Raben, USA & Brian Kavanagh, USA<br />
Rooms: 201 + 203<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
A Randomized Phase II Study of S-1 and Cisplatin vs Vinorelbine and<br />
Cisplatin with Concurrent Radiotherapy for Locally Advanced NSCLC:<br />
WJOG5008L - Junichi Shimizu, Japan<br />
Chemoradiotherapy versus Radiotherapy Alone in Elderly Patients with<br />
Stage III Non-Small Cell Lung Cancer: A Systematic Review - David Dawe,<br />
Canada<br />
The NARLAL2 Phase III Trial: Heterogeneous FDG-Guided Dose<br />
Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer<br />
Group - Tine Schytte, Denmark<br />
Dynamic Changes in Cell-Free Circulating Tumor DNA to Track Tumor<br />
Response and Risk of Recurrence in Stage III Non-Small Cell Lung Cancer<br />
- Steven Lin, USA<br />
Discussant - Joan Schiller, USA<br />
Pattern of Loco-Regional Failure after Definitive Chemo Radiotherapy<br />
for NSCLC. Results from NARLAL, a Phase II Randomized Trial - Tine<br />
Schytte, Denmark<br />
Risk Factor of Morbidity and Mortality of Surgical Resection after<br />
Induction Therapy in Patients with Stage IIIA-N2 Lung Cancer - Jong Ho<br />
Cho, South Korea<br />
Mutation Profile Prognostic Value in Stage III Non Small Cell Lung Cancer<br />
(NSCLC) Patients Treated with Chemo-Radiotherapy (CRT) - Cecile Le<br />
Pechoux, France<br />
30
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Incorporating Erlotinib Into Chemoradiation Therapy for Unresectable<br />
Stage IIIA/B NSCLC: Interim Results of Ongoing Phase II Randomized<br />
Trial - Jin Soo Lee, South Korea<br />
Discussant - Billy Loo, USA<br />
Isotoxic Dose Escalation and Acceleration in Lung Cancer<br />
Chemoradiotherapy - David Landau, United Kingdom<br />
Stage III NSCLC in the Elderly: Patient Characteristics Predictive for<br />
Tolerance and Survival of Chemoradiation in Daily Clinical Practice -<br />
Maryska Janssen-Heijnen, Netherlands<br />
Clinical Impact of Frequent Surveillance Imaging in the First Year<br />
following Chemoradiation for Locally Advanced Non-Small Cell Lung<br />
Cancer - Nima Harandi, USA<br />
Endostatin Combined with Paclitaxel, Carboplatin, and Radiotherapy in<br />
Patients with Unresectable Locally Advanced Non-Small Cell Lung<br />
Cancer - Yaping Xu, China<br />
Discussant - Corey Langer, USA<br />
16:45 - 18:15 Mini Oral 08: Prognostic/Predictive Biomarkers<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Thomas Stinchcombe, USA & Nick Pavlakis, Australia<br />
Room: Mile High Ballroom 4a - 4f<br />
Quantitative Mass Spectrometry Proteomics Identifies FRalpha and<br />
GARFT as Predictive Biomarkers in NSCLC Patients Treated With<br />
Pemetrexed - Abdulrahman Alshehri ?, USA<br />
Prediction of Response to Pemetrexed in NSCLC by<br />
Immunohistochemical Phenotyping Based on Gene Expression Profiles -<br />
Sabine Visser, Netherlands<br />
Tumour Molecular Profiling and Quantitative Detection of Circulating<br />
Biomarkers in Patients with Non-Small Cell Lung Cancer (NSCLC) - James<br />
Spicer, UK<br />
Discussant - David Spigel, USA<br />
VeriStrat® and Epidermal Growth Factor Receptor Mutation Status in a<br />
Phase 1b/2 Study of Cabozantinib +/- Erlotinib in Non-Small Cell Lung<br />
Cancer - Sukhmani Padda, USA<br />
A Survival Comparison Study of Chinese Patients with Primary Lung<br />
Adenocarcinoma Harboring ALK Rearrangements Detected in Different<br />
Methods with Crizotinib Treatment - Xiaomin Niu, China<br />
Prognostic Significance of FGFR1 Amplification in Patients with Lung<br />
Squamous Cell Carcinoma - Qi Zhang, China<br />
Discussant - Peter Hammerman, USA<br />
VEGF-Mediated Cell Survival in NSCLC: Implications for Epigenetic<br />
Targeting of VEGF Receptors as a Therapeutic Approach - Martin Barr,<br />
Ireland<br />
Anti-Tumor Efficacy of Interleukin-27 in Non Small Cell Lung Cancer -<br />
Giuseppe Cipollone, Italy<br />
31
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Co-Occurrence of Driver Mutations of MAPK and PI3K Pathways in Non<br />
Small Cell Lung Cancer: A Report from Lung Cancer Genomics Ireland<br />
(LCGI) Study - Shereen Rafee, Ireland<br />
Genome-Wide Association Analysis Identifies Novel Genetic<br />
Determinants of Cancer Metastasis in Korean Lung Adenocarcinoma -<br />
Yoohwa Hwang, South Korea<br />
Proteomic Profiling of Pulmonary Cancer with Squamous Cell Histology -<br />
Hanibal Bohnenberger, Germany<br />
Driver Mutation Status in Resected Stage I Lung Adenocarcinoma:<br />
Correlation with Radiographic CT Findings - Michael Lanuti, USA<br />
Discussant - Justin Gainor, USA<br />
16:45 - 18:15 Mini Oral 09: Drug Resistance<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Liza Villaruz, USA & John Minna, USA<br />
Rooms: 205 + 207<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Inhibiting Tankyrase Prevents Epithelial-To-Mesenchymal Transition and<br />
Synergizes with EGFR-Inhibition in Wnt-Dependent NSCLC Lines -<br />
Hannah Scarborough, USA<br />
Transcriptome-Metabolome Reprogramming of EGFR-Mutant NSCLC<br />
Contributes to Early Adaptive Drug-Escape via BCL-xL Mitochondrial<br />
Priming - Patrick Ma, USA<br />
Characterization of Afatinib or EGFR T790M Specific Inhibitor (WZ8040<br />
or AZD9291) Resistant Lung Cancer Cells (PC9) - Anya Maan-Yuh Lin,<br />
Taiwan<br />
Identification of Effective Drug Combinations to Prevent or Delay<br />
Resistance to the EGFR Mutant Selective Inhibitor Rociletinib (CO-1686)<br />
- Andrew Simmons, USA<br />
Discussant - Christine Lovly, USA<br />
Oncogenic Drivers including RET and ROS1 plus PTEN Loss and MET by<br />
IHC in Patients with Lung Adenocarcinomas: Lung Cancer Mutation<br />
Consortium 2.0 - Bruce Johnson, USA<br />
Activation of the MET Kinase Confers Acquired Resistance to FGFR-<br />
Targeted Therapy in FGFR-Dependent Squamous Cell Carcinoma of the<br />
Lung - Byoung Chul Cho, South Korea<br />
Secondary C805S Mutation in HER2 Gene Confers Acquired Resistance<br />
to HER2 Kinase Inhibitors in HER2 Mutant Lung Cancer - Takayuki<br />
Kosaka, USA<br />
Discussant - Edward Garon, USA<br />
Tumor Angiogenesis in LKB1-Mutant Non-Small Cell Lung Cancer<br />
(NSCLC) - Irene Guijarro, USA<br />
Adaptor Re-Programming and Acquired Resistance in RET-Fusion<br />
Positive NSCLC - Sarah Nelson, USA<br />
HDAC Inhibitors Overcome New Generation EGFR-TKI-Resistance<br />
Caused by Homozygous BIM Polymorphism in EGFR Mutant Lung Cancer<br />
- Seiji Yano, Japan<br />
32
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
<br />
<br />
Neuropilin-2 Promotes Acquired Resistance to EGFR-TKI Associated with<br />
the Epithelial?Mesenchymal Transition in Lung Cancer - Harry Drabkin,<br />
USA<br />
Discussant - Clarissa Mathias, Brazil<br />
16:45 - 18:15 Mini Oral 10: ALK and EGFR<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Timothy Yap, United Kingdom & Tianhong Li, USA<br />
Room: Mile High Ballroom 1a - 1f<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Frequency of Concomitant EGFR, EML4-ALK or KRAS Alterations in<br />
NSCLC Patients and Correlation with Response to Treatment - Paola<br />
Ulivi, Italy<br />
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Co-<br />
Altered Lung Adenocarcinoma - Weijing Cai, China<br />
Evolution of Concurrent Driver Mutations in Lung Adenocarcinoma<br />
Patients on EGFR TKI Therapy Uncovered by Comprehensive Molecular<br />
Profiling - Collin Blakely, USA<br />
Discussant - Tony Mok, Hong Kong<br />
ALK Rearrangements in Non-Small Cell Lung Cancer: Comprehensive<br />
Integration of Genomic, Gene Expression and Protein Analysis - Johanna<br />
Mattsson, Sweden<br />
Incidence of ALK Gene Rearrangements in a Prospectively,<br />
Consecutively Collected Caucasian Population with Pulmonary<br />
Adenocarcinomas - Birgit Skov, Denmark<br />
Lung Adenocarcinomas Co-Expressing TTF-1, MUC5B and/or MUC5AC<br />
Show a High Incidence of ALK Rearrangement and a Poor Prognosis -<br />
Dongmei Lin, China<br />
Discussant - Benjamin Besse, France<br />
Comprehensive Genomic Profiling Identifies EGFR Exon 19 Deletions in<br />
NSCLC Not Identified by Standard of Care Testing - Siraj Ali, USA<br />
A Multicenter Prospective Biomarker Study in Afatinib-Treated Patients<br />
with EGFR-Mutation Positive Non-Small Cell Lung Cancer - Koichi<br />
Azuma, Japan<br />
Classification of EGFR Gene Mutation Status Using Serum Proteomic<br />
Profiling Predicts Tumor Response in Patients with Stage IIIB or IV NSCLC<br />
- XiaoQing Liu, China<br />
Preclinical Activity of AZD9291 in EGFR-Mutant NSCLC Brain Metastases<br />
- Peter Ballard, United Kingdom<br />
Prediction of Human Pharmacokinetics, Efficacious Dose and Bbb<br />
Penetration of a Novel Egfr Inhibitor for Treating Nsclc with Cns<br />
Metastasis - Ziqiang (Zack) Cheng, China<br />
Brain Metastasis at Diagnosis and EGFR Mutational Status in Non-Small<br />
Cell Lung Cancer - Apar Ganti, USA<br />
Discussant - Oscar Arrieta Rodriguez, Mexico<br />
33
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
16:45 - 18:15 Mini Oral 11: Tobacco Control and Prevention<br />
Track: Prevention and Tobacco Control<br />
Moderators: Sam Janes, United Kingdom & Emily Stone, Australia<br />
Rooms: 601 + 603<br />
The Upshot of Passive Smoke (ETS) Exposure on Pneumonia Risk in<br />
Children Under 7 Years in Nigeria - Blessing Obiazi-Odiase, Nigeria<br />
Frizzled9 as a Predictor of Response to Iloprost Chemoprevention of<br />
Lung Cancer - Meredith Tennis, USA<br />
Switching to Smokeless Tobacco Use as a Smoking Cessation Method in<br />
India - Gomathyamma Mini, India<br />
A New Preclinical Model of Airway Progenitor Cells to Identify<br />
Responders to Iloprost-Mediated Chemoprevention - Moumita Ghosh,<br />
USA<br />
Prevalence Use of Others Tobacco Products: Findings from the ITC Brazil<br />
Survey - Cristina Perez, Brazil<br />
Comprehensive Tobacco Control Programs Reduce Tobacco Use and<br />
Secondhand Smoke Exposure: A Systematic Review - Jeffrey Reynolds,<br />
USA<br />
The Relationship between Smoking Status and Prognostic Factors after<br />
Surgery in Lung Cancer Patients with Chronic Obstructive Pulmonary<br />
Disease - Masaya Yotsukura, Japan<br />
Smoking Cessation Results in a Clinical Lung Cancer Screening Program -<br />
Andrea Borondy Kitts, USA<br />
Trends in Lung Cancer Mortality Attributable to Smoking, Years of<br />
Potential Life Lost and Financial Cost, Puerto Rico 1983-2010 - Cecile<br />
Marques-Goyco, Puerto Rico<br />
Quality of Lung Cancer Treatment in Two Neighbouring Regions of<br />
Germany and Denmark - Niels Henrik Holländer, Denmark<br />
Lung Cancer and Smoking in Nepal - Madan Piya, Nepal<br />
Is There Any Role for Residential Radon in Patients with Non Small Cell<br />
Lung Cancer (NSCLC) Harbouring Molecular Alterations? Preliminary<br />
Results - Pilar Garrido, Spain<br />
16:45 - 18:15 Mini Oral 12: Biomarkers and Lung Nodule Management<br />
Track: Screening and Early Detection<br />
Moderators: Jill Siegfried, USA & Harvey Pass, USA<br />
Rooms: 401 - 404<br />
A Novel Serum 4-MicroRNA Signature for Lung Cancer Detection -<br />
Ernest Nadal, Spain<br />
Clinical Utility of Chromosomal Aneusomy in High Risk Individuals -<br />
Anna Barón, USA<br />
Comprehensive Analysis of MicroRNA Expression Patterns in Lung<br />
Adenocacinoma Presenting with GGNs and Non-Tumorous Tissues - Yayi<br />
He, China<br />
34
Monday, <strong>September</strong> 7, <strong>2015</strong><br />
Blinded Evaluation of the LuCED test to Detect Early Stage Lung Cancer -<br />
Michael Meyer, USA<br />
Discussant - Luis Montuenga, Spain<br />
Bioconductance Compared to 18FDG-PET in Evaluating CT-Detected<br />
Lung Lesions - Rex Yung, USA<br />
Exhaled Breath Analysis in Lung Cancer - One Stop Shop for Diagnosis,<br />
Staging and EGFR Analysis - Nir Peled, Israel<br />
Validation of Autoantibody Panel for Early Detection of Lung Cancer in<br />
Chinese Population - Shengxiang Ren, China<br />
Progress with an RCT of the Detection of Autoantibodies to Tumour<br />
Antigens in Lung Cancer Using the Early CDT-Lung Test in Scotland<br />
(ECLS) - Frank Sullivan, Canada<br />
Discussant - Harvey Pass, USA<br />
Screening for Lung Cancer with the Early CDT-Lung and Computed<br />
Tomography - James Jett, USA<br />
Validation of Blood-Based Biomarker for Classification of Patients with<br />
Indeterminate Pulmonary Nodules - Charlie Birse, USA<br />
Early Detection of Lung Cancer Using DNA Methylation in Plasma and<br />
Sputum - Alicia Hulbert, USA<br />
Exhaled microRNAs as Potential Biomarkers of Lung Cancer Case versus<br />
Control Status - Simon Spivack, USA<br />
Discussant - Avrum Spira, USA<br />
18:30 - 20:00 Symposium supported by Clovis Oncology: Critical Insights on Mutant-Specific<br />
Epidermal Growth Factor Receptor Inhibitors for NSCLC<br />
Chair: Edward Kim, USA<br />
Room: 601 + 603<br />
Website: www.ecgcme.com/T790M<br />
First- and Second-Generation EGFR TKIs in Mutant-Unselected and<br />
Mutant-Sensitive NSCLC - Lecia Sequist<br />
Third-Generation EGFR TKIs in Mutant-Specific NSCLC - Jonathan<br />
Goldman<br />
Exploring the Use of Immunotherapy EGFR-TKI Resistance in NSCLC -<br />
David Gandara<br />
Thoughts From the Chair - Edward Kim<br />
20:00 – 23:00 Faculty Dinner (by invitation only)<br />
Room: Seawell Ballroom, Denver Center for the Performing Arts<br />
35
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
07:00 - 08:00 Symposium supported by Myriad: Improving the Care of Patients with Early-<br />
Stage Lung Adenocarcinoma: Role of Prognostic Signatures<br />
Rooms: 201 + 203<br />
Symposium supported by Celgene: The New Frontier in NSCLC - Beyond EGFR,<br />
VEGF and ALK: Expanding the Paradigm to Include Patients Without<br />
Actionable mutations - CRITICAL QUESTIONS and CASE BASED LEARNING<br />
Speakers: Mark Socinski, USA & Roy Herbst, USA & Gregory Riely, USA<br />
Room: Mile High Ballroom 2 + 3<br />
<br />
Webpage: www.bmli.com/live/nsclc/index.php<br />
The target audience for this symposium on managing NSCLC patients without<br />
actionable mutations includes medical oncologists, hematologists, radiation<br />
oncologists, surgical oncologists, pathologists, Fellows, Physician Assistants,<br />
oncology nurses/Nurse Practitioners, oncology pharmacists, and other allied<br />
health-care professionals involved in the treatment, care and management of<br />
patients with NSCLC. Lung cancer is treated optimally by a multi-disciplinary<br />
approach and, thus, all of the aforementioned clinician specialties are invited to<br />
participate in this symposium.<br />
Symposium supported by Pfizer: Recent Advancements in the Identification<br />
and Treatment of ALK+ Metastatic NSCLC<br />
Room: 401 - 404<br />
07:00 - 08:00 Highlights of the Previous Day HOD 01: Treatment of Advanced, Localized and<br />
LocoRegional Disease and Small Cell, Thymoma, Mesothelioma<br />
Track: Highlights from Monday, <strong>September</strong> 7<br />
Room: Four Seasons Ballroom F1 + F2<br />
<br />
<br />
<br />
<br />
Treatment of Advanced Disease - Yi-Long Wu, China<br />
Treatment of Localized Disease - Jessica Donington, USA<br />
Treatment of LocoRegional Disease - Chandra Belani, USA<br />
Small Cell/Thymoma/Mesothelioma/Other – Martin Edelman, USA<br />
07:00 - 08:00 Highlights of the Previous Day HOD 02: Biology, Pathology, Molecular Testing,<br />
Prevention, Tobacco Control, Screening and Early Detection<br />
Track: Highlights from Monday, <strong>September</strong> 7<br />
Room: Four Seasons Ballroom F3 + F4<br />
<br />
Biology, Pathology, Molecular Testing - Kenneth O'Byrne, Australia<br />
36
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
Prevention, Tobacco Control - Carolyn Dresler, USA<br />
Screening, Early Detection - Claudia Henschke, USA<br />
07:00 - 08:00 MTE 12: Meet the Expert: Therapy for Driver Mutation Positive Advanced<br />
NSCLC (Ticketed Session)<br />
Track: Treatment of Advanced Disease - NSCLC<br />
Speaker: Federico Cappuzzo, Italy<br />
Room: 103<br />
07:00 - 08:00 MTE 13: Meet the Expert: Standard of Care in Rare Thoracic Malignancies<br />
(Ticketed Session)<br />
Track: Community Practice<br />
Speaker: Nicolas Girard, France<br />
Room: 105<br />
07:00 - 08:00 MTE 14: Meet the Expert: Proposal of Revised (8th) Edition of TNM Staging<br />
System for Lung Cancer (Ticketed Session)<br />
Track: Treatment of Localised Disease - NSCLC<br />
Speaker: Mark Krasnik, Denmark<br />
Room: 107<br />
07:00 - 08:00 MTE 15: Meet the Expert: Management of Major Airway and Vascular<br />
Obstruction (Ticketed Session)<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Speaker: Georgios Stamatis, Germany<br />
Room: 109<br />
07:00 - 08:00 MTE 16: Meet the Expert: Living with Cancer and Sexuality (Ticketed Session)<br />
Track: Palliative and Supportive Care<br />
Speaker: Luca Incrocci, Netherlands<br />
Room: 111<br />
07:00 - 08:00 MTE 17: Meet the Expert: Dealing with Metastatic Bone Disease in Lung<br />
Cancer - Prevention of SREs and Pain (Ticketed Session)<br />
Track: Palliative and Supportive Care<br />
Speaker: Vera Hirsh, Canada<br />
Room: 102 + 104 + 106<br />
37
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
07:00 - 08:00 MTE 18: Meet the Expert: Chemoprevention Trials: Past, Present, and Future<br />
(Ticketed Session)<br />
Track: Prevention & Tobacco Control<br />
Speaker: Dennis Wigle, USA<br />
Room: 108 + 110 + 112<br />
07:00 - 08:00 MTE 19: Meet the Expert: Electronic Nicotine Delivery Devices (ENDS):<br />
eCigarettes (Ticketed Session)<br />
Track: Prevention & Tobacco Control<br />
Speaker: Kenneth Cummings, USA<br />
Room: 702 + 704 + 706<br />
07:00 - 08:00 MTE 20: Meet the Expert: Biology and Pathology of Neuroendocrine Cancers:<br />
Small Cell Lung Cancer - Call for Action (Ticketed Session)<br />
Track: Small Cell Lung Cancer<br />
Speakers: Keith Kerr, United Kingdom & Ilona Linnoila, USA<br />
Room: 708 + 710 + 712<br />
07:00 - 08:00 MTE 21: Meet the Expert: Early Detection of Central Airway Lesions: Biology<br />
and Practical Clinical Approaches (Ticketed Session)<br />
Track: Screening and Early Detection<br />
Speakers: Annette McWilliams, Australia & Gabriella Sozzi, Italy<br />
Room: 703<br />
<br />
<br />
Early Detection of Central Airway Lesions: Biology and Practical Clinical<br />
Approaches - Annette McWilliams, Australia<br />
Biomarkers for Early Detection of Lung Cancer - Gabriella Sozzi, Italy<br />
07:00 - 08:00 MTE 22: Meet the Expert: Diagnosis and Treatment of MPM: Overview<br />
(Ticketed Session)<br />
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies<br />
Speaker: Arnauld Scherpereel, France<br />
Room: 205 + 207<br />
08:15 - 09:45 Plen 02: Plenary Session: Lung Cancer: IASLC Global Initiatives<br />
Track: Plenary<br />
Chairs: Fred R. Hirsch, USA & Silvia Novello, Italy<br />
Room: Plenary Hall (Bellco Theatre)<br />
<br />
<strong>2015</strong> WHO Classification of the Pathology and Genetics of Tumors of the<br />
Lung - William Travis, USA<br />
38
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
Revised (8th) Edition of TNM Staging System for Lung Cancer - Ramon<br />
Rami-Porta, Spain<br />
09:45 - 10:45 Networking Break and Poster Session 2<br />
Room: Exhibit Hall (Hall B + C)<br />
Refreshments will be provided<br />
09:45 - 10:45 Press Conference 3<br />
Moderator: Dr. Everett Vokes, Congress Co-Chair, John Ultmann Professor and<br />
Chair, Department of Medicine at the University of Chicago<br />
Room: 108 + 110 + 112<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Daily Theme: Lung Cancer: A Women’s Disease - Dr. Silvia Novello,<br />
Associate Professor, Department of Oncology, University of Turin-Italy<br />
Revised (8th) Edition of TNM Staging System for Lung Cancer - Dr.<br />
Ramon Rami-Porta, Thoracic Surgery Service, Hospital Universitari<br />
Mutua Terrassa, Barcelona, Spain<br />
<strong>2015</strong> WHO Classification of the Pathology and Genetics of Tumors of the<br />
Lung - Dr. William Travis, Attending Thoracic Pathologist, Dept. of<br />
Pathology, Memorial Sloan Kettering Cancer Center, New York<br />
Abstract – Increasing Incidence of Non-Smoking Lung Cancer:<br />
Presentation of Patients with Early Disease to a Tertiary Institution in<br />
the UK - Dr. Eric Lim, Royal Brompton and Harefield NHS Trust, London<br />
Abstract – Increasing Incidence of Never Smokers in Non Small Cell Lung<br />
Cancer (NSCLC) Patients - Dr. Lorraine Pelosof, Assistant Professor, UT<br />
Southwestern Medical Center, Dallas, Texas<br />
Abstract – Oncogenic Profiling in Lung Adenocarcinoma Emerged in the<br />
Youth - Dr. Kosuke Tanaka, Department of Cancer Genetics, Nagoya<br />
University Graduate School of Medicine; Division of Molecular<br />
Oncology, Aichi Cancer Center Research Institute, Japan<br />
Abstract – The Genomics of Young Lung Cancer Study - Dr. Barbara<br />
Gitlitz, Associate Professor of Clinical Medicine at USC Keck School of<br />
Medicine, Los Angeles<br />
Q & A<br />
09:50 - 10:40 Exhibit Showcase Session: Lilly: Shared Voice – Individualizing Patient –<br />
Centered Communication for Advanced Lung Cancer Patients<br />
Room: Exhibit Showcase Theater in the Exhibit Hall (Halls B + C)<br />
10:45 - 12:15 Oral Session 16: Clinical Care of Lung Cancer and Advanced Biopsies<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Joel Neal, USA & Qinghua Zhou, China<br />
39
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
Room: Mile High Ballroom 2a - 3b<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Brain Metastases<br />
(BMs) from Advanced Lung Cancer : A Large Retrospective Cohort Study<br />
- Chiara Bennati, Italy<br />
Thromboembolic and Bleeding Risk with Adjuntctive LMWHs<br />
Anticoagulation in Lung Cancer Patients. Meta-Analysis of Randomized<br />
Trials - Janusz Kowalewski, Poland<br />
Acceptability of NSCLC, NOS in Advanced Disease: An Assessment of US<br />
Oncologists, Pulmonologists and Pathologists - Tara Herrmann, USA<br />
Discussant - Robert Pirker, Austria<br />
Retrospective Analysis of ctDNA EGFR Mutations in the Phase III,<br />
Randomized IMPRESS Study - Kenneth Thress, USA<br />
Quantification of Mutant Alleles in Circulating Tumor DNA from<br />
Advanced Non-Small Cell Lung Cancer - Jie Wang, China<br />
Intratumor Heterogeneity of EGFR Activating Mutations Analyzed in<br />
Single Cancer Cells in Advanced NSCLC Patients - Qiuyi Zhang, China<br />
Discussant - Philip Mack, USA<br />
10:45 - 12:15 Oral Session 17: EGFR Mutant Lung Cancer<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Peter Meldgaard, Denmark & Enriqueta Felip, Spain<br />
Room: Four Seasons Ballroom F3 + F4<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
First-Line Icotinib versus Cisplatine/Pemetrexed plus Pemetrexed<br />
Maintenance in Advanced NSCLC Patients with EGFR Mutation - Yuankai<br />
Shi, China<br />
Randomized Trial of Gefitinib with and without Pemetrexed as First-Line<br />
Therapy in East-Asian Patients with Advanced NS NSCLC with EGFR<br />
Mutations - Ying Cheng, China<br />
Biomarkers for Efficacy in JO25567 Study Evaluating Erlotinib plus<br />
Bevacizumab versus Erlotinib in Advanced NSCLC with EGFR Mutation -<br />
Shinji Atagi, Japan<br />
Discussant - Lecia Sequist, USA<br />
Clinical Outcomes in Patients with Non-Small-Cell Lung Cancer (NSCLC)<br />
Harboring Rare Epidermal Growth Factor Receptor (EGFR) Mutations -<br />
Pedro Domingues, Brazil<br />
Phase I/II Study of INC280 plus Erlotinib in Patients with MET Expressing<br />
Adenocarcinoma of the Lung - Caroline McCoach, USA<br />
Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M Positive<br />
Lung Cancer - Geoffrey Oxnard, USA<br />
Gefitinib/Chemotherapy vs Chemotherapy in EGFR Mutation-Positive<br />
NSCLC Resistant to First-Line Gefitinib: IMPRESS T790M Subgroup<br />
Analysis - Tony Mok, Hong Kong<br />
Discussant - Tetsuya Mitsudomi, Japan<br />
40
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
10:45 - 12:15 Oral Session 18: Non PD1 Immunotherapy and Angiogenesis<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Charles Butts, Canada & Karen Reckamp, USA<br />
Room: Four Seasons Ballrom F1 + F2<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of<br />
Advanced NSCLC: Phase 2b Results - Elisabeth Quoix, France<br />
MUC1-Targeted Dendritic Cell-Based Vaccine Immunotherapy in<br />
Patients with Standard Treatments-Refractory Non-Small-Cell Lung<br />
Cancer - Koji Teramoto, Japan<br />
Discussant - Johan Vansteenkiste, Belgium<br />
Anti-Angiogenic Therapy in Advanced Non-Small Cell Lung Cancer<br />
(NSCLC): A Meta-Analysis of Phase 3 Randomized Trials - Jacques<br />
Raphael, Canada<br />
Early Predictive Value of Perfusion-Computed Tomography (pCT) in<br />
Advanced NSCLC Patients Treated with Bevacizumab: IMPACT Trial -<br />
Fran Aya, Spain<br />
Effect of Anti-VEGF Therapy on MDSCs' Population in the Peripheral<br />
Blood of Non-Small Cell Lung Cancer (NSCLC) Patients - Athanasios<br />
Kotsakis, Greece<br />
Discussant - Primo Lara Jr., USA<br />
10:45 - 12:15 Oral Session 19: Radiation for Localized Lung Cancer<br />
Track: Treatment of Localized Disease - NSCLC<br />
Moderator: Dirk De Ruysscher, Belgium<br />
Rooms: 102 + 104 + 106<br />
The SPACE Study: A Randomized Phase II Trial Comparing SBRT and<br />
3DCRT in Stage I NSCLC Patients; Final Analysis including HRQL -<br />
Andreas Hallqvist, Sweden<br />
Higher Risk of Failure and Death after Stereotactic Lung Radiotherapy<br />
for T2 Lung Cancer - Matthew Johnson, USA<br />
NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiotherapy<br />
(SBRT) for Central Tumors - Adverse Events - Andrea Bezjak, Canada<br />
Discussant - Francoise Mornex, France<br />
Japanese Multicenter Study of Stereotactic Body Radiotherapy for 661<br />
Medically Operable Patients with Stage I Non-Small Cell Lung Cancer -<br />
Takafumi Komiyama, Japan<br />
Tumor Location Is Associated with Recurrence Pattern and Survival after<br />
SBRT in Early Stage NSCLC Patients - Barbara Stam, Netherlands<br />
A Novel Nomogram for Predicting Distant Metastases after Lung<br />
Stereotactic Body Radiotherapy for Early Stage Lung Cancer - Steven Oh,<br />
USA<br />
41
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
10:45 - 12:15 Oral Session 20: Chemoradiotherapy<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Moderators: George Blumenschein, USA & Joe Chang, USA<br />
Rooms: 201 + 203<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
A Systematic Review of Carboplatin-Paclitaxel versus Cisplatin-Etoposide<br />
Concurrent with Thoracic Radiation for Stage III NSCLC Patients - Conor<br />
Steuer, USA<br />
Safety Results of the Consolidation Phase of a Phase III (PROCLAIM):<br />
Pemetrexed, Cisplatin or Etoposide, Cisplatin plus Thoracic Radiation<br />
Therapy followed by Consolidation Cytotoxic Chemotherapy in Locally<br />
Advanced Nonsquamous Non-small Cell Lung Cancer - Ramaswamy<br />
Govindan, USA<br />
Radiation Dose Escalation in Patients with Locally Advanced Non-Small<br />
Cell Lung Cancer; 60 Month Follow-Up of a Randomized Phase II Trial -<br />
Jose Belderbos, Netherlands<br />
Discussant - Gregory Videtic, USA<br />
Elective Nodal Irradiation Does Not Alter Isolated Nodal Failure and<br />
Survival Outcomes in Stage III NSCLC Patients Undergoing<br />
Chemoradiotherapy - Erkan Topkan, Turkey<br />
Outcomes of Intensity Modulated and 3D-Conformal Radiotherapy for<br />
Stage III Non-Small Cell Lung Cancer in NRG Oncology/RTOG 0617 -<br />
Stephen Chun, USA<br />
Survival Impact of Post-Operative Therapy Modalities after Incomplete<br />
and Complete Surgical Resection for Non-Small Cell Lung Cancer in the<br />
US - Matthew Smeltzer, USA<br />
Discussant - Andrea Bezjak, Canada<br />
10:45 - 12:15 Oral Session 21: Biology - Moving Beyond the Oncogene to Oncogene-<br />
Modifying Genes<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderator: Artur Katz, Brazil<br />
Room: Mile High Ballroom 4a - 4f<br />
Adaptive Survival Signaling in Oncogenic Fusion Kinase Addicted NSCLC -<br />
Aria Vaishnavi, USA<br />
Landscape and Functional Significance of KRAS Co-Mutations in Lung<br />
Adenocarcinoma (LUAC) - Ferdinandos Skoulidis, USA<br />
KEAP1-Mutations and NFE2L2-Mutations in Patients with Non-Small Cell<br />
Lung Cancer (NSCLC) - Rieke Frank, Germany<br />
Discussant - Daniel Morgensztern, USA<br />
p53/KRAS mutation status does not predict sensitivity to chemotherapy<br />
in NSCLC PDXs - Céline Mascaux, Canada<br />
Two Faces of YAP: Oncogenic in Lung Tumor Malignant Progression but<br />
Inhibitory in Phenotypic Transition - wenjing Zhang, China<br />
Discussant - Francesco Grossi, Italy<br />
42
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
10:45 - 12:15 Oral Session 22: Moving Beyond a Smoking Related-Cancer to the Young,<br />
Never-smokers and Inherited Disease<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Kenichi Suda, Japan & Heather Wakelee, USA<br />
Room: Mile High Ballroom 1a - 1f<br />
Increasing Incidence of Never Smokers in Non Small Cell Lung Cancer<br />
(NSCLC) Patients - Lorraine Pelosof, USA<br />
Spectrum of Cancer Types in Kindreds with NSCLC and EGFR T790M<br />
Mutations: Results from INHERIT EGFR - Georgia Wiesner, USA<br />
Inter-, and Intratumoural Genomic Heterogeneity of Primary Pulmonary<br />
Adenocarcinoma in Never Smokers - Marissa Daniels, Australia<br />
Discussant - Paolo Boffetta, USA<br />
The Genomics of Young Lung Cancer Study - Barbara Gitlitz, USA<br />
Whole Exome Sequencing to Profile the Genomic Landscapes of Young<br />
Patients (pts) Diagnosed with Non-Small Cell Lung Cancer (NSCLC) -<br />
Patrick Ma, USA<br />
Oncogenic Profiling in Lung Adenocarcinoma Emerged in the Youth -<br />
Kosuke Tanaka, Japan<br />
Discussant - Benjamin Levy, USA<br />
10:45 - 12:15 Oral Session 23: Prevention and Cancer Risk<br />
Track: Prevention and Tobacco Control<br />
Moderators: Nico van Zandwijk, Australia & Nasser Hanna, USA<br />
Rooms: 601 + 603<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
A Randomized Phase IIb Trial of Myo-Inositol in Smokers with Bronchial<br />
Dysplasia - Stephen Lam, Canada<br />
Pioglitazone for the Chemoprevention of Lung Cancer - Robert Keith,<br />
USA<br />
Role of Inflammatory Infiltrates in Promoting Persistence or Regression<br />
of Bronchial Dysplasia - Daniel Merrick, USA<br />
Discussant - Eva Szabo, USA<br />
Increased Proportion of Female and Young Mesothelioma Cases Are<br />
Indicators of Environmental Exposure to Carcinogenic Mineral Fibers in<br />
Nevada - Francine Baumann, USA<br />
Radon Gas Exposure and Lung Cancer in a Cohort of Lung Cancer<br />
Patients Who Never Smoked - Gwyn Bebb, Canada<br />
Interactions Between Smoking and the Dietary Inflammatory Index in<br />
Relation to Lung Cancer in the Prostate Lung Colorectal and Ovarian<br />
Trial - Azza Shoaibi, USA<br />
Discussant - Michele Carbone, USA<br />
10:45 - 12:15 Oral Session 24: CT Detected Nodules - Predicting Biological Outcome<br />
Track: Screening and Early Detection<br />
Moderators: Kavita Garg, USA & Keith Kerr, United Kingdom<br />
43
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
Rooms: 401 - 404<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Natural History of Pulmonary Subsolid Nodules: A Prospective<br />
Multicenter Study - Ryutaro Kakinuma, Japan<br />
Quantification of Growth Patterns of Screen-Detected Lung Cancers:<br />
The NELSON Trial - Marjolein Heuvelmans, Netherlands<br />
Increasing Incidence of Non-Smoking Lung Cancer: Presentation of<br />
Patients with Early Disease to a Tertiary Institution in the UK - Maria<br />
Elena Cufari, United Kingdom<br />
Discussant - Giulia Veronesi, Italy<br />
Reclassification of Lung Cancers Detected by CT Imaging in the American<br />
College of Radiology Imaging Network National Lung Screening Trial* -<br />
Wilbur Franklin, USA<br />
Stratification of Lung Adenocarcinomas in the National Lung Screening<br />
Trial - Tobias Peikert, USA<br />
Behavior Differences of Screen-Detected Lung Cancers in the CT Arm of<br />
the National Lung Screening Trial (NLST) - Matthew Schabath, USA<br />
Discussant - Masayuki Noguchi, Japan<br />
10:45 - 12:15 Oral Session 25: Biology and Other Issues in SCLC<br />
Track: Small Cell Lung Cancer<br />
Moderators: Julien Sage, USA & Luis Montuenga, Spain<br />
Rooms: 605 + 607<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Screening for Small Cell Lung Cancer: Analysis of the National Lung<br />
Cancer Screening Trial Data - Anish Thomas, USA<br />
Vasculogenic Mimicry in Small Cell Lung Cancer - Caroline Dive, United<br />
Kingdom<br />
Establishment of Lung Cancer Xenograft Models Derived from<br />
Bronchoscopy Biopsy and Investigating Mechanism of Refractory Small<br />
Cell Lung Cancer - Jie Wang, China<br />
Discussant - Charles Rudin, USA<br />
Predictive and Prognostic Significance of Myeloid-Derived Suppressor<br />
Cells in Patients with Small-Cell Lung Cancer - Ying Cheng, China<br />
Association of Expression of PD-L1 with the Tumor Immune<br />
Microenvironment in Small Cell Lung Cancer - Hui Yu, USA<br />
DNA Methylation in Small Cell Lung Cancer Defines Distinct Disease<br />
Subtypes and Correlates with High Expression of EZH2 - John Poirier,<br />
USA<br />
Discussant - Caroline Dive, United Kingdom<br />
10:45 - 12:15 Oral Session 26: Clinical Trials 2<br />
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies<br />
Moderators: Arnaud Scherpereel, France & Charles Thomas, USA<br />
Rooms: 702 + 704 + 706<br />
44
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Initial Analyses of the IASLC Malignant Pleural Mesothelioma (MPM)<br />
Database: Implications for the 8th Edition AJCC and UICC Staging<br />
Manuals - Valerie Rusch, USA<br />
What Are the Risks and Benefits of Extended Pleurectomy Decortication<br />
for Mesothelioma? A Review of the Largest Institutional Series in the UK<br />
- Annabel Sharkey, United Kingdom<br />
Predictive and Prognostic Value of Clinical TNM Staging for Patients with<br />
Malignant Pleural Mesothelioma Undergoing Surgery - Ritu Gill, USA<br />
Discussant - Marc de Perrot, Canada<br />
Symptom Study of Radiotherapy in Mesothelioma (SYSTEMS), a Phase II<br />
Study - Noelle O'Rourke, United Kingdom<br />
Prospective Assessment of Proton Therapy for Malignant Pleural<br />
Mesothelioma - Yun Li, USA<br />
Early Signs of Clinical Activity of a MicroRNA-Based Therapy in a Phase I<br />
Study in Recurrent Malignant Pleural Mesothelioma - Nico van<br />
Zandwijk, Australia<br />
Discussant - Andreas Rimner, USA<br />
10:45 - 12:15 Oral Session 27: Care<br />
Track: Advocacy<br />
Moderators: Merel Nissenberg Mountain, USA & Janet Freeman-Daily, USA<br />
Rooms: 708 + 710 + 712<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Bridging the Quality Chasm in Lung Cancer Care: Stakeholder<br />
Perspectives on Multidisciplinary Care in a Community Hospital Setting -<br />
Raymond Osarogiagbon, USA<br />
Patients' Attitudes and Physicians' Perceptions Toward Maintenance<br />
Therapy for Advanced NSCLC: A Multicenter Italian Survey - Maria<br />
Vittoria Pacchiana, Italy<br />
Patient Advocates in the Lung Cancer Diagnostic Pathway: A Qualitative<br />
Study of Interviews with Lung Cancer Patients and Their Caregivers -<br />
Nicole Rankin, Australia<br />
Discussant - Guneet Walia, USA<br />
"Care for Outcome" in Lung Cancer: A Santeon's Value Based Health<br />
Care Project - C.M. van Loenhout, Netherlands<br />
Disparities in Lung Cancer Incidence and Management Care in France: A<br />
Nationwide Cohort Study (the TERRITOIRE Study) - Christos Chouaid,<br />
France<br />
Impact of Regulatory Delays in Approving Oncology Drugs in a<br />
Developing Country: Mortality Associated with Lack of Access to<br />
Crizotinib in Brazil - Pablo Barrios, Brazil<br />
Discussant - Jim Baranski, USA<br />
10:45 - 12:15 Mini Oral 13: Genetic Alterations and Testing<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Yasuhiro Koh, Japan & Roman Thomas, Germany<br />
45
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
Rooms: 205 + 207<br />
Clinicopathological Profiles of ROS1 Positive Patients Screened by FISH -<br />
Jamie Sheren, USA<br />
Detection of ALK Rearrangement and EGFR Mutation in Primary<br />
Pulmonary Lymphoepithelioma-Like Carcinoma - Ying Liang, China<br />
Characterization of MET Gene and MET Protein Expression in Lung<br />
Cancer - Theresa Boyle, USA<br />
Characterization of Gene Mutations and Copy Number Alterations in<br />
Chinese Squamous Cell Lung Carcinomas - Yuankai Shi, China<br />
Discussant - Marc Ladanyi, USA<br />
Mutation Prevalence for Oncogenic Drivers in Lung Adenocarcinoma -<br />
Christopher Rivard, USA<br />
Kinome Targeted Deep Sequencing Identifies Novel Mutations in Korean<br />
Adenocarcinoma of the Lung - Yoohwa Hwang, South Korea<br />
Targetable Genomic Aberrations in Squamous Cell Lung Cancer (SCC): A<br />
Report from the Lung Cancer Genomics Ireland (LCGI) Study - Shereen<br />
Rafee, Ireland<br />
Next-Generation Sequencing Analysis of Driver Gene Mutations in<br />
Pleomorphic Carcinoma of the Lung - Saki Manabe, Japan<br />
Discussant - Lucian Chirieac, USA<br />
Detection of Rare Clinically Actionable Mutations in NSCLC Metastatic to<br />
the Brain by Targeted Next Generation Sequencing - Laura Tafe, USA<br />
The Abundance of EGFR Mutations Could Be More Better Predictor for<br />
EGFR-TKI Therapy in Advanced Non-Small Cell Lung Cancer - Xuefei Li,<br />
China<br />
Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Mutations (EGFRm)<br />
and Breast Cancer (BC): A Retrospective Analysis - enric Carcereny,<br />
Spain<br />
S768I Mutation in the EGFR Gene in Patients with Lung Cancer -<br />
Konstantinos Leventakos, USA<br />
Discussant - Lynette Sholl, USA<br />
10:45 - 12:15 Mini Oral 14: Pre-Clinical Therapy<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderator: Lynnette Fernandez-Cuesta, France & Adi Gazdar, USA<br />
Room: Mile High Ballroom 2c - 3c<br />
<br />
<br />
<br />
<br />
EGFR-Mutated PDX in NSCLC: Molecular Fidelity and Correlation of PDX<br />
and Patient Response to EGFR Inhibition - Jonathan Riess, USA<br />
TAE226, a Bis-Anilino Pyrimidine Compound, Shows Anti-Tumor Effect<br />
on EGFR-Mutant Non-Small Cell Lung Cancer Cells including T790M<br />
Mutant - Hiromasa Yamamoto, Japan<br />
New Monoclonal Antibody Targeting on Basic Fibroblast Growth Factor<br />
against Lung Cancer In Vitro and In Vivo - Meng Xu, China<br />
In Vitro and in Vivo Evaluation of the Kinase Inhibitor, MGCD516, in TRK<br />
and RET Fusion Cancer Cells - Robert Doebele, USA<br />
46
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
Discussant - James DeGregori, USA<br />
High-Affinity α3β1 Integrin Ligand LXY30 for the Screening, Imaging and<br />
Targeted Drug Delivery in Non-Small Cell Lung Cancer (NSCLC) -<br />
Tianhong Li, USA<br />
Bavituximab Activates CD8+ TILs in a 3D Ex Vivo System of Lung Cancer<br />
Patients Derived Tumors With Negative PD-L1 Expression - Soner Altiok,<br />
USA<br />
HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung<br />
Adenocarcinoma Cells and Inhibits Lung Cancer Stem Cells - Vera<br />
Levina, USA<br />
Discussant - Rafal Dziadziuszko, Poland<br />
CAY10603, a Novel Inhibitor of HDAC6, Suppresses Non-Small Cell Lung<br />
Cancer Cell Growth via Modulating Both Autophagy and Apoptosis<br />
Pathways - Zhihao Wang, China<br />
Establishment of a Lung Cancer Patient-Derived Xenografts Panel -<br />
Mattia Boeri, Italy<br />
Genomic Profiling of Patient-Derived Xenografts Identify Passenger<br />
Aberrations Associated with Better Prognosis in Non-Small Cell Lung<br />
Cancer - Nhu-An Pham, Canada<br />
Small Molecule Demonstrates Potent Tumor Suppression by Inhibiting<br />
the PI3K/AKT Pathway in Non-Small Cell Lung Cancer - Gavitt Woodard,<br />
USA<br />
Suppression of Lung Cancer Growth by CD26/DPP4 Inhibitor - Ignacio<br />
Gil-Bazo, Spain<br />
Discussant - Federico Cappuzzo, Italy<br />
12:30 - 13:00 Exhibit Showcase Session by Guardant Health: Guardant Health: Guardant360:<br />
Clinical Impact of Biopsy-Free Tumor Sequencing in NSCLC<br />
Speaker: Richard Lanman, USA<br />
Room: Exhibit Showcase Theater in the Exhibit Hall (Halls B + C)<br />
12:30 - 14:00 Symposium supported by Merck: Immuno-Oncology in Advanced NSCLC: Debates<br />
and Controversies<br />
Room: Plenary Hall (Bellco Theatre)<br />
<br />
http://medscape.org/townhall/io-nsclc<br />
14:15 - 15:45 GR 01: Grand Rounds: Management of challenging clinical scenarios in<br />
localized lung cancer<br />
Track: Treatment of Localised Disease - NSCLC<br />
Chairs: John Mitchell, USA & Gail Darling, Canada<br />
Rooms: 601 + 603<br />
<br />
T4 NSCLC Involving the Great Vessels: Role for resection? - David<br />
Harpole, USA<br />
47
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
Should All Lung Tumors Invading the Chest Wall be Treated Like<br />
Pancoast Tumors? - Brendon Stiles, USA<br />
T4 Lung Tumors According to the New Classification - What is the Role<br />
of Surgery? - Daniel Boffa, USA<br />
Salvage Surgery After Definitive Chemoradiation Therapy (CRT) - Eric<br />
Vallieres, USA<br />
14:15 - 15:45 GR 02: Grand Rounds: Difficult Mesothelioma Cases<br />
Track: Thymoma, Mesothelioma & other Thoracic Malignancies / Nursing and<br />
Allied Professionals<br />
Chairs: Jaime de la Garza, Mexico & Andreas Rimner, USA & Anne Tsao, USA<br />
Rooms: 102 + 104 + 106<br />
Case 1: A 70 Year Old with a Biphasic Stage I MPM - Harvey Pass, USA<br />
Case 2: A 65 Year Old with an Uncytoreduceable MPM - Paul Baas,<br />
Netherlands<br />
Case 3: A 65 Year Old with a Clinical Stage II MPM and Chest Pain -<br />
Joseph Friedberg, USA<br />
Addressing the Needs of the Mesothelioma Patient Who Has Exhausted<br />
Treatment Options: Palliation and Support for Family and Patient -<br />
Helen Clayson, United Kingdom & Liz Darlison, United Kingdom &<br />
Mary Hesdorffer, USA<br />
14:15 - 15:45 MS 11: Mini Symposium: New Approaches to Combined Modality Therapy for<br />
Stage III Disease<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Chairs: David Jablons, USA & Jan van Meerbeeck, Belgium<br />
Rooms: 605 + 607<br />
<br />
<br />
<br />
<br />
The Future of Radiation Therapy in Combined Modality Therapy - Rafal<br />
Dziadziuszko, Poland<br />
Future Role of Surgery (Timing, Patient Selection, and New Techniques)<br />
- Walter Weder, Switzerland<br />
New Systemic Approaches (Targeted Therapies and Immune Therapies)<br />
- Hossein Borghaei, USA<br />
Overview of Current International Randomized Trials - Simon Ekman,<br />
Sweden<br />
14:15 - 15:45 MS 12: Mini Symposium: NSCLC Stems Cells: Are They a Real Target?<br />
Track: Treatment of Advanced Disease - NSCLC<br />
Chairs: Caroline Dive, United Kingdom & Kazuhiko Nakagawa, Japan<br />
Room: Mile High Ballroom 2c - 3c<br />
<br />
Biology of Cancer Stem Cells - Neil Watkins, Australia<br />
48
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
Current Therapeutic Targets and Ongoing Trials - Maximilian Diehn,<br />
USA<br />
Where To Go From Here? - Rafael Rosell, Spain<br />
Tumor-Propagating Cells in Non-Small Cell Lung Cancers - Carla Kim,<br />
USA<br />
14:15 - 15:45 MS 13: Mini Symposium: The Other “–omics”<br />
Track: Biology, Pathology & Molecular Testing<br />
Chairs: James Herman, USA & Ite Laird-Offringa, USA<br />
Room: Mile High Ballroom 2a - 3b<br />
<br />
<br />
<br />
<br />
Epigenomics - James Herman, USA<br />
Proteomics and Phosphoproteomics - Eric Haura, USA<br />
Genomics – Beyond the Driver Oncogene (Role of Tumor Suppressors,<br />
TP53, LKB1, PTEN, etc.) - Kwok-Kin Wong, USA<br />
Integrating “omics” for a Unified View of Lung Cancer - James Spicer,<br />
United Kingdom<br />
14:15 - 15:45 MS 14: Mini Symposium: Chemo Prevention Clinical Trials<br />
Track: Prevention & Tobacco Control<br />
Chairs: York Miller, USA & Pieter E. Postmus, Netherlands<br />
Rooms: Room 401 - 404<br />
<br />
<br />
<br />
<br />
Preclinical Models: How Good Are They? - Robert Keith, USA<br />
Clinical Trials: Who Are the Proper Cohorts and How Do You Recruit<br />
Subjects? - Stephen Lam, Canada<br />
Pathologic Biomarkers of Risk and Benefit of Treatment – Dan Merrick,<br />
USA<br />
Chemoprevention Clinical Trials: How Do We Move Forward? How Do<br />
We Identify Valid End Points? - Eva Szabo, USA<br />
14:15 - 15:45 MS 15: Mini Symposium: Current Screening Trials, Current Evidence and<br />
Screening Algorithms<br />
Track: Screening and Early Detection<br />
Chairs: Peter Mazzone, USA & Tatiana Vidaurre-Rojas, Peru<br />
Room: Four Seasons Ballroom F3 + F4<br />
<br />
<br />
<br />
<br />
NLST, USPSTF recommendations —Is Screening Going to Happen in<br />
USA? - James Mulshine, USA<br />
NELSON Emerging Data - Harry de Koning, Netherlands<br />
UKLS Impact of Utilization of Risk Assessment in Trial Selection - John<br />
Field, United Kingdom<br />
Screening in Japan - the JECS Study - Motoyasu Sagawa, Japan<br />
49
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
14:15 - 15:45 MS 16: Mini Symposium: Novel SCLC Therapies<br />
Track: Small Cell Lung Cancer<br />
Chairs: Carlos Barrios, Brazil & Nagahiro Saijo, Japan<br />
Room: Mile High Ballroom 4a - 4f<br />
PARP Inhibitors and DNA Damage - Lauren Byers, USA<br />
Stem Cell/Notch/Hedgehog - David Carbone, USA<br />
PI3K/AKT/mTOR - Shigeki Umemura, Japan<br />
Immunotherapy (Checkpoint Inhibitors) - Martin Reck, Germany<br />
Aurora Kinase and Cyclin Kinase Inhibitors - Clarissa Mathias, Brazil<br />
New Chemotherapies (Eribulin, Aldoxorubicin, Etirinotecan, MM398) -<br />
Ramaswamy Govindan, USA<br />
14:15 - 15:45 MS 17: Mini Symposium: Immunotherapy for Mesothelioma<br />
Track: Thymoma, Mesothelioma & other Thoracic Malignancies<br />
Chairs: Dean Fennell, United Kingdom & Takashi Nakano, Japan<br />
Rooms: 201 + 203<br />
<br />
<br />
<br />
<br />
Overview: Immunotherapy in Mesothelioma - Anna Nowak, Australia<br />
Immunotoxins and Mesothelin Antibody - Raffit Hassan, USA<br />
DC Vaccination - Joachim Aerts, Netherlands<br />
CTLA4 and PD-1 - Hedy Lee Kindler, USA<br />
14:15 - 15:45 MS 18: Mini Symposium: Advocacy Snapshots<br />
Track: Advocacy<br />
Chairs: Patricia Mondragon, Mexico & Kim Norris, USA<br />
Room: 703<br />
Tobacco Controls Impact on Lung Cancer - Glenda Colburn, Australia<br />
Advocates Making a Responsible Case for High-Risk Screening -<br />
Toshiyuki Sawa, Japan<br />
Developing a Framework for Excellence in Lung Cancer Screening – The<br />
Lung Cancer Alliance Experience – Laurie Fenton-Ambrose, USA<br />
Lung Cancer – A Health Issue for Women - Stefania Vallone, Italy<br />
Excellence In Treatment – Exporting Teaching Hospital Standards of<br />
Care to the Community Hospital Setting - Scott Santarella, USA &<br />
Danielle Hicks, USA<br />
14:15 - 15:45 MS 19: Mini Symposium: Global Nursing Issues in Lung Cancer<br />
Track: Nursing and Allied Professionals<br />
Chairs: Patricia Hollen, USA & Beth Ivimey, Australia<br />
Rooms: 708 + 710 + 712<br />
<br />
Nursing Challenges in Clinical Trials - Christel Oyen, Belgium<br />
50
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
Screening for Distress, the 6th Vital Sign - Review and Practical<br />
Implications - Maria Ftanou, USA<br />
Trends in Oncology Nursing in Japan - Keiko Iino, Japan<br />
The Importance of Pre- and Early Postoperative Rehabilitation in NSCLC<br />
patient (Design and Rationale for the PROLUCA Study) - Malene Missel,<br />
Denmark<br />
Ethical Challenges in Conducting Clinical Research in Lung Cancer -<br />
Angela Tod, United Kingdom<br />
The Lung Cancer Patient - Addressing Issues of Survivorship - Maria<br />
Guerin, United Kingdom<br />
14:15 - 15:45 ED 06: Education Session: Treatment of Elderly and High Risk Patients with<br />
Localized NSCLC<br />
Track: Treatment of Localised Disease - NSCLC<br />
Chairs: Andrea Ardizzoni, Italy<br />
Rooms: 702 + 704 + 706<br />
<br />
<br />
<br />
<br />
Medical Oncology - Aminah Jatoi, USA<br />
Radiation Therapy - David Ball, Australia<br />
Surgery - Michael Weyant, USA<br />
Pulmonary - Gerard Silvestri, USA<br />
14:15 - 15:45 ED 07: Education Session: How to Treat Advanced Squamous Carcinoma of the<br />
Lung<br />
Track: Treatment of Advanced Disease - NSCLC<br />
Chairs: Byoung Chul Cho, South Korea & Primo Lara, USA<br />
Room: Four Seasons Ballroom F1 + F2<br />
Overview of the Histology and Potential Driver Mutations - Peter<br />
Hammerman, USA<br />
Current State of the Art - Glenwood Goss, Canada<br />
Lung Master Protocol in Squamous Cell Lung Cancer (Lung-MAP, S1400)<br />
- David R. Gandara, USA<br />
Targeting Gene Amplification in Squamous Cancer - Paul Paik, USA<br />
14:15 - 15:45 ED 08: Education Session: Talking with Patients<br />
Track: Palliative and Supportive Care<br />
Chairs: Luis Alberto Mas Lopez, Peru & Norma Pilnik, Argentina<br />
Rooms: 108 + 110 + 112<br />
Transitioning to End of Life Care: Who Should Lead the Discussion? –<br />
Daniel Handel, USA<br />
The Art of Taking Care of Patients, The Art of Giving Bad News – Ana<br />
Oton, USA<br />
51
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
Depression, The Silent Killer – Luis Ubillos, Uruguay<br />
Coping Mechanisms for People with Lung Cancer and their Families -<br />
Natalie Doyle, United Kingdom<br />
14:15 - 15:45 ED 09: Education Session: Tissue is the Issue: Improving Diagnostic Yield in the<br />
Age of Minimally Invasive Procedures<br />
Track: Community Practice<br />
Chairs: Philip Cagle, USA & Neal Lindeman, USA<br />
Room: Mile High Ballroom 1a - 1f<br />
Optimal Biopsy, Challenges - Sanja Dacic, USA<br />
Difficulties Coordinating Care - Ray Osarogiagbon, USA<br />
What Do You Do with Tissue Once Collected? What Tests Are Useful? -<br />
Marileila Varella-Garcia, USA<br />
Prioritization of Tissue Use - Thomas Hensing, USA<br />
14:15 - 15:45 Pro Con PC 02: Pro vs Con: Is There a Role for EGFR TKIs in EGFR Mutation<br />
Negative Disease?<br />
Track: Treatment of Advanced Disease /Biology, Pathology & Molecular Testing<br />
Chairs: Sumitra Thongprasert, Thailand & Yi-Long Wu, China<br />
Rooms: 205 + 207<br />
<br />
<br />
Pro - Scott Laurie, Canada<br />
Con - Lecia Sequist, USA<br />
Pro Con PC 02: Pro vs Con: Whole Exome Sequencing vs. Selected Testing (e.g.,<br />
ALK and EGFR)<br />
Track: Treatment of Advanced Disease /Biology, Pathology & Molecular Testing<br />
Chairs: Peter Meldgaard, Denmark & Kostas Syrigos, Greece<br />
Rooms: 205 + 207<br />
<br />
<br />
Pro – Ignacio Wistuba, USA<br />
Con - Yasushi Yatabe, Japan<br />
15:45 - 16:45 Networking Break and Poster Session 2<br />
Room: Exhibit Hall (Hall B + C)<br />
Refreshments will be provided<br />
16:45 - 18:15 Oral Session 28: T Cell Therapy for Lung Cancer<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Prasad Adusumilli, USA & Egbert Smit, Netherlands<br />
Room: Four Seasons Ballroom F1 + F2<br />
52
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
Checkpoint Blockade Augments TCR Engineered Adoptive T Cell Therapy<br />
for Lung Cancer - Edmund Moon, USA<br />
Mesothelin-Targeted CAR T-Cell Therapy for the Treatment of<br />
Heterogeneous Antigen-Expressing Lung Adenocarcinoma - Aurore<br />
Morello, USA<br />
Genetic-Engineering Strategies to Enhance CAR T-Cell Therapy Efficacy<br />
against PD-L1 Expressing Lung Adenocarcinoma and Mesothelioma -<br />
Leonid Cherkassky, USA<br />
Tumor-Targeted Radiation Therapy Helps Overcome the Solid Tumor T-<br />
Cell Infiltration Barrier and Promotes Mesothelin CAR T-Cell Therapy -<br />
Marissa Mayor, USA<br />
Mesothelin and MUC16 (CA125) Are Antigen-Targets for CAR T-Cell<br />
Therapy in Primary and Metastatic Lung Adenocarcinoma - Takashi<br />
Eguchi, USA<br />
Discussant - Egbert Smit, Netherlands<br />
16:45 - 18:15 Oral Session 29: MASCC-IASLC Joint Session: Palliative and Supportive Care<br />
Track: Palliative and Supportive Care<br />
Moderators: Paul van Houtte, Belgium<br />
Rooms: 708 + 710 + 712<br />
<br />
<br />
<br />
<br />
<br />
<br />
Results From Phase III Trials of Anamorelin in Advanced Non-Small Cell<br />
Lung Cancer Patients with Cachexia: ROMANA 1 and 2 - Amy<br />
Abernethy, USA<br />
ONO-7643/Anamorelin for the Treatment of Cancer Cachexia in<br />
Advanced NSCLC Patients: Results From the Phase 2 Study in Japan -<br />
Nobuyuki Katakami, Japan<br />
Efficacy of the Antiemetic Combination Agent, NEPA, in Patients with<br />
Lung Cancer Receiving Platinum Chemotherapy - Paul Hesketh, USA<br />
The Impact of Perioperative Immunonutrition on Tissue Healing and<br />
Infection Related Morbidity in Patients Undergoing Lung Resection for<br />
NSCLC - Güven Olgaç, Turkey<br />
Skeletal Muscle and Lean Body Mass Loss Are Associated with Poorer<br />
Prognosis in Patients with NSCLC Treated with Afatinib - Martha De La<br />
Torre-Vallejo, Mexico<br />
Low Prognostic Nutritional Index Correlates with Worse Survival in<br />
Patients with Advanced NSCLC following EGFR-TKIs - Yunpeng Yang,<br />
China<br />
16:45 - 18:15 Oral Session 30: Community Practice<br />
Track: Community Practice<br />
Moderators: Patricia Kho, Singapore & Robert Jotte, USA<br />
Room: Mile High Ballroom 2c - 3c<br />
<br />
Evolution in the Surgical Care of Non-Small Cell Lung Cancer (NSCLC)<br />
Patients in the Mid-South Quality of Surgical Resection (MS-QSR) Cohort<br />
- Edward Robbins, USA<br />
53
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Treatment of Non-Small Cell Lung Cancer in Patients with a High<br />
Comorbidity Index - Jorge Rios, USA<br />
Access to Cancer Directed Therapies and Cancer Specialists in Patients<br />
with Metastatic Lung Cancer - Apar Ganti, USA<br />
Discussant - Stephen Swisher, USA<br />
Clinical Implementation of the NextDaySeq Lung Panel for Identification<br />
of Clinically Actionable Variants in Non-Small Cell Lung Cancer - Xiaohua<br />
Shi, China<br />
Genomic Analysis of Lung Cancer Tumors from Hispanic Patients Living<br />
in the US - Luis Raez, USA<br />
Different Mutation Profiles and Clinical Characteristics Among Hispanic<br />
Patients with NSCLC Could Explain The "Hispanic Paradox" - María<br />
Castillo, Mexico<br />
Discussant - Edward Kim, USA<br />
16:45 - 18:15 Mini Oral 15: Chemotherapy Developments for Lung Cancer<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Lucio Crinò, Italy & Chandra Belani, USA<br />
Room: Mile High Ballroom 1a - 1f<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
A Phase I/II Study Evaluating the Combination of Resminostat and<br />
Docetaxel for Platinum-Pretreated NSCLC - Atsushi Horiike, Japan<br />
NEJ016: Phase II Study of CBDCA and Weekly PTX plus BEV Followed by<br />
BEV for Highly Selected Elderly Non-Squamous NSCLC Patients - Ou<br />
Yamaguchi, Japan<br />
Phase I & II Studies of the Decitabine-Genistein Drug Combination in<br />
Advanced Solid Tumours - Normand Blais, Canada<br />
Phase I Study of Continuous Intravenous Infusion of Rh-Endostatin<br />
Combined with Pemetrexed and Carboplatin in Advanced NSCLC - Yan<br />
Huang, China<br />
Discussant - Gilberto Lopes Júnior, Brazil<br />
Impact of Three and Further Lines in Advanced Non-Small Cell Lung<br />
Cancer Patients According to Molecular Profile: A Retrospective Analysis<br />
- Enric Carcereny, Spain<br />
Prognostic Importance of Pretreatment Sodium Levels in Patients of<br />
NSCLC Treated with Pemetrexed-Platinum Doublet Chemotherapy -<br />
Manjunath Nookala Krishnamurthy, India<br />
A Phase II Study of Pemetrexed plus Carboplatin Followed by<br />
Maintenance Pemetrexed in Elderly Patients with Advanced Non-<br />
Squamous NSCLC - Motohiro Tamiya, Japan<br />
Bayesian Network Meta-Comparison of Maintenance Treatments for<br />
Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients - Gilberto De<br />
Lima Lopes, Brazil<br />
Discussant - Lucio Crinò, Italy<br />
Optimal Second Line Chemotherapy after 1st Line Pemetrexed and<br />
Cisplatin Treatment in EGFR Mutation Negative Advanced NSCLC<br />
Patients - Sung Yong Lee, South Korea<br />
54
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
Satisfaction with Therapy and the Relation with Quality of Life in<br />
Patients with Advanced NSCLC Receiving Chemotherapy - Sabine Visser,<br />
Netherlands<br />
An Evaluation of Chemotherapy Regimens in an Unselected Population<br />
of NSCLC Patients - Stefan Grant, USA<br />
The Role of Breath Sampling in Monitoring Response to Treatment in<br />
Lung Cancer - Nir Peled, Israel<br />
16:45 - 18:15 Mini Oral 16: EGFR Mutant Lung Cancer 2<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Gregory Riely, USA & Marina Garassino, Italy<br />
Room: Four Seasons Ballroom F3 + F4<br />
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment<br />
Response in Advanced Non-Small Cell Lung Cancer With Uncommon<br />
Mutations - Masaki Kanazu, Japan<br />
Rare and Common EGFR Mutations in Patients with Advanced NSCLC<br />
Treated with EGFR-TKIs: A Registry-Based Study - Milos Pesek, Czech<br />
Republic<br />
Dose Optimization of Rociletinib for EGFR Mutated NSCLC - Jonathan W.<br />
Goldman, USA<br />
Activity of Rociletinib in EGFR Mutant NSCLC Patients with a History of<br />
CNS Involvement - D. Ross Camidge, USA<br />
Discussant - Caicun Zhou, China<br />
AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA Study<br />
Phase II Extension Cohort - James Chih-Hsin Yang, Taiwan<br />
AZD9291 in Treatment-Naïve EGFRm Advanced NSCLC: AURA First-Line<br />
Cohort - Suresh Ramalingam, USA<br />
AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA2 Phase<br />
II Study - Tetsuya Mitsudomi, Japan<br />
Design, Execution, and Preliminary Biomarker Results from Paired<br />
Tumor Biopsy Cohorts of the AZD9291 AURA Trial - Pasi Jänne, USA<br />
Discussant - Martin Reck, Germany<br />
Plasma HGF Reduction Is Associated with Better Prognosis in EGFR-<br />
Positive Advanced Lung Adenocarcinoma Patients Treated with Afatinib<br />
- Oscar Arrieta Rodriguez, Mexico<br />
Lung Adenocarcinoma Transformation into Small-Cell Lung Cancer after<br />
Treatment: Clinical Evidence and the Exploratory Mechanism - Jie<br />
Wang, China<br />
A Randomized Controlled Trial of Erlotinib versus Gefitinib in Advanced<br />
Non-Small-Cell Lung Cancer Harboring EGFR Mutations (CTONG0901) -<br />
Jin-ji Yang, China<br />
A Phase 1 Study of Erlotinib and Ruxolitinib in Patients with EGFR-<br />
Mutant Lung Cancers and Acquired Resistance to Erlotinib Therapy -<br />
Helena Yu, USA<br />
Discussant - Trever Bivona, USA<br />
55
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
16:45 - 18:15 Mini Oral 17: WT EGFR, Angiogenesis and OMD<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Rafal Dziadziuszko, Poland & Ronald Feld, Canada<br />
Room: Mile High Ballroom 4a - 4f<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Maintenance with Gefitinib/Pemetrexed (G/P) or P After Induction<br />
P/Platinum for Stage IV Lung Adenocarcinoma with No Sensitizing EGFR<br />
Mutation - Chun-Ming Tsai, Taiwan<br />
SWOG 0709: Randomized Phase II Trial of Erlotinib vs. Erlotinib plus<br />
Carboplatin/Paclitaxel in Patients (Pts) with Advanced Non-Small Cell<br />
Lung Cancer (NSCLC) and Impaired Performance Status (PS2) as Selected<br />
by Serum Proteomics - Primo Lara Jr., USA<br />
Prognostic and Predictive Value of the VeriStrat Classifier in Chemo-<br />
Naive NSCLC Patients Treated with Erlotinib or Placebo (TOPICAL Trial) -<br />
Siow-Ming Lee, United Kingdom<br />
Erlotinib in 2nd Line in Advanced Squamous NSCLC: Final Results of the<br />
Pepita Cohort - Alain Vergnenegre, France<br />
Discussant - Ross Soo, Singapore<br />
Subgroup Analysis of East Asian Patients in the Phase III REVEL Trial - Jin-<br />
Hyoung Kang, South Korea<br />
Efficacy of Nintedanib/Docetaxel after Bevacizumab, Pemetrexed or<br />
Taxanes Therapy - David Heigener, Germany<br />
Tumor Growth Over Time with Nintedanib/Docetaxel or<br />
Placebo/Docetaxel in Adenocarcinoma NSCLC: Analysis From the LUME-<br />
Lung 1 Study - Martin Reck, Germany<br />
Discussant - Thomas John, Australia<br />
Oligometastatic Non-Small-Cell Lung Cancer and Unresectable Primary<br />
Tumor: Safety and Efficacy of Radical Treatment - Javier Garde-<br />
Noguera, Spain<br />
Results of Radical Local Treatment of Non-Small Cell Lung Cancer<br />
Patients with One or Two Synchronous Metastases - Margriet Kwint,<br />
Netherlands<br />
Survival Analysis of Stage IV NSCLC with Synchronous Isolated<br />
Metastasis in a Large Retrospective Cohort - Anne Claire Toffart, France<br />
Prognosis of Stage III NSCLC Patients Presenting with Isolated Brain<br />
Failure after Definitive Concurrent Chemoradiotherapy - Erkan Topkan,<br />
Turkey<br />
Survival Analysis following Pulmonary Metastasectomy for Non-Small<br />
Cell Lung Cancer - Hyo-Jun Jang, South Korea<br />
Discussant - Melissa Johnson, USA<br />
16:45 - 18:15 Mini Oral 18: Radiation Topics in Localized NSCLC<br />
Track: Treatment of Localized Disease - NSCLC<br />
Moderators: David Raben, USA & Sue Yom, USA<br />
Rooms: 601 + 603<br />
56
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Stereotactic Body Radiation v. Observation for Early-Stage NSCLC in<br />
Elderly Patients - Ronica Nanda, USA<br />
Stereotactic Body Radiotherapy Is Safe and Effective in Octo- and<br />
Nonagenarians for the Treatment of Early Stage Lung Cancer - Heike<br />
Peulen, Netherlands<br />
Immune Activation in Early Stage Non-Small Cell Lung Cancer (NSCLC)<br />
following Stereotactic Ablative Radiotherapy (SABR) and Surgery -<br />
Joachim Aerts, Netherlands<br />
Tumor Volume Variations and Related Dosimetric Impact During<br />
Stereotactic Body Radiation Therapy for Lung Cancer - Luigi Moretti,<br />
Belgium<br />
Discussant - Hak Choy, USA<br />
Validation of High Risk Features on CT for Detection of Local Recurrence<br />
After SBRT for Stage I NSCLC - Heike Peulen, Netherlands<br />
Early Results of a Quality Assurance Program in a Randomized Trial of<br />
Stereotactic Body Radiotherapy for Stage I Medically Inoperable Lung<br />
Cancer - Anand Swaminath, Canada<br />
A Systematic Review of Comparative Effectiveness Studies of Surgery<br />
versus SABR in Early Stage Lung Cancer: How Good Is the Data? -<br />
Alexander Louie, Canada<br />
Survival of Elderly Patients after SABR for Early Lung Cancers - A<br />
Population Based Retrospective Comparison of Survival among Age<br />
Cohorts - Devin Schellenberg, Canada<br />
Does Motion Management Technique for Lung SBRT Influence Local<br />
Control? - Gregory Videtic, USA<br />
Assessment of Dose Response via Regional Lung Perfusion following<br />
Stereotactic Radiotherapy for Lung Cancer - Ross McGurk, USA<br />
Can Stereotactic Ablative Radiotherapy (SABR) Improve Patient<br />
Selection for Lung Cancer Surgery and Reduce Perioperative Mortality? -<br />
Drew Moghanaki, USA<br />
Pre-Existing Pulmonary Fibrosis Increases the Risk of Radiation<br />
Pneumonitis - Sorcha Campbell, United Kingdom<br />
Discussant - Wilfried Eberhardt, Germany<br />
16:45 - 18:15 Mini Oral 19: Surgical Topics in Localized NSCLC<br />
Track: Treatment of Localized Disease - NSCLC<br />
Moderators: David Jablons, USA & Brendon Stiles, USA<br />
Rooms: 605 + 607<br />
<br />
<br />
<br />
Benefits of Surgical Treatment and Complementary Utility of Metabolic<br />
Tumor Volume in Selecting Therapy for Stage III NSCLC - Yonglin Pu,<br />
USA<br />
Mediastinal Nodal Involvement in Patients with Clinical Stage I Non-<br />
Small-Cell Lung Cancer -Possibility of Rational Lymph Node Dissection- -<br />
Tomohiro Haruki, Japan<br />
Subcarinal Lymph Node Dissection Is Also Necessary in Upper<br />
Lobectomies for Lung Cancer - Jens Eckardt, Denmark<br />
57
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Relationship Between Adequacy of Intra-Operative Lymph Node<br />
Sampling During Surgical Resection of NSCLC and Survival - Richard<br />
Booton, United Kingdom<br />
Discussant – Michael Weyant, USA<br />
External Validation of a Chinese Developed Survival Score in a Western<br />
Cohort Undergoing Surgery for Non-Small Cell Lung Cancer - Ulas<br />
Kumbasar, United Kingdom<br />
ICG Fluorescence Localization of Small Sized Pulmonary Nodules for<br />
VATS - Takashi Anayama, Japan<br />
Validation of a Surgical Predictive Score for 90 Day Mortality in Lung<br />
Cancer and Comparison with Thoracoscore - Emma O'Dowd, United<br />
Kingdom<br />
Adjunct Intraop Cone Bean CT (CBCT) with Real Time 3D Overlay<br />
Improves Diagnostic Accuracy of Electromagnetic Navigational<br />
Bronchoscopy (ENB) - Sandeep Sachidananda, USA<br />
Use of Electromagnetic Navigational Bronchoscopy to Localize<br />
Pulmonary Nodules Prior to Minimally Invasive Sublobar Resection -<br />
Sandeep Sachidananda, USA<br />
The Value of Video-Assisted Mediastinoscopic Lymphadenectomy in<br />
Clinical Stage I Non-Small Cell Lung Cancers - Akif Turna, Turkey<br />
Nodal Staging via Robotic-Assisted Thoracic Surgery for Clinical Stage I<br />
Non-Small Cell Lung Cancer - Vanessa Dipasquale, USA<br />
Survival After Sub-Lobar Resection for Early Stage Lung Cancer:<br />
Methodological Obstacles in Comparing the Efficacy to Lobectomy -<br />
Emanuela Taioli, USA<br />
Discussant - Jesper Pedersen, Denmark<br />
16:45 - 18:15 Mini Oral 20: Surgery<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Moderator: Giulia Veronesi, Italy<br />
Rooms: 201 + 203<br />
<br />
<br />
<br />
<br />
<br />
<br />
Do Secondary Lung Cancers Have the Same Disease-Specific Survival and<br />
Overall Survival as Primary Lung Cancers? - Cameron Stock, USA<br />
Risk-Adjusted Margin Positivity (RAMP) Rate as a Surgical Quality Metric<br />
for Non-Small-Cell Lung Cancer in the US National Cancer Data Base<br />
(NCDB) - Chun Chieh Lin, USA<br />
The Survival Impact of Missed Lymph Node Metastasis in Surgically<br />
Resected Non-Small Cell Lung Cancer (NSCLC) - Nicholas Faris, USA<br />
Right-Sided vs Left-Sided Pneumonectomy after Induction Therapy for<br />
Non-Small Cell Lung Cancer - Chi-Fu Yang, USA<br />
Discussant - Ugo Pastorino, Italy<br />
The Importance of Sleeve Lobectomy after Induction Therapy for<br />
Patients with Stage IIIA-N2 Lung Cancer: The Avoidance of<br />
Pneumonectomy - Jong Ho Cho, South Korea<br />
58
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Extended Cervical Mediastinoscopy (ECM) for Biopsy of AortoPulmonary<br />
Window (APW) Lymph Nodes and an APW Index (APWI) Useful in<br />
Patient Selection - Robert Cameron, USA<br />
Survival in Unexpected Multi-Station pN2 Following Surgical Resection<br />
of NSCLC - Richard Booton, United Kingdom<br />
Discussant – Valerie Rusch, USA<br />
Prognostic Impact of Lymph Node Ratio in Patients with Pathologic<br />
Stage N1 Non-Small Cell Lung Cancer - Sumin Shin, South Korea<br />
Lymph Node Impact on Conversion of VATs Lobectomy to Open<br />
Thoractomy - Yun Li, China<br />
Advancements in Bronchoplasty as Treatments for Lung Cancer: Single<br />
Institutional Review of 213 Patients - Takeshi Nagayasu, Japan<br />
A Prospective Comparison of FDG-PET & EBUS for Determining the<br />
Extent of Mediastinal Lymph Node Involvement in NSCLC - Daniel<br />
Steinfort, Australia<br />
Discussant - Gail Darling, Canada<br />
16:45 - 18:15 Mini Oral 21: Novel Targets<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Benjamin Levy, USA & Daniel Shao Weng Tan, Singapore<br />
Room: Mile High Ballroom 2a - 3b<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Purinergic Signaling in NSCLC - First in Vivo Data and Potential<br />
Therapeutic Targets - Severin Schmid, Germany<br />
CCT68127 Is a next Generation CDK2/9 Inhibitor with Potent<br />
Antineoplastic Activity Against Lung Cancer Cells - Masanori Kawakami,<br />
USA<br />
CACNA2D1 Is a Novel Biomarker for Tumor Initiating Cells and Has<br />
Therapeutic Effect in Non-Small Cell Lung Cancer - Yuanyuan Ma, China<br />
HS3ST3B1 Is a Novel Regulator of TGF-Beta Mediated EMT and<br />
Regulated by miR-218 in Lung Cancer - Yongsheng Wang, China<br />
Discussant - Sanjay Popat, United Kingdom<br />
Role of the Focal Adhesion Protein Paxillin in Lung Cancer - From<br />
Genetic Alterations to Novel Mitochondrial Functionality - Rifat Hasina,<br />
USA<br />
Oncogenic EZH2 Is an Actionable Target in Patients with<br />
Adenocarcinoma of the Lung (LUAD) - George Simon, USA<br />
Bombesin Receptor Subtype-3: An Underappreciated Growth Factor in<br />
Lung Cancer - Paola Moreno, USA<br />
Discussant - Jin Soo Lee, South Korea<br />
The TORK/DNA-PK Inhibitor CC-115 Shows Combination Anti-<br />
Proliferative Effects with Erlotinib in NSCLC Cells Resistant to EGFR<br />
Inhibition - Simon Ekman, USA<br />
A Novel Cell Line Model of EGFR Exon 20 Insertion Mutations - Adriana<br />
Estrada-Bernal, USA<br />
Identification of a First in Class TWIST1 Inhibitor with Activity in KRAS<br />
Mutant NSCLC - Timothy Burns, USA<br />
59
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
Discussant - Giuseppe Giaccone, USA<br />
16:45 - 18:15 Mini Oral 22: New Technology<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Lauren Byers, USA & Yasushi Yatabe, Japan<br />
Rooms: 205 + 207<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Detecting ALK, ROS1 and RET Fusion Genes in Advanced Non-Small Cell<br />
Lung Cancer (NSCLC) Using a Novel Multiplexed NCounter-Based Assay -<br />
Noemi Reguart, Spain<br />
Clinically Adoption of MSK-IMPACT, a Hybridization Capture-Based next<br />
Generation Sequencing Assay, for the Assessment of Lung<br />
Adenocarcinomas - Maria Arcila, USA<br />
Next Generation Immunohistochemical Stains; True Multiplex<br />
(Quadruple) Immunohistochemical Panel for Non-Small Cell Lung<br />
Carcinoma - Charalambos Solomides, USA<br />
Discussant - Johan Botling, Sweden<br />
Quality Control Process for NGS to Minimize False Positives - Carl<br />
Morrison, USA<br />
The Challenge of Molecular Testing for Clinical Trials in Advanced Non-<br />
Small Cell Lung Cancer Patients: Analysis of a Prospective Database -<br />
Stefanie Lepers, Belgium<br />
An in Vitro Biomimetic Multi-Organ Microfluidic Chip System to Test<br />
Lung Cancer Metastasis - Qi Wang, China<br />
Development of a Protein Viewer for Displaying Variants of Unknown<br />
Significance in Relation to Actionable Mutations and Protein Domains -<br />
Antonios Papanicolau-Sengos, USA<br />
Discussant - Peter Mazzone, USA<br />
A New Approach to Large Scale Proteomic Profiling to Uncover Tumor<br />
Phenotypes - Rachel Ostroff, USA<br />
A Clinical Platform for Examining Mechanism-Driven Chemotherapeutic<br />
Agents - Cherie Erkmen, USA<br />
Nanotechnology for the Treatment of Lung Cancer: The Future of<br />
Targeted Therapy - Gannu Praveen Kumar, India<br />
Molecular Characterisation of SCLC Using Both Circulating Tumour DNA<br />
and Circulating Tumour Cells Isolated from the Same Whole Blood<br />
Sample - Dominic Rothwell, United Kingdom<br />
Discussant - Eric Haura, USA<br />
16:45 - 18:15 Mini Oral 23: Lung Cancer Risk: Genetic Susceptibility and Airway Biology<br />
Track: Screening and Early Detection<br />
Moderators: Pieter E. Postmus, Netherlands & Robert Young, New Zealand<br />
Rooms: 401 - 404<br />
<br />
Risk of Lung Cancer in Female Non-Smokers Requires Extended<br />
Screening Guidelines - Michael Jaklitsch, USA<br />
60
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
COPD Severity by GOLD Status and Lung Cancer Risk: Results from a<br />
Large Prospective Screening Study (NLST-ACRIN Cohort Analysis, N=18,<br />
714) - Raewyn Hopkins, New Zealand<br />
Targeted Exome Sequencing of Smokers Susceptible and Resistant to<br />
Chronic Obstructive Pulmonary Disease - Yanhong Liu, USA<br />
Familial Clustering of Lung Cancer (LC) Cases in a South European<br />
Population (sEp) - Ignacio Gil-Bazo, Spain<br />
A Case-Control Study on the Genetic Risks for Development of Lung<br />
Adenocarcinoma in Never-Smoking Hong Kong Population - Li Han,<br />
Hong Kong<br />
Discussant - York Miller, USA<br />
The Airway Field of Injury Reflects Metabolic Changes Associated with<br />
the Presence of Lung Squamous Premalignant Lesions - Sarah Mazzilli,<br />
USA<br />
Comparison of in Vivo Raman and NIR Spectroscopy and EBUS as<br />
Confirmatory Method for Ideal Biopsy Area during Bronchoscopic<br />
Navigation - Jiri Votruba, Czech Republic<br />
Clinical Application of Computer Assistant Diagnostic System in Probe-<br />
Based Confocal Laser Endomicroscopy (pCLE) for Pulmonary Diseases -<br />
Dawei Yang, China<br />
Subtraction of Allelic Fractions (Delta- θ): A Sensitive Metric to Detect<br />
Chromosomal Alterations in Heterogeneous Premalignant Specimens -<br />
Ichiro Nakachi, Japan<br />
Discussant - Luc Thiberville, France<br />
HAases and HAS in Lung/Bronchial Pre-Neoplastic Lesions: Impact on<br />
Prognosis - Vanessa De Sá, Brazil<br />
Extracellular Sulfatase SULF2: A Potential Biomarker for the Early<br />
Detection of Lung Cancer - Hassan Lemjabbar-Alaoui, USA<br />
Circulating Long Non-Coding RNA GAS5 Is a Novel Biomarkers for the<br />
Diagnosis of Non-Small Cell Lung Cancer - Yong Song, China<br />
Discussant - Céline Mascaux, France<br />
16:45 - 18:15 Mini Oral 24: Epidemiology, Early Detection, Biology<br />
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies<br />
Moderators: Jenette Creaney, Australia & Michele Carbone, USA<br />
Rooms: 102 + 104 + 106<br />
Pleural and Peritoneal Malignant Mesothelioma in Women Correlated<br />
to Occupational, Domestic and Environmental Asbestos Exposure -<br />
Vasiliki Panou, Denmark<br />
Mesothelioma Risk in Turkey - Muzaffer Metintas, Turkey<br />
Asbestos Knowledge and Awareness Level - Selma Metintas, Turkey<br />
Cluster Analysis of Malignant Mesothelioma Incidence in Louisiana -<br />
Elizabeth Levitzky, USA<br />
Discussant - Marjorie Zauderer, USA<br />
Mesothelioma in Finland: 10 Year Population-Based Cohort Between<br />
2000-2009 - Ilkka Ilonen, Finland<br />
61
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Infrared Spectroscopy as a Novel Approach in Differential Diagnosis of<br />
Malignant Pleural Mesothelioma from Lung Cancer Using Pleural Fluid -<br />
Salih Emri, Turkey<br />
Breath Analysis by Ion Mobility Spectrometry Allows Discrimination of<br />
Pleural Mesothelioma Patients From Controls - Kevin Lamote, Belgium<br />
Cell-Free MicroRNA miR-625-3p Is Elevated in the Blood of Patients with<br />
Thoracic Malignancies - Michaela Kirschner, Australia<br />
Discussant - Takashi Nakano, Japan<br />
Expression of PD-1 and Its Ligands in Human Malignant Pleural<br />
Mesothelioma - Elly Marcq, Belgium<br />
Assessment of PD-L1, TGF-β Expression and Tumor-Infiltrating CD8+ T<br />
Cells in Advanced Thymic Epithelial Tumors - Jie Wang, China<br />
Molecular and Pathological Features of Different Malignant Pleural<br />
Mesothelioma (MPM) Histologic Subtypes - Giulia Pasello, Italy<br />
Use of Next Generation Sequencing to Improve Lung Tumor<br />
Immunotherapy - Bruce Robinson, Australia<br />
Discussant - Enriqueta Felip, Spain<br />
16:45 - 18:15 Mini Oral 25: Trials, Radiation and Other<br />
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies<br />
Moderators: Jose Clavero, Chile & Raffit Hassan, USA<br />
Rooms: 702 + 704 + 706<br />
A Phase II Study of Dovitinib in Previously-Treated Malignant Pleural<br />
Mesothelioma: The Ontario Clinical Oncology Group DOVE-M Trial -<br />
Scott Laurie, Canada<br />
A Clinical Study on Intra-Thoracic Chemotherapy of Recombinant<br />
Human Endostatin Combined with Cisplatin for Malignant Pleural<br />
Effusion - Xingsheng Hu, China<br />
Potent Anti-Mesothelioma Activity by the Novel Naftopidil Analogue<br />
HUHS1015; Preclinical Evidence for Treatment - Kozo Kuribayashi,<br />
Japan<br />
Utilizing Molecular Profiling to Identify Potential Therapies in<br />
Sarcomatoid Lung Cancer - Panagiotis Fidias, USA<br />
Discussant - Anne Tsao, USA<br />
Appropriate Time of Adjuvantr Adiotherapy for Thymoma with MG After<br />
Thymectomy - Lei Yu, China<br />
Clinical Activity of Lucitanib in Advanced Thymic Epithelial Tumours -<br />
Benjamin Besse, France<br />
Systemic Treatment in Advanced Thymic Epithelial Tumors. Insights<br />
From a Prospective Cohort of 888 Patients Enrolled in RYTHMIC -<br />
Nicolas Girard, France<br />
Percutaneous Cryoablation for Recurrent Mesothelioma following Lung<br />
Sparing Pleurectomy and Decortication: Safety and Efficacy - Fereidoun<br />
Abtin, USA<br />
Discussant - Francoise Mornex, France<br />
62
Tuesday, <strong>September</strong> 8, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
Optimization of Gross Tumour Volume Definition in Lung-Sparing<br />
Volumetric Modulated Arc Therapy for Pleural Mesothelioma - Dirk De<br />
Ruysscher, Belgium<br />
Hospital Resource Utilization and Outcomes of Pleurectomy Compared<br />
to Extrapleural Pneumonectomy for Mesothelioma - Robert Cameron,<br />
USA<br />
Survival Prediction Model of Repeated Pulmonary Metastasectomy for<br />
Osteosarcoma: A Nomogram and Regression Trees - Haewon Lee, South<br />
Korea<br />
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia<br />
(DIPNECH): Descriptive Analysis and Overall Survival - Mukesh Kumar,<br />
USA<br />
Discussant - John Edwards, United Kingdom<br />
18:30 - 20:00 Symposium supported by Boehringer Ingelheim: Individual EGFR Mutations:<br />
Informing First-Line Treatment in EGFR Mutation-Positive NSCLC<br />
Chair: Ramaswamy Govindan, USA<br />
Rooms: 205 + 207<br />
<br />
<br />
<br />
<br />
<br />
Welcome and Introductions - Ramaswamy Govindan, USA<br />
The Role of Biomarker Testing in Advanced NSCLC - Shirish Gadgeel,<br />
USA<br />
ErbB Family Blockade in EGFR mutation-positive NSCLC - David Carbone,<br />
USA<br />
First-Line Treatment of EGFR Mutation-Positive NSCLC: Patient Case<br />
Study - Panos Fidias, USA<br />
Final Questions and Meeting Close - Ramaswamy Govindan, USA<br />
*Agenda: click here<br />
20:00 - 23:00 Gala Dinner (Ticketed Event)<br />
Room: Hall A<br />
63
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
07:00 - 08:00 Symposium supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers<br />
Squibb Company and Genentech BioOncology: The Current and Emerging Role<br />
of Immune Checkpoint Inhibitors in the Management of Lung Cancer<br />
Rooms: 401 - 404<br />
<br />
Website:<br />
www.researchtopractice.com/Meetings/IASLC<strong>2015</strong>/Immunotherapy<br />
07:00 - 08:00 Symposium supported by Boehringer Ingelheim Pharmaceuticals Inc.: ERBB<br />
Family Blockade in NSCLC: Expert Perspectives on Optimizing Management<br />
Chair: Barbara Gitlitz, USA<br />
Rooms: 601 + 603<br />
Website: www.ecgcme.com/erbb<br />
<br />
<br />
<br />
<br />
EGFR Testing and ERBB Family Members/Inhibitors - Geoffrey Oxnard<br />
Critical Updates on EGFR-TKIs in Selected Populations - Anne Tsao<br />
Addressing the Challenge of Acquired Resistance to EGFR TKIs - Helena<br />
Yu<br />
Thoughts From the Chair - Barbara Gitlitz<br />
07:00 - 08:00 Highlights of the Previous Day HOD 03: Treatment of Advanced, Localized and<br />
LocoRegional Disease and Small Cell, Thymoma, Mesothelioma<br />
Track: Highlights from Tuesday, <strong>September</strong> 8<br />
Room: Four Seasons Ballroom F1 + F2<br />
<br />
<br />
<br />
<br />
Treatment of Advanced Disease - Luis Paz-Ares, Spain<br />
Treatment of Localized Disease - Mark Kris, USA<br />
Treatment of LocoRegional Disease - Ronald Natale, USA<br />
Small Cell/Thymoma/Mesothelioma/Other - Martin Edelman, USA<br />
07:00 - 08:00 Highlights of the Previous Day HOD 04: Biology, Pathology, Molecular Testing,<br />
Prevention, Tobacco Control, Screening and Early Detection<br />
Track: Highlights from Tuesday, <strong>September</strong> 8<br />
Room: Four Seasons Ballroom F3 + F4<br />
<br />
<br />
<br />
Biology, Pathology, Molecular Testing - Philip Cagle, USA<br />
Prevention, Tobacco Control - Silvia Novello, Italy<br />
Screening, Early Detection - Pieter E. Postmus, Netherlands<br />
07:00 - 08:00 MTE 23: Meet the Expert: Standard Therapy for Advanced NSCLC in Absence of<br />
Driver Mutations (Ticketed Session)<br />
64
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
Track: Treatment of Advanced Disease - NSCLC<br />
Speaker: Corey Langer, USA<br />
Room: 103<br />
07:00 - 08:00 MTE 24: Meet the Expert: Rising to the Challenge of Testing Small Biopsy<br />
Specimens (Ticketed Session)<br />
Track: Biology, Pathology & Molecular Testing<br />
Speaker: Lynette Sholl, USA<br />
Room: 105<br />
07:00 - 08:00 MTE 25: Meet the Expert: New Therapies for Squamous Cell Carcinoma<br />
(Ticketed Session)<br />
Track: Community Practice<br />
Speaker: Shirish Gadgeel, USA<br />
Room: 107<br />
07:00 - 08:00 MTE 26: Meet the Expert: Multidisciplinary Approach to a Comprehensive CT<br />
Screening Program (Ticketed Session)<br />
Track: Community Practice<br />
Speaker: David Midthun, USA<br />
Room: 109<br />
07:00 - 08:00 MTE 27: Meet the Expert: Modern Approaches to Radiotherapy in Stage III<br />
Disease (Ticketed Session)<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Speaker: Maria Werner-Wasik, USA<br />
Room: 111<br />
07:00 - 08:00 MTE 28: Meet the Expert: Need for Team Building in Caring for Patients with<br />
Thoracic Malignancies (Ticketed Session)<br />
Track: Nursing and Allied Professionals<br />
Speaker: Melissa Culligan, USA & Richard Gralla, USA<br />
Room: 102 + 104 + 106<br />
07:00 - 08:00 MTE 29: Meet the Expert: Managing Side Effects from Tyrosine Kinase<br />
Inhibitors (Ticketed Session)<br />
Track: Palliative and Supportive Care<br />
Speaker: Anne Fraser, New Zealand<br />
Room: 108 + 110 + 112<br />
65
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
07:00 - 08:00 MTE 30: Meet the Expert: Cachexia (Ticketed Session)<br />
Track: Palliative and Supportive Care<br />
Speakers: Amy Abernethy, USA & Jeffrey Crawford, USA<br />
Room: 702 + 704 + 706<br />
07:00 - 08:00 MTE 31: Meet the Expert: Smoking Cessation Integrated with Screening<br />
(Window of Opportunity) (Ticketed Session)<br />
Track: Prevention & Tobacco Control<br />
Speakers: Denise Aberle, USA & Jamie Ostroff, USA<br />
Room: 708 + 710 + 712<br />
07:00 - 08:00 MTE 32: Meet the Expert: Treatment of Early Stage SCLC (Ticketed Session)<br />
Track: Small Cell Lung Cancer<br />
Speakers: Jacek Jassem, Poland & Eric Lim, United Kingdom<br />
Room: 703<br />
07:00 - 08:00 MTE 33: Meet the Expert: (Debate on) Prognostic Biomarkers in Mesothelioma<br />
(Ticketed Session)<br />
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies<br />
Speakers: Raphael Bueno, USA & Bruce Robinson, Australia<br />
Room: 201 + 203<br />
08:15 - 09:45 Plen 03: Plenary Session: Science Drives Lung Cancer Advances<br />
Track: Plenary<br />
Chairs: Tetsuya Mitsudomi, Japan & Tony Mok, Hong Kong<br />
Room: Plenary Hall (Bellco Theatre)<br />
<br />
<br />
<br />
<br />
<br />
Lung Cancer Genomes - Adenocarcinoma - Matthew Meyerson, USA<br />
Lung Cancer Genomes - Squamous Cell Carcinoma/Small Cell - Roman<br />
Thomas, Germany<br />
Molecular Mechanisms of Drug Resistance - Pasi Janne, USA<br />
Personalized Medicine - Jean-Charles Soria, France<br />
Mouse Models of SCLC and NSCLC - Anton Berns, Netherlands<br />
09:45 - 10:45 Press Conference 4<br />
Moderator: Dr. Paul A. Bunn, Jr., Distinguished Professor of Medicine at the<br />
University of Colorado Denver School of Medicine<br />
Room: 108 + 110 + 112<br />
66
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
Daily Theme: Science Drives Lung Cancer Advances - Dr. David R.<br />
Gandara, Professor of Medicine, Division of Hematology/Oncology,<br />
Director, Thoracic Oncology Program, Senior Advisor to the Director,<br />
UC Davis Comprehensive Cancer Center, Sacramento, California<br />
Abstract – Randomized Phase III Trial of Adjuvant Chemotherapy with or<br />
without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC):<br />
Results of E1505 - Dr. Heather Wakelee, Associate Professor of<br />
Medicine (Oncology) at the Stanford University Medical Center,<br />
Stanford, California<br />
Abstract – Stopping Smoking Reduces Mortality in Low-Dose Computed<br />
Tomography (LDCT) Screening Volunteers - Dr. Ugo Pastorino, Director<br />
Thoracic Surgery, IRCCS Istituto Nazionale dei Tumori Foundation,<br />
Milan, Italy<br />
Abstract – Multiregion Whole Exome and Transcriptome Sequencing<br />
Defines the Genomic Spectrum of EGFR+ NSCLC and Reveals Novel<br />
Mechanisms of TKI Resistance - Dr. Daniel Shao Weng Tan, Consultant,<br />
Medical Oncology, National Cancer Centre, Singapore<br />
Abstract – A Randomized, Phase III Study Comparing<br />
Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or<br />
without Concurrent Cetuximab in Patients with Advanced Non-Small<br />
Cell Lung Cancer (NSCLC): SWOG S0819 - Dr. Roy Herbst, Ensign<br />
Professor of Medicine, Professor of Pharmacology, Chief of Medical<br />
Oncology, Director, Thoracic Oncology Research Program, Associate<br />
Director for Translational Research, Yale Comprehensive Cancer<br />
Center, Yale School of Medicine, New Haven, Connecticut<br />
Abstract – EGFR IHC and FISH Correlative Analyses (SQUIRE Trial):<br />
Necitumumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin in 1st-<br />
Line Squamous NSCLC - Dr. Fred R. Hirsch, IASLC CEO, Congress<br />
President, Professor of Medicine and Pathology, University of<br />
Colorado<br />
Q & A<br />
09:45 - 10:45 Networking Break and Poster Session 3<br />
Room: Exhibit Hall (Hall B + C)<br />
Refreshments will be provided<br />
10:45 - 12:15 Plen 04: Presidential Symposium incl. Top 4 Abstracts<br />
Track: Plenary<br />
Chairs: Tony Mok, Hong Kong & Fred R. Hirsch, USA<br />
Room: Plenary Hall (Bellco Theatre)<br />
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or<br />
Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent<br />
Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer<br />
(NSCLC): SWOG S0819 - Roy Herbst, USA<br />
67
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Discussant – Robert Pirker, Austria<br />
Randomized Phase III Trial of Adjuvant Chemotherapy with or without<br />
Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results<br />
of E1505- Heather Wakelee, USA<br />
Discussant - Paul A. Bunn, Jr, USA<br />
Multiregion Whole Exome and Transcriptome Sequencing Defines the<br />
Genomic Spectrum of EGFR+ NSCLC and Reveals Novel Mechanisms of<br />
TKI Resistance - Daniel Shao Weng Tan, Singapore<br />
Discussant - Roman Thomas, Germany<br />
Stopping Smoking Reduces Mortality in Low-Dose Computed<br />
Tomography (LDCT) Screening Volunteers - Ugo Pastorino, Italy<br />
Discussant - Nise Yamaguchi, Brazil<br />
12:30 - 14:00 Symposium supported by Astellas Scientific and Medical Affairs Inc,<br />
AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc,<br />
Foundation Medicine, Genentech BioOncology and Novartis Pharmaceuticals<br />
Corporation: Targeted Treatment of Non-Small Cell Lung Cancer: Current<br />
Algorithms and New Agents<br />
Room: Plenary Hall (Bellco Theatre)<br />
<br />
Website: www.researchtopractice.com/Meetings/IASLC<strong>2015</strong>/Mutations<br />
14:15 - 15:45 GR 03: Grand Rounds: Extensive Small Cell with Excellent Response to 1st Line<br />
Rx (PCI, Chest and/or Oligomet RT) and Second Line / Treatment of Thymic<br />
Malignancies<br />
Track: Small Cell Lung Cancer / Thymoma, Mesothelioma and Other Thoracic<br />
Malignancies<br />
Chairs: Bruce Johnson, USA & Brian Kavanagh, USA / Paris Kosmidis, Greece &<br />
Enrico Ruffini, Italy<br />
Rooms: 102 + 104 + 106<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Part 1: Extensive Small Cell with Excellent Response to 1st Line Rx (PCI,<br />
Chest and/or Oligomet RT) and Second Line<br />
SCLC Therapy - Ritsuko Komaki, USA<br />
Systemic Therapy of Extensive Stage Small Cell Lung Cancer (SCLC):<br />
Contrasting Therapeutic Principles for SCLC and Non-small Cell Lung<br />
Cancer (NSCLC) in <strong>2015</strong> - Nevin Murray, Canada<br />
Part 2: Treatment of Thymic Malignancies<br />
Surgery - Frank Detterbeck, USA<br />
Radiotherapy - Daniel Gomez, USA<br />
Biology and Standard Treatment - Giuseppe Giaccone, USA<br />
Thymic Epithelial Tumors: New Hope on the Horizon with Novel<br />
Therapeutic Strategies - Benjamin Besse, France<br />
14:15 - 15:45 GR 04: Grand Rounds: Problems in Advanced Metastatic Disease<br />
68
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
Track: Treatment of Advanced Disease - NSCLC<br />
Chairs: Karen Kelly, USA & Robert Pirker, Austria<br />
Rooms: 702 + 704 + 706<br />
<br />
<br />
<br />
<br />
Case of a Patient with EGFR Mutation Positive Disease and Two Small<br />
Brain Metastases - Corinne Faivre-Finn, United Kingdom<br />
Leptomeningeal Carcinomatosis - Ross Soo, Singapore<br />
Systemic Treatment with Organ Failure - Paul Wheatley-Price, Canada<br />
A Case of Recurrent Clotting in Lung Cancer Despite Initial<br />
Anticoagulation - Rachel Rosovsky, United States<br />
14:15 - 15:45 MS 20: Mini Symposium: Joint Imaging/Therapy Conference<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Chairs: Odd Terje Brustugun, Norway & Dominique Grunenwald, France<br />
Rooms: 601 + 603<br />
<br />
<br />
<br />
<br />
Imaging for Surgical Treatment Decision and Planning - Hans Hoffmann,<br />
Germany<br />
Imaging for Radiation Therapy Planning - Jeffrey Bogart, USA<br />
Optimal Monitoring after Combined Modality Treatment (Imaging and<br />
Markers) - Michael MacManus, Australia<br />
Prevention, Diagnosis and Treatment of Radiation Pneumonitis - Laurie<br />
Gaspar, USA<br />
14:15 - 15:45 MS 21: Mini Symposium: Immunotherapy Predictive Biomarkers<br />
Track: Biology, Pathology & Molecular Testing<br />
Chairs: Kwun Fong, Australia & Philip Dennis, USA<br />
Room: Four Seasons Ballroom F1 + F2<br />
<br />
<br />
<br />
<br />
Overview of Immunotherapy - Julie Brahmer, USA<br />
PD1/PDL1 Biomarker Strategies - Elisabeth Brambilla, France<br />
Assessment of Immune Cells in Tumor Biopsies as a Biomarker - Ignacio<br />
Wistuba, USA<br />
Search for Genetic/Molecular Predictors of Immune Checkpoint Therapy<br />
- Role of KRAS, LKB1, Other Genetic Markers as Predictors for<br />
Immunotherapy - Scott Gettinger, USA<br />
14:15 - 15:45 MS 22: Mini Symposium: Variety in the Oncogene (Does the Exact Mutation<br />
Matter?)<br />
Track: Biology, Pathology & Molecular Testing<br />
Chairs: Robert Doebele, USA & Giorgio Scagliotti, Italy<br />
Room: Mile High Ballroom 4a - 4f<br />
<br />
EGFR Mutations (e.g., Exon 18 vs. 19 vs. 20 vs. 21) - Daniel Costa, USA<br />
69
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
ALK, ROS1, and RET – Does the Partner Gene Matter? - Christine Lovly,<br />
USA<br />
MET - Gene Amplification vs. Overexpression vs. Exon 14 Skipping - Ravi<br />
Salgia, USA<br />
KRAS – Are All KRAS Mutations the Same? - Thomas Stinchcombe, USA<br />
14:15 - 15:45 MS 23: Mini Symposium: Risk Factors: Beyond the Cigarette<br />
Track: Prevention & Tobacco Control<br />
Chairs: Nise Yamaguchi, Brazil<br />
Rooms: 605 + 607<br />
Radon and Lung Cancer - Boris Melloni, France<br />
Air Pollution-Outdoor; Biomass Smoke; Cooking Fuels - Paolo Boffetta,<br />
USA<br />
Legalization of Marijuana: Implication for Lung Health - James Jett, USA<br />
Other Tobacco Products Electronic Devices/Water Pipes/Hookas -<br />
Elizabeth Durmowicz, USA<br />
Cost Efficacy of Tobacco Cessation Versus Treatment of Lung Cancer -<br />
William K Evans, Canada<br />
14:15 - 15:45 MS 24: Mini Symposium: CT Screening: Minimize Harm/Cost and Risk<br />
Assessment<br />
Track: Screening and Early Detection<br />
Chairs: David Midthun, USA & Jesper Pedersen, Denmark<br />
Room: Four Seasons Ballroom F3 + F4<br />
Definition of Positive Cases and False Positives - David Yankelevitz, USA<br />
Computer Assisted Lung Cancer Screening: Automated CT Image<br />
Analysis - Anthony Reeves, USA<br />
Role of PET Scan in Workup of Nodules - Ugo Pastorino, Italy<br />
Biomarkers in Selection for CT Screening/Management of Nodules -<br />
Harvey Pass, USA<br />
14:15 - 15:45 MS 25: Mini Symposium: Lung Carcinogenesis<br />
Track: Screening and Early Detection<br />
Chairs: Wilbur Franklin, USA & Harubumi Kato, Japan<br />
Rooms: Mile High Ballroom 2a - 3b<br />
<br />
<br />
<br />
<br />
<br />
Early Airway Disease - Sam Janes, United Kingdom<br />
Transcriptional Profiling of Malignant Lesions - Brigitte Gomperts, USA<br />
Peripheral Premalignancy - Ming Tsao, Canada<br />
Molecular Pathology of Alveolar Premalignancy - Masayuki Noguchi,<br />
Japan<br />
Premalignant Lesions: Cytokines and Microenvironment - Steven<br />
Dubinett, USA<br />
70
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
14:15 - 15:45 MS 26: Mini Symposium: Genomic Alterations and Drug Targets<br />
Track: Small Cell Lung Cancer / Biology, Pathology & Molecular Testing<br />
Chairs: David Beer, USA & Jonathan Goldman, USA<br />
Room: Mile High Ballroom 2c - 3c<br />
<br />
<br />
<br />
<br />
<br />
Genomic Alterations - James Yang, Taiwan<br />
The MYC/MAX and the SWI/SNF Networks: Biological Understanding<br />
and Therapeutic Applications - Montse Sanchez-cespedes, Spain<br />
Targeting ASCL1 in Neuroendocrine Lung Cancers via a MAPK-Regulated<br />
Double-Negative Feedback Loop - John Minna, USA<br />
FGFR1 Co-Activation Networks in Lung Cancer - Lynn Heasley, USA<br />
Drug Screening Targets - Christine Lee Hann, USA<br />
14:15 - 15:45 MS 27: Mini Symposium: Advocacy in Practice<br />
Track: Advocacy<br />
Chairs: Tommy Bjork, Sweden & Aoife McNamara, Ireland<br />
Room: 703<br />
Influencing Clinical Trials to Meet Patients’ Needs and End-Points –<br />
Involving the Patient from the Neginning - Dickran Kazandjian, USA<br />
Incorporating Quality of Life & Palliative Care Measures in Clinical Trial<br />
Designs - Raphael Catane, Israel<br />
Let’s Yarn About Lung Cancer - An Indigenous Community Project in<br />
Regional Australia – Kerrie Callaghan, Australia<br />
Supporting Lung Cancer Survivors – Living with and Beyond Lung Cancer<br />
- Janet Freeman-Daily, USA<br />
14:15 - 15:45 MS 28: Mini Symposium: Future Clinical Trials<br />
Track: Other<br />
Chairs: Mary Redman, USA & Sumithra Mandrekar, USA<br />
Rooms: 205 + 207<br />
<br />
<br />
<br />
<br />
Trial Designs - Mary Redman, USA<br />
Master Protocols - Shakun Malik, USA<br />
Biomarkers - Fred R. Hirsch, USA<br />
Drug Development and Drug Approval- Richard Gaynor, USA<br />
14:15 - 15:45 ED 10: Education Session: Controversies in Stage IIIA Disease<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Chairs: Chandra Belani, USA & Everett Vokes, USA<br />
Rooms: 201 + 203<br />
71
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
Staging and Decision Making in Patient Selection-Surgery - Kenji Suzuki,<br />
Japan<br />
Multiple Modality Choices: Combinations, Sequences, Subsets - Kathy<br />
Albain, USA<br />
Induction Chemotherapy as an Investigational Strategy - Wilfried<br />
Eberhardt, Germany<br />
Case Presentation - Kemp Kernstine, USA<br />
14:15 - 15:45 ED 11: Education Session: Extending Personalized Treatment Beyond EGFR<br />
Track: Community Practice<br />
Chairs: Roman Perez-Soler, USA & Ross Camidge, USA<br />
Rooms: 401 - 404<br />
<br />
<br />
<br />
<br />
What Testing is Needed for Clinical Treatment? - Paul A. Bunn, Jr, USA<br />
Communicating with Pathologists About Molecular Testing - Cesar<br />
Octavio Lara-Torres, Mexico<br />
1st Line and Beyond for ALK, ROS-1, BRAF, RET, FGFR Positive Lung<br />
Cancer - David Spigel, USA<br />
Prioritizing New Agents When More Than One Is Available and<br />
Combining Targeted Agents - Ross Camidge, United States<br />
14:15 - 15:45 ED 12: Education Session: Caring for the Lung Cancer Patient<br />
Track: Nursing and Allied Professionals<br />
Chairs: Anne Fraser, New Zealand & Michelle Turner, USA<br />
Rooms: 108 + 110 + 112<br />
<br />
<br />
<br />
<br />
<br />
<br />
Management of Paraneoplastic Syndrome - John White, United<br />
Kingdom<br />
Addressing the Nutritional Needs of the Lung Cancer Patient - Melissa<br />
Culligan, USA<br />
Navigating Care for the Lung Cancer Patient - Vanessa Beattie, United<br />
Kingdom<br />
The Role of the Occupational Therapist in the Care of Lung Cancer<br />
Patients - Kahren White, USA<br />
Overcoming the Challenges of Getting Patients Through Chemo and XRT<br />
– Wilma Uyterlinde, Netherlands<br />
Importance of Exercise in Lung Cancer Treatment - Carol Michaels, USA<br />
14:15 - 15:45 ED 13: Education Session: The EGF Receptor and Targeting T790M<br />
Track: Treatment of Advanced Disease - NSCLC<br />
Chairs: Michael Boyer, Australia & Matthew Gubens, USA<br />
Room: Mile High Ballroom 1a - 1f<br />
<br />
Biological Background and Controversies - Benjamin Solomon, Australia<br />
72
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
Detecting T790M in Blood and Tumor - Dara Aisner, USA<br />
How to Make the Best Use of "Old" Drugs - Geoff Oxnard, USA<br />
3rd Generation EGFR TKI - Keunchil Park, South Korea<br />
14:15 - 15:45 Pro Con PC 03: Pro vs Con: Prophylactic Cranial Irradiation (PCI) Post<br />
Chemotherapy Response<br />
Track: Small Cell Lung Cancer / Treatment of Advanced Disease - NSCLC<br />
Chairs: Anthony Brade, Canada & Umberto Ricardi, Italy<br />
Rooms: 708 + 710 +712<br />
<br />
<br />
Pro - Berend Slotman, Netherlands<br />
Con - Nobuyuki Yamamoto, Japan<br />
Pro Con PC 03: Pro vs Con: Is There a Role for Radiation in Oligometastatic<br />
Disease?<br />
Track: Small Cell Lung Cancer / Treatment of Advanced Disease - NSCLC<br />
Chairs: Andrea Bezjak, Canada & Jin Soo Lee, South Korea<br />
Rooms: 708 + 710 + 712<br />
<br />
<br />
Pro - Cecile Le Pechoux, France<br />
Con - Walter Curran, USA<br />
15:45 - 16:45 Networking Break and Poster Session 3<br />
Room: Exhibit Hall (Hall B + C)<br />
Refreshments will be provided<br />
15:45 - 16:45 IASLC Business Meeting<br />
Room: Mile High Ballroom 2a - 3b<br />
16:45 - 18:15 Oral Session 31: PD1 Axis Inhibition<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Jared Weiss, USA & Brendan Luey, New Zealand<br />
Room: Four Seasons Ballroom F1 + F2<br />
<br />
<br />
<br />
PD-L1 Expression as Predictive Biomarker in Patients with NSCLC: A<br />
Pooled Analysis - Francesco Passiglia, Italy<br />
Pembrolizumab for NSCLC: Immune-Mediated Adverse Events and<br />
Corticosteroid Use - Natasha Leighl, Canada<br />
Evaluation of Disease-Related Symptoms in Patients with Advanced<br />
Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or<br />
Docetaxel - Richard Gralla, USA<br />
73
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
Discussant - Karen Kelly, USA<br />
High Intratumoral T Cell Infiltration Correlated with Mutational Load<br />
and Response to Pembrolizumab in Non-Small Cell Lung Cancer - Siwen<br />
Hu-Lieskovan, USA<br />
An Exploratory Responder Analysis of Best RECIST Response and<br />
Survival in Patients with Metastatic Squamous NSCLC Treated with<br />
Nivolumab - Diko Kazandjian, USA<br />
A Phase II Trial of Pembrolizumab for Untreated Brain Metastases from<br />
Non-Small Cell Lung Cancer - Sarah Goldberg, USA<br />
Discussant - David Gerber, USA<br />
16:45 - 18:15 Oral Session 32: EGFR WT and MT Targeting<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderator: Kenneth O'Byrne, Australia & David R. Gandara, USA<br />
Room: Four Seasons Ballroom F3 + F4<br />
Tumor Genomic Analysis from LUX-Lung 8: A Phase III Trial of Afatinib<br />
versus Erlotinib in Squamous Cell Carcinoma of the Lung - Glenwood<br />
Goss, Canada<br />
Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated<br />
with Second-Line Erlotinib: Subgroup Analysis from WILT Study - Javier<br />
De Castro, Spain<br />
Efficacy and Safety of Necitumumab Continuation Therapy in Phase 3<br />
SQUIRE Study - Tudor Ciuleanu, Romania<br />
Discussant - Yi-Long Wu, China<br />
EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): Necitumumab +<br />
Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin in 1st-Line Squamous<br />
NSCLC - Fred R. Hirsch, USA<br />
Intercalating and Maintenance Use of Gefitinib plus Chemotherapy<br />
versus Chemotherapy Alone in Selected Advanced NSCLC: A Phase ?<br />
Study - Shun Lu, China<br />
Randomized Phase II Trial of Sequential Gefitinib and<br />
Pemetrexed/Cisplatin Chemotherapy for Stage IIIB/IV Lung<br />
Adenocarcinoma in Never Smokers - Jin Soo Lee, South Korea<br />
Discussant - David R. Gandara, USA<br />
16:45 - 18:15 Oral Session 33: ALK<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Shirish Gadgeel, USA<br />
Room: Mile High Ballroom 1a - 1f<br />
<br />
<br />
Crizotinib Outcome and Post-Progression Management in ALK+ NSCLC:<br />
IFCT-1302 CLINALK - Michael Duruisseaux, France<br />
Time to Progression and Post-Progression Survival in ALK+ Ceritinib-<br />
Treated NSCLC - Geoffrey Liu, Canada<br />
74
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of<br />
Alectinib in ALK+ NSCLC - Alice Shaw, USA<br />
Discussant - Daniel Shao Weng Tan, Singapore<br />
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pre-<br />
Treated ALK+ NSCLC - Shirish Gadgeel, USA<br />
Brigatinib (AP26113) Efficacy and Safety in ALK+ NSCLC: Phase 1/2 Trial<br />
Results - Scott Gettinger, USA<br />
Clinical Activity and Safety of the ALK/ROS1 TK Inhibitor PF-06463922 in<br />
Advanced NSCLC - TM Bauer, USA<br />
Discussant - Myung-Ju Ahn, South Korea<br />
16:45 - 18:15 Oral Session 34: Quality/Survival/Prognosis in Localized Lung Cancer<br />
Track: Treatment of Localized Disease - NSCLC<br />
Moderator: Byoung Chul Cho, South Korea<br />
Rooms: 201 + 203<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Compliance with Follow-Up Programs After Surgery for Non-Small Cell<br />
Lung Cancer in the Phase III IFCT-0302 Trial - Virginie Westeel, France<br />
Impact of Attainment of National Comprehensive Cancer Network<br />
(NCCN) Quality Parameters on Patient Survival after Resection of Lung<br />
Cancer - Nicholas Faris, USA<br />
Prognostic Factors in Early Stage NSCLC: Analysis of the Placebo Group<br />
in the MAGRIT Study - Byoung Chul Cho, South Korea<br />
Discussant - Raymond Osarogiagbon, USA<br />
Survival Implications of Variation in the Lymph Node (LN) Count in<br />
ACOSOG Z0030 (Alliance) - Raymond Osarogiagbon, USA<br />
Impact of Surgeons' Attainment of Quality Resection Parameters on<br />
Non-Small-Cell Lung Cancer (NSCLC) Patients' Survival - Raymond<br />
Osarogiagbon, USA<br />
Prevalence, Prognostic Implications and Survival Modulators of<br />
Incompletely Resected Non-Small Cell Lung Cancer (NSCLC) in the US -<br />
Raymond Osarogiagbon, USA<br />
Discussant - Mark Krasnik, Denmark<br />
16:45 - 18:15 Oral Session 35: Surgical Approaches in Localized Lung Cancer<br />
Track: Treatment of Localized Disease - NSCLC<br />
Moderator: Marc de Perrot, Canada & John Mitchell, USA<br />
Rooms: 601 + 603<br />
<br />
<br />
<br />
<br />
Surgical Approach and Disease Recurrence in NSCLC Patients in the<br />
MAGRIT Study - Eric Vallieres, USA<br />
Wedge Resection vs Segmentectomy for Patients with T1A N0 Non-<br />
Small Cell Lung Cancer - Chi-Fu Yang, USA<br />
Salvage Surgery for Local Failures after Stereotactic Ablative<br />
Radiotherapy for Lung Malignancies – Berend Slotman, Netherlands<br />
Discussant - David Jones, USA<br />
75
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
The Role of Surgical Mediastinal Resection in CT Screen-Detected Lung<br />
Cancer Patients - Daniel Nicastri, USA<br />
Limited Resection for Non-Small Cell Lung Cancer Referring to Pathology<br />
- Motoki Yano, Japan<br />
The Feasibility and Safety of Complete VATS for NSCLC Under Non-<br />
Intubated Intravenous Anesthesia in Comparison with Intubated<br />
Anesthesia - Jun Liu, China<br />
Discussant - Bernward Passlick, Germany<br />
16:45 - 18:15 Oral Session 36: Translational Science/Radiation<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Moderator: Everett Vokes, USA & Brian Kavanagh, USA<br />
Room: Mile High Ballroom 2c - 3c<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients with<br />
Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer - Wen<br />
Feng, China<br />
Efficacy of Chemo-Radiotherapy (CRT) in Stage III Non-Small Cell Lung<br />
Cancer (NSCLC) and PD-L1 Expression - Julien Adam, France<br />
Discussant<br />
Nintedanib Safely Reduces Late Radiation-Induced Lung Damage: A<br />
Preclinical Study with a High Precision Image-Guided Small Animal<br />
Irradiator - Dirk De Ruysscher, Belgium<br />
Results of a National Database Review of Video-Assisted Thoracoscopic<br />
versus Open Lobectomy after Induction Therapy - Jennifer Wilson, USA<br />
4D-VQ-PET/CT Imaging Allows Strong Correlation Between Radiotherapy<br />
Dose and Change in Lung Ventilation, Perfusion and Density - Shankar<br />
Siva, Australia<br />
Results of a National Test Run of Treatment Plans for the Standard Arm<br />
of a Dose Escalation Trial for Locally Advanced NSCLC - Tine Bjørn<br />
Nielsen, Denmark<br />
Discussant – Paul van Houtte, Belgium<br />
16:45 - 18:15 Oral Session 37: Novel Targets<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderator: Suresh Ramalingam, USA & Erik Thunnissen, Netherlands<br />
Room: Mile High Ballroom 4a - 4f<br />
<br />
<br />
<br />
FISHing TRK Activation by Gene Rearrangements in Non Small Cell Lung<br />
Cancer - Marileila Varella-Garcia, USA<br />
Protein Tyrosine Phosphatase Non Receptor 11 PTPN11/Shp2 as a<br />
Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung<br />
Cancer NSCLC - Yasir Elamin, Ireland<br />
Discussant - Luis Raez, USA<br />
76
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
Comprehensive Genomic Profiling (CGP) of Advanced Cancers Identifies<br />
MET Exon 14 Alterations That Are Sensitive to MET Inhibitors - Ignatius<br />
Ou, USA<br />
Prevalence and Clinical Association of MET Gene Amplification in<br />
Patients with NSCLC: Results from the ETOP Lungscape Project - Erik<br />
Thunnissen, Netherlands<br />
Defining MET Copy Number Driven Lung Adenocarcinoma Molecularly<br />
and Clinically - Sinéad Noonan, USA<br />
Lung Cancer Mutation Consortium Pathologist Panel Evaluation of MET<br />
Protein - Theresa Boyle, USA<br />
Discussant - Glen Weiss, USA<br />
16:45 - 18:15 Oral Session 38: Liquid Biopsies<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Ming Tsao, Canada & Jie Wang, China<br />
Room: Mile High Ballroom 2a - 3b<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
A Prospective Study of Rapid Plasma Genotyping Utilizing Sequential<br />
ddPCR and NGS in Newly Diagnosed Advanced NSCLC Patients - Adrian<br />
Sacher, USA<br />
Biopsy-Free Circulating Tumor DNA Assay Identifies Actionable<br />
Mutations in Lung Cancer - Victoria Villaflor, USA<br />
Assessing the Feasibility of Detecting ALK Fusions with qRT-PCR Assays<br />
in Cell-Free Plasma RNA - Xiaoju Max Ma, USA<br />
Dynamic Changes in EGFR Mutation Circulating Tumor DNA in Urine on<br />
Anti-EGFR Therapy - Hatim Husain, USA<br />
Identification of Actionable Tumor Alterations in Circulating Cell-Free<br />
Tumor DNA (cf DNA) Using Digital Sequencing from NSCLC Patients -<br />
Philip Mack, USA<br />
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early<br />
Predictor of Clinical Response to Tyrosine Kinase Inhibitors - Rita Chiari,<br />
Italy<br />
Discussant - Geoffrey Oxnard, USA<br />
16:45 - 18:15 Oral Session 39: Potential Biomarkers for CT Screening<br />
Track: Screening and Early Detection<br />
Moderators: Kwun Fong, Australia & Nir Peled, Israel<br />
Rooms: 401 - 404<br />
<br />
<br />
<br />
<br />
Multiplexing Serum Proteins and Circulating Autoantibody for Detection<br />
of Lung Cancer - Bing Xia, China<br />
Early Detection of Lung Cancer by a FISH-Based Sputum Test - William<br />
Burfeind Jr., USA<br />
Clinical Utility of a Blood Based Circulating Tumour DNA Signature for<br />
the Diagnosis of Lung Cancer - Eric Lim, United Kingdom<br />
Discussant - Anil Vachani, USA<br />
77
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
Identification of miRNAs as Biomarkers for Early Diagnosis of Lung<br />
Cancers - Shirong Zhang, China<br />
Whole Blood microRNA Expression May Not Be Useful for Screening<br />
Non-Small Cell Lung Cancer - Santosh Patnaik, USA<br />
A Bronchial Genomic Classifier Measured in Airway Epithelial Cells<br />
Improves Diagnostic Sensitivity of Bronchoscopy for Lung Cancer - Anil<br />
Vachani, USA<br />
Discussant - Jill Siegfried, USA<br />
16:45 - 18:15 Oral Session 40: Biology 1<br />
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies<br />
Moderators: Christian Brambilla, France & Raphael Bueno, USA<br />
Rooms: 702 + 704 + 706<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
PD-L1 Is Highly Expressed in Malignant Mesothelioma and PD-1+<br />
Lymphocytes within Malignant Effusions Induce PD-L1 Expression -<br />
Swati Khanna, USA<br />
Molecular Landscape of Malignant Mesothelioma from Whole Exome<br />
Sequencing - Shir Kiong Lu, United Kingdom<br />
Combination Therapy with a CD40-Agonist and Dendritic Cell<br />
Immunotherapy Has Synergistic Effects in a Murine Mesothelioma<br />
Model - Joachim Aerts, Netherlands<br />
Discussant - Yoshitaka Sekido, Japan<br />
The Cancer Stem Cell Inhibitors VS-6063 and VS-5584 Exhibit Synergistic<br />
Anticancer Activity in Pre-Clinical Models of Mesothelioma - Jonathan<br />
Pachter, USA<br />
Sarcomatoid Differentiation During Progression of Malignant Pleural<br />
Mesothelioma - Isabelle Opitz, Switzerland<br />
Xpo1 Inhibition: A Promising Therapeutic Strategy in Thymic Epithelial<br />
Tumors - Fabio Conforti, USA<br />
Discussant - Thierry Marie Jahan, USA<br />
16:45 - 18:15 Mini Oral 26: Circulating Tumor Markers<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Michael Macmanus, Australia & Charu Aggarwal, USA<br />
Rooms: 205 + 207<br />
<br />
<br />
<br />
<br />
Tumour Molecular Profiling and Quantitative Detection of Circulating<br />
Biomarkers in Patients with Non-Small Cell Lung Cancer (NSCLC) - Frank<br />
McCaughan, United Kingdom<br />
Deep Sequencing Reveals the Significance of Plasma DNA Concentration<br />
and Mutational Burden in Advanced Non-Small-Cell Lung Cancer<br />
Patients - Li Zhang, China<br />
Detecting C-MET Amplification in Blood and Tumor Tissue of Non-Small<br />
Cell Lung Cancer - meiyu Fang, China<br />
Discussant - Ravi Salgia, USA<br />
78
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Immunophenotyping of Circulating T Cells and TILs with Chemotherapy<br />
and Phased Ipilimumab in Non-Small Cell Lung Cancer - Frank Dunphy,<br />
USA<br />
Cytological Criteria Based in the Characterization of CTCs for<br />
Assessment the Response to Erlotinib - Maria Jose Serrano, Spain<br />
Circulating Tumor Cells (CTC) Enrichment as Liquid-Biopsy for Molecular<br />
and Genomic Characterization in ALK-Rearranged (ALK+) Lung Cancer -<br />
Patrick Ma, USA<br />
A Correlative Plasma Biomarker Analysis of the Combination of<br />
Bevacizumab and Chemotherapy for Advanced Non-Small-Cell Lung<br />
Cancer - Ling-yu Ding, China<br />
Correlation between Circulating Tumor Biomarkers and Positron-<br />
Emission Tomography in Advanced Non-Small Cell Lung Cancer - Carlo<br />
Genova, Italy<br />
Discussant - Balazs Halmos, USA<br />
Longitudinal Monitoring of EGFR Mutations in Plasma of EGFR Mutant<br />
NSCLC Patients Treated with EGFR TKIs: Korean Lung Cancer Consortium<br />
- Ji Yun Lee, South Korea<br />
Circulating Tumor DNA for Noninvasive Monitoring of Non-Small Cell<br />
Lung Cancer Patients Receiving EGFR-Targeted Therapies - Dana Tsui,<br />
United Kingdom<br />
Serial ctDNA Assessment of Response and Resistance to EGFR-TKI for<br />
Patients with EGFR-L858R Mutant Lung Cancer from a Prospective Trial -<br />
Qing Zhou, China<br />
Noninvasive Identification of EGFR-T790M Mediated Resistant NSCLC<br />
Patients Using Plasma CfDNA - Di Zheng, China<br />
Discussant - Roman Perez-Soler, USA<br />
16:45 - 18:15 Mini Oral 27: Biology and Other Issues in SCLC<br />
Track: Small Cell Lung Cancer<br />
Moderators: Paul A. Bunn Jr. USA & Julien Sage, USA<br />
Rooms: 605 + 607<br />
<br />
<br />
<br />
<br />
<br />
<br />
Investigation of Chimeric Antigen Receptor T Cells as a Novel<br />
Immunotherapy for SCLC - Warren Denning, USA<br />
RPS25 Is Essential for the Translation of the Seneca Valley Virus Genome<br />
and Proliferative Capacity of Small Cell Lung Cancer Cell Lines - Linde A.<br />
Miles, USA<br />
PD-L1 Expression in Small Cell Lung Carcinoma: An<br />
Immunohistochemical Analysis of 26 Cases Using Two Anti-PD-L1<br />
Antibodies - Peter Illei, USA<br />
PD-L1 and C-MET Expression and Survival in Patients with Small Cell<br />
Lung Cancer - Yun Fan, China<br />
Discussant - Joel Neal, USA<br />
Acquired Resistance Mechanisms in Small Cell Lung Cancer Mediated by<br />
the Cancer Stem Cell Marker Calcium Channel ?2?1 Subunit - Jie Wang,<br />
China<br />
79
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
A Meta-Analysis of Clinical Trials on the Risk of Hyponatraemia in Cancer<br />
Patients Treated with Targeted Therapies - Rossana Berardi, Italy<br />
Discussant - Edgardo Santos, USA<br />
18:30 - 20:00 Oral Session 41: Immune Biology, Microenvironment and Novel Targets<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Sukhmani Padda, USA & Raphael Nemenoff, USA<br />
Room: Four Seasons Ballroom F1 + F2<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Tumor-Infiltrating B Lymphocytes Characterized by CD79a and MUM1<br />
Independently Predict Outcome in Patients with Non-Small Cell Lung<br />
Cancer - Sacha Rothschild, Germany<br />
Novel Mechanism of Immune-Tolerance and Cancer Metastasis Due to<br />
Aberrant Expression of Natural Killer Immunoglobulin-Like Receptors<br />
(KIRs) - Daniel Chan, USA<br />
Myeloid Derived Supressor Cells and Their Clinical Relevance in Non-<br />
Small Cell Lung Cancer - Oscar Arrieta Rodriguez, Mexico<br />
Discussant - Naiyer Rizvi, USA<br />
Targeting Phosphatidylserine-Mediated Immune Suppression Enhances<br />
the Efficacy of Immune Checkpoint Blockade in Pre-Clinical Tumor<br />
Models - Rolf Brekken, USA<br />
Transcriptional Profiling of Distinct Macrophage Subsets in Lung Tumor<br />
Microenvironment Reveals Their Functional Heterogeneity - Joanna<br />
Poczobutt, USA<br />
The Identification of Therapeutic Targets in Lung Cancer Based on<br />
Transcriptomic and Proteomic Characterization of Cancer-Testis<br />
Antigens - Dijana Djureinovic, Sweden<br />
Discussant - Roy Herbst, USA<br />
18:30 - 20:00 Oral Session 42: Drug Resistance<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Robert Doebele, USA & James DeGregori, USA<br />
Room: Mile High Ballroom 4a - 4f<br />
<br />
<br />
<br />
<br />
<br />
ALK-Rearranged NSCLC Adaptive Cell Plasticity with Early Onset TGFb2<br />
Mediated Precision Drug Escape through PRC-2 Epigenetic<br />
Reprogramming - Patrick Ma, USA<br />
Qualitative and Quantitative Heterogeniety in Acquiring Resistance to<br />
EGFR Kinase Inhibitors in Lung Cancer - Kenichi Suda, Japan<br />
Discussant - Lynn Heasley, USA<br />
Rictor Alterations Elicit Mechanisms of Survival Advantage and<br />
Resistance to Targeted Therapy in Non-Small Cell Lung Cancer (NCSLC) -<br />
Julie Izzo, USA<br />
SMARCA4/BRG1 Is a Biomarker for Predicting Efficacy of Cisplatin-Based<br />
Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) - Erica Bell, USA<br />
81
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
Cancer Stem Cells: Targeting Aldehyde Dehydrogenase 1 (ALDH1) as a<br />
Novel Strategy in Cisplatin Resistant Non-Small Cell Lung Cancer? -<br />
Martin Barr, Ireland<br />
Discussant - Seiji Yano, Japan<br />
18:30 - 20:00 Oral Session 43: Enhancing Physical Wellbeing in Lung Cancer<br />
Track: Nursing and Allied Professionals<br />
Moderators: Gleneara Bates, USA & Mary Hesdorffer, USA<br />
Rooms: 102 + 104 + 106<br />
Guideline for Patient Information on Enhanced Recovery in Thoracic<br />
Surgery - Jenny Mitchell, United Kingdom<br />
Which Patients Are Assessed by a Lung Cancer Nurse Specialist: A UK<br />
National Lung Cancer Audit Study - Angela Tod, United Kingdom<br />
The Rationale of Exercise in Patients with Inoperable Lung Cancer -<br />
Morten Quist, Denmark<br />
Discussant - Marianne Davies, USA<br />
Development and Evaluation of Health and Wellbeing Events for People<br />
Affected by Lung Cancer - Sally Moore, United Kingdom<br />
Improving Surviorship through Prehabiltiation for Thoracic Cancer<br />
Patients - Karen Clayton, United Kingdom<br />
Performance Status (PS): Is There a Correlation Between Doctor and<br />
Patient? - Karen Clayton, United Kingdom<br />
Discussant - Beth Ivimey, Australia<br />
18:30 - 20:00 Mini Oral 29: Meta Analyses and Trial Conduct<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderator: Daniel Morgensztern, USA & Mary Redman, USA<br />
Room: Mile High Ballroom 2a - 3b<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Squamous Cell Carcinoma of Lung in the United States: Analysis of the<br />
National Cancer Database (NCDB) - Madhusmita Behera, USA<br />
Effect of Statins and Metformin on Survival in Patients with Non-Small<br />
Cell Lung Cancer - Narjust Duma, USA<br />
Prognostic Value of Biomarkers Associated with Glucose Metabolism<br />
and Systemic Inflammation in Advanced On-Small Cell Lung Cancer<br />
(NSCLC) - Mary Fidler, USA<br />
The Use of Metformin and Proper Glycemic Control Are Associated with<br />
Improved Survival in Non-Small Cell Lung Cancer Patients - Oscar Arrieta<br />
Rodriguez, Mexico<br />
Discussant - David Stewart, Canada<br />
Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real<br />
World Population of Advanced Lung Cancer Patients? - Paul Wheatley-<br />
Price, Canada<br />
CNS Disease Enrollment Criteria for NSCLC Drug Trials - Caroline<br />
McCoach, USA<br />
82
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Innovation in Non-Small Cell Lung Cancer (NSCLC): Where Are the<br />
Clinically Meaningful Outcomes? - Lisa Hess, USA<br />
Recommendations for Standardized Efficacy Data Specifications in Lung<br />
Cancer - Sean Khozin, USA<br />
Discussant - Mary Redman, USA<br />
Assessing Patient-Reported Symptoms in Non-Small Cell Lung Cancer<br />
Clinical Trials - Alicyn Campbell, USA<br />
Patients with Advanced Non-Small Cell Lung Cancer: Are Research<br />
Biopsies a Barrier to Participation in Clinical Trials? - Charles Lim,<br />
Canada<br />
Safety and Clinical Implications of Repeat Tumor Biopsy (RTB) in<br />
Patients with Advanced Lung Cancer: A Retrospective Institutional Study<br />
- Eberechi Agwa, USA<br />
Using a Bayesian Adaptive Phase II Trial Design to Test Multiple Genetic-<br />
Marker-Directed Drugs in the National Lung Matrix Trial - Lucinda<br />
Billingham, United Kingdom<br />
Discussant - Barbara Gitlitz, USA<br />
18:30 - 20:00 Mini Oral 30: New Kinase Targets<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Keunchil Park, South Korea & Miguel Villalona, USA<br />
Room: Four Seasons Ballroom F3 + F4<br />
Oncolytic Reovirus in Combination with Paclitaxel/Carboplatin in NSCLC<br />
Patients with Ras Activated Malignancies, Long Term Results - Miguel<br />
Villalona, USA<br />
Phase II Study of Defactinib, VS-6063, a Focal Adhesion Kinase (FAK)<br />
Inhibitor, in Patients with KRAS Mutant Non-Small Cell Lung Cancer<br />
(NSCLC) - David Gerber, USA<br />
Smoking Predicts Sensitivity to PARP Inhibitor, Veliparib, in Advanced<br />
NSCLC Patients - Normand Blais, Canada<br />
A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the<br />
Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC:<br />
ECOG-ACRIN E1512 - Joel Neal, USA<br />
Discussant - Nathan Pennell, USA<br />
Activity of AUY922 in NSCLC Patients With EGFR Exon 20 Insertions -<br />
Zofia Piotrowska, USA<br />
Crizotinib in Patients with ROS1 NSCLC. Preliminary Results of the AcSé<br />
Trial - Denis Moro-Sibilot, France<br />
ROS1 Resistance to Crizotinib Is Mediated by an Activating Mutation in<br />
c-KIT - Rafal Dziadziuszko, Poland<br />
Clinical Response to Entrectinib in a Patient with NTRK1-Rearranged<br />
Non-Small Cell Lung Cancer (NSCLC) - Anna Farago, USA<br />
<br />
<br />
Discussant - Daniel Tan, Singapore<br />
Efficacy and Safety of Dovitinib in Advanced Squamous Cell Lung Cancer<br />
with FGFR1 Amplification: A Single-Arm, Phase II Study - Sung Hee Lim,<br />
South Korea<br />
83
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
A Phase II Trial of Pictilisib with Chemotherapy in First-Line Non-<br />
Squamous NSCLC - Benjamin Besse, France<br />
A Phase II Trial of Pictilisib with Chemotherapy in First-Line Squamous<br />
NSCLC - David Spigel, USA<br />
Discussant - John Heymach, USA<br />
18:30 - 20:00 Mini Oral 31: ALK<br />
Track: Treatment of Advanced Diseases - NSCLC<br />
Moderators: Shakun Malik, USA & Sai-Hong Ou, USA<br />
Room: Mile High Ballroom 1a - 1f<br />
Diverse Characteristics of ALK+ NSCLC Patients in the United States -<br />
Edmond Bendaly, USA<br />
Real-World Characteristics and Outcomes for ALK+ NSCLC in Korea -<br />
Keunchil Park, South Korea<br />
Crizotinib Outcomes in ALK-Positive Advanced NSCLC Patients with Brain<br />
Metastases - Keith Davis, USA<br />
Intracranial Efficacy of First-Line Crizotinib vs. Chemotherapy in ALK-<br />
Positive NSCLC - Benjamin Solomon, Australia<br />
Discussant - Alice Shaw, USA<br />
Crizotinib and Interstitial Lung Disease: Systematic Review of Four<br />
Clinical Trials - Ken Yoneda, USA<br />
Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non-<br />
Small Cell Lung Cancer - Yan Zhang, China<br />
Real-World Persistence and Adherence to Crizotinib in over 3800 US<br />
Patients - Ruslan Horblyuk, USA<br />
Association of Crizotinib Toxicity with Pharmacokinetics and<br />
Pharmacogenomics in Non-Small Cell Lung Cancer Harboring ALK Fusion<br />
Gene - Yuichi Tambo, Japan<br />
<br />
<br />
<br />
<br />
<br />
<br />
Discussant - Sai-Hong Ou, USA<br />
Comparison of Different ALK Tests in Non-Small Cell Lung Cancer<br />
(NSCLC) Patients before and after Crizotinib and Their Clinical Outcome -<br />
Anthonie Van Der Wekken, Netherlands<br />
Quality of Life for Crizotinib vs. Chemotherapy in Asian ALK-Positive<br />
NSCLC Patients - Fiona Blackhall, United Kingdom<br />
Symptoms and QOL with Ceritinib in ALK+ NSCLC Patients with/without<br />
Brain Metastases - Lucio Crinò, Italy<br />
PROs with Ceritinib in ALKi-Naive ALK+ NSCLC Patients with and without<br />
Brain Metastases - Keunchil Park, South Korea<br />
Discussant - Leora Horn, USA<br />
18:30 - 20:00 Mini Oral 32: Topics in Localized Lung Cancer<br />
Track: Treatment of Localized Disease - NSCLC<br />
Moderators: Daniel Boffa, USA & Thomas D'Amico, USA<br />
Rooms: 201 + 203<br />
84
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Computed Tomography Lymphography by Transbronchial Injection of<br />
Iopamidol for Preoperative Non-Small Cell Lung Cancer Patients -<br />
Hiromitsu Takizawa, Japan<br />
Characteristics of Non-Small Cell Lung Cancer (NSCLC) Patients Who<br />
Underwent Curative-Intent Surgical Resections in China - Jian Zhou,<br />
China<br />
Accuracy of Respiratory Dynamic Computed Tomography for the<br />
Detection of Pleural Adhesions - Junko Tokuno, Japan<br />
Clinico-Pathological Correlations and the Role of Brain MRI in Combined<br />
Clinical Staging for Resectable Lung Cancer - Wael Hanna, Canada<br />
Clinical Impacts of Tumor Hypoxia Imaging with FAZA and ATSM PET in<br />
NSCLC - Tomonari Kinoshita, Japan<br />
A Phase I Feasibility Study of Kilovoltage Intrafraction Monitoring for<br />
Lung Cancer - Fiona Hegi-Johnson, Australia<br />
Identification of a Meta-Gene Network Associated with Metformin<br />
Sensitivity and Recurrence in Stage I Non-Small Cell Lung Cancer - Casey<br />
Frankenberger, USA<br />
The Combination of Serum Biomarkers CYFRA 21-1 and CEA in the<br />
Prognostication of Early Stage Non-Small Cell Lung Cancer (NSCLC) -<br />
Thomas Muley, Germany<br />
10 Years of National Lung Cancer Audit in the UK - Michael Peake,<br />
United Kingdom<br />
Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell<br />
Lung Cancer Patients with or without Icotinib Consolidation Therapy -<br />
Siyang Feng, China<br />
Racial/Ethnic and Gender Differences in Treatment and Survival of Early-<br />
Stage Non-Small Cell Lung Cancer in an Integrated Health Care System -<br />
Lori Sakoda, USA<br />
Primary Early-Stage Lung Cancer Following Head and Neck Cancer: A<br />
Population Based Study of Treatment and Survival in the Netherlands -<br />
Berend Slotman, Netherlands<br />
18:30 - 20:00 Mini Oral 33: Radiotherapy and Complications<br />
Track: Treatment of Locoregional Disease - NSCLC<br />
Moderator: Stuart Burri, USA<br />
Rooms: 601 + 603<br />
Prospective Phase II Trial of SBRT for Centrally-Located Lung Cancer -<br />
Jeffrey Bradley, USA<br />
Dose-Escalated Radiotherapy for NSCLC: Heart Doses versus Survival in<br />
IDEAL-CRT - Sindu Vivekanandan, United Kingdom<br />
Heart Dose Is Associated with Shorter Overall Survival for Patients<br />
Treated with Chemo-Radiation for Locally Advanced NSCLC - Jan-Jakob<br />
Sonke, Netherlands<br />
Acute Radiation Pneumonitis in Lung Cancer Treated with Volumetric<br />
Modulated Arc Therapy - Bing Xia, China<br />
Discussant – David Raben, USA<br />
85
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Prospective Monitoring of Lung Function Test with CO and NO Diffusion<br />
during Thoracic Radiotherapy: Preliminary Results of the CONORT Study<br />
- Sébastien Couraud, France<br />
A Restrospective Study of Shrinking Field Radiation Therapy in<br />
Chemoradiothrapy for Stage III Non-Small Cell Lung Cancer - Yaping Xu,<br />
China<br />
Feasibility & Efficacy of Hypofractionated Radiotherapy in LA-NSCLC: A<br />
Phase II Study - Sushmita Pathy, India<br />
Impact of Tumor Regression and Need for Re-Plan during Radiation<br />
Therapy for Stage IIIB Lung Cancer: Dosimetric Comparison between<br />
IMRT and IMPT - Heerim Nam, South Korea<br />
Discussant - Dirk De Ruysscher, Belgium<br />
Locally Advanced NSCLC Elderly Patients Assessed by Multidimensional<br />
Geriatric Assessment and Treated with Concurrent Chemoradiation -<br />
Ernest Nadal, Spain<br />
Analysis of Acute Radiation-Induced Esophagitis in NSCLC Pts Using<br />
Lyman NTCP Model - Jian Zhu, China<br />
Locally Advanced NSCLC: Patient Preferences Regarding Prophylactic<br />
Cranial Irradiation - A Discrete Choice Experiment - Margot Lehman,<br />
Australia<br />
Discussant - Kenneth Rosenzweig, USA<br />
18:30 - 20:00 Mini Oral 34: RNA and miRNA<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Céline Mascaux, France & Luhua (Jingbo) Wang, China<br />
Rooms: 205 + 207<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
MicroRNA Profiling of a Familial Primary Pulmonary Enteric<br />
Adenocarcinoma - Ingrid Garajová, Italy<br />
Prognostic Impact of Bcl-2 Depends on Tumor Histology and Expression<br />
of MALAT-1 lncRNA in NSCLC - Rainer Wiewrodt, Germany<br />
Novel microRNA Prognostic Signature in Malignant Pleural<br />
Mesothelioma - Francesco Grossi, Italy<br />
Serum MicroRNA-139-5p Is a Biomarker of Bone Metastasis in Lung<br />
Cancer Patient - Song Xu, China<br />
Discussant - Christopher Rivard, USA<br />
MicroRNA 10b, 27a and 27b Are Upregulated in Lung Cancer Cell with<br />
Epidermal Growth Factor (EGFR) Mutation Resistant to EGFR TKI - Chao<br />
Huang, USA<br />
A Novel microRNA Signature Associated with Cisplatin Resistance in<br />
NSCLC - Martin Barr, Ireland<br />
MiR-33B Inhibit EMT Through Wnt/β-Catenin/ZEB1 Pathway in Lung<br />
Adenocarcinoma - Min Li, China<br />
The Long Non-Coding RNA AK126698 Modulates Wnt/β-Catenin<br />
Signaling Through FZD-8 Silencing in Non-Small-Cell Lung Cancer - xiao<br />
Fu, China<br />
Discussant - Glen Reid, Australia<br />
86
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
Identification and Functional Characterization of Non-Small Cell Lung<br />
Cancer-Associated Splice Variants and Splicing Factors - Ruben Pio,<br />
Spain<br />
Oncofetal miRNA Expression Inactivates Nuclear Factor I/B, a Critical<br />
Regulator of Lung Development and Lung Adenocarcinoma<br />
Pathogenesis - Daiana Becker-Santos, Canada<br />
Long Noncoding RNA BC070487 Represses ZNFX1 during Tobacco-<br />
Induced Lung Carcinogenesis - Sichuan Xi, USA<br />
Biological Role of Prognostic MicroRNAs (MiRNAs) in Squamous Lung<br />
Cancer Cell Lines - Martyna Filipska, Poland<br />
Discussant - David Beer, USA<br />
18:30 - 20:00 Mini Oral 35: Biology<br />
Track: Biology, Pathology, and Molecular Testing<br />
Moderators: Theresa Boyle, USA & Mark Kris, USA<br />
Room: Mile High Ballroom 2c - 3c<br />
Genetic Alterations in the Fanconi Anemia Pathway in Lung Cancers -<br />
Wenrui Duan, USA<br />
Inhibitor of Differentiation 1 (Id-1) Gene Silencing Reduces Liver<br />
Metastases Formation in a NSCLC Animal Model - Ignacio Gil-Bazo,<br />
Spain<br />
N-Myc Downstream Regulated Gene 1(NDRG1) Promotes the Stem-Like<br />
Properties of Lung Cancer Cells Through Stabilized C-Myc - kai Wang,<br />
China<br />
Degradation of FGFR1/Akt/Src/C-Raf/Erk by Arsenic Trioxide and FGFR<br />
Inhibitor in Squamous Cell Lung Cancer - Sze Kwan Lam, Hong Kong<br />
Discussant - Mark Kris, USA<br />
Genome-Wide Methylome Alterations in Lung Cancer - Simon Spivack,<br />
USA<br />
ATM Mutations in Cancer Cell Lines Predict Higher Mutation Rates and<br />
Genetic Instability - D. Gwyn Bebb, Canada<br />
Functional Role of Cancer Associated Fibroblasts in Non-Small Cell Lung<br />
Cancer Patients - Roya Navab, Canada<br />
Sonic Hedgehog Is Required for Tumor Progression in a Mouse Model of<br />
Small Cell Lung Cancer - Anette Szczepny, Australia<br />
Discussant - Bruce Johnson, USA<br />
Mutant ARAF Drives Lung Carcinogenesis Through a Distinct Oncogenic<br />
Mechanism - Luiz H. Araujo, USA<br />
Stratifin Accelerates Progression of Lung Adenocarcinoma at an Early<br />
Stage - Aya Shiba, Japan<br />
Targeting Cancer Stem Cell Factor BMI1 to Sensitize Non-Small Cell Lung<br />
Cancer to Chemotherapy and Radiation Therapy - Kunal Chaudhary,<br />
USA<br />
Microthrombosis Enhances Extravasation via Myeloid Hypoxia-Inducible<br />
Factors - Colin Evans, United Kingdom<br />
Discussant – Jonathan Goldman, USA<br />
87
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
18:30 - 20:00 Mini Oral 36: Imaging and Diagnostic Workup<br />
Track: Screening and Early Detection<br />
Moderator: Feng-Ming (Spring) Kong, USA<br />
Rooms: 401 - 404<br />
Three-Dimensional Quantitative Computed Tomography Evaluation of<br />
Pulmonary Adenocarcinoma Using Image-Analysis Software - Kazunori<br />
Hata, Japan<br />
Newly Detected Solid Nodules at Incidence CT Lung Cancer Screening<br />
Rounds: Occurrence and Lung Cancer Probability - Marjolein<br />
Heuvelmans, Netherlands<br />
Multi-Nodularity in Baseline CT Lung Cancer Screening and Relationship<br />
with Lung Cancer Probability - Marjolein Heuvelmans, Netherlands<br />
Automated Measurement of Malignancy Risk of Lung Nodule Detected<br />
by Screening Computed Tomography - Alexander Ritchie, Australia<br />
Computer Vision Tool and Technician as First Reader of Lung Cancer<br />
Screening CT - Alexander Ritchie, Australia<br />
Discussant - Matthew Steliga, USA<br />
Diagnostic Value of Electromagnetic Navigation Bronchoscopy for<br />
Peripheral Pulmonary Lesions : A Randomized Controlled Trial - Sun<br />
Jiayuan, China<br />
18F-FDG PET Imaging Utilization in the National Lung Screening Trial -<br />
Viswam Nair, USA<br />
CT-Guided Cutting Needle Lung Biopsy Using "Liquid Withdraw"<br />
Technique: Prominently Reduced Incidence of Pneumothorax - Rutian<br />
Li, China<br />
Discussant - Dominique Grunenwald, France<br />
Pre-Operative Fine Needle Aspiration (FNA) for Diagnosis of Suspected<br />
Early Stage Lung Cancer Reduces Non-Malignant Resection Rate - Julie<br />
Barta, USA<br />
Diagnosis of Peripheral Lung Nodules: Cost Analysis of EMB/EBUS<br />
Compared to TTNB - K. Adam Lee, USA<br />
Quantitative Computed Tomography as Predictor of Cardiopulmonary<br />
Complication after Lobectomy for Lung Cancer in COPD Patients -<br />
Yoshiyuki Yasuura, Japan<br />
Improving Pathways to Early Lung Cancer Diagnosis: Process Mapping<br />
and Qualitative Analysis - Nicole Rankin, Australia<br />
18:30 - 20:00 Mini Oral 37: SCLC Therapy<br />
Track: Small Cell Lung Cancer<br />
Moderators: David Ettinger, USA & George Simon, USA<br />
Rooms: 605 + 607<br />
<br />
Chk1 Inhibition Enhances Cisplatin Cytotoxicity Regardless of p53 Status<br />
in Human Small Cell Lung Cancer Cells - Wei-Hsun Hsu, USA<br />
88
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
The Novel HSP90 Inhibitor-SN-38 Conjugate (STA-12-8666), Is Highly<br />
Active in Preclinical Models of Small Cell Lung Cancer (SCLC) - Yanis<br />
Boumber, USA<br />
Survival after Surgery for pN1 and pN2 Small Cell Lung Cancer: A<br />
Comparison with Surgical Treatment of Non-Small Cell Lung Cancer -<br />
Chi-Fu Yang, USA<br />
Discussant - M Catherine Pietanza, USA<br />
Carfilzomib, Carboplatin and Etoposide for Previously Untreated<br />
Extensive-Stage Small Cell Lung Cancer: Initial Results from a Phase 1b/2<br />
Study - Firas Badin, USA<br />
Randomized Phase II Trial of CODE or Amrubicin Plus Cisplatin<br />
Chemotherapy after Chemoradiotherapy for Limited-Disease Small Cell<br />
Lung Cancer - Ikuo Sekine, Japan<br />
PCI Survival Improvement for Extensive Stage SCLC Limited to Patients<br />
on Maintenance Systemic Therapy: A Secondary Analysis of CALGB<br />
30504 - Joseph Salama, USA<br />
Pazopanib as Second Line Treatment of Platinum Sensitive SCLC<br />
Patients: A Multicenter Phase II Trial of the Hellenic Oncology Research<br />
Group - Athanasios Kotsakis, Greece<br />
Discussant - Taofeek Owonikoko, USA<br />
Factors Associated with Severe Pneumonitis for Limited Stage Small Cell<br />
Lung Cancer - Ritsuko Komaki, USA<br />
Inter-Observer Variability in Hippocampus Delineation on MRI Scans for<br />
Hippocampal Avoidance Prophylactic Cranial Irradiation Trial - Jose<br />
Belderbos, Netherlands<br />
Survival Trends of Small Cell Lung Cancer (SCLC) in the United States: A<br />
SEER Database Analysis - Lata Nawal, USA<br />
Discussant - Nevin Murray, Canada<br />
18:30 - 20:00 Mini Oral 38: Biology and Prognosis<br />
Track: Thymoma, Mesothelioma and Other Thoracic Malignancies<br />
Moderator: Ryosuke Tsuchiya, Japan & Murry Wynes, USA<br />
Rooms: 702 + 704 + 706<br />
<br />
<br />
<br />
<br />
<br />
FAK Inhibitor VS-6063 Targets Mesothelioma Cancer Stem Cells:<br />
Rationale for Maintenance Therapy after Conventional Chemotherapy -<br />
David Weaver, USA<br />
BAP1 Inactivation in Mesothelioma Is Highly Prevalent - Marjorie<br />
Zauderer, USA<br />
Validation of a Specific Missense GTF2I Mutation in More Indolent<br />
Thymic Epithelial Tumours - Spyridon Gennatas, United Kingdom<br />
BRCA1/OCT1/MAD2L1 Axis Regulates a Bifurcating Apoptotic Pathway<br />
Induced by Vinorelbine in Mesothelioma - Sara Busacca, United<br />
Kingdom<br />
Discussant - Jan Van Meerbeeck, Belgium<br />
89
Wednesday, <strong>September</strong> 9, <strong>2015</strong><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
FP1039/GSK3052230 with Chemotherapy in Patients with Fibroblast<br />
Growth Factor (FGF) Pathway Deregulated Squamous NSCLC or MPM -<br />
Pilar Garrido, Spain<br />
RITA Enhances Mithramycin-Mediated Growth Arrest and Apoptosis of<br />
Malignant Pleural Mesothelioma Cells In-Vitro and In-Vivo - Mahadev<br />
Rao, USA<br />
Contemporary Analysis of Prognostic Factors in Patients with<br />
Unresectable Malignant Pleural Mesothelioma (MPM) - Andrea Bille,<br />
USA<br />
The Prognostic Significance of Nodal Metastatic Burden in Survival<br />
following Radical Surgery for Malignant Pleural Mesothelioma - Annabel<br />
Sharkey, United Kingdom<br />
Discussant - Jonathan Riess, USA<br />
Tumor Volume and Epithelioid Differentiation Are Independent<br />
Predictors of Survival in Malignant Pleural Mesothelioma - Diana<br />
Kircheva, USA<br />
Multiplex Immunofluorescence Identifies Differences in Immune<br />
Microenvironment & Prognostic Biomarkers between Mesothelioma<br />
Subtypes - Tanguy Seiwert, USA<br />
Survival Outcomes in Malignant Pleural Mesothelioma Patients Fit for<br />
Surgery According to Type of Procedure and Completeness of Resection<br />
- Maurizio Infante, Italy<br />
Surgery and Not Radiation Improves Survival in Malignant Pleural<br />
Mesothelioma - Andrea Wolf, USA<br />
Discussant - Harvey Pass, USA<br />
90